ࡱ>  f]^_`abcdepkU bjbjnn Faaff########8.$*&#Q+2.p...1V5L6|~~~~~~$1`i#En1@1EE##.. LLLEr#.#.|LE|LLj.@FPh!0QJ GGnGjjVG# J7;8L?AJ7J7J7eJbJ7J7J7QEEEEGJ7J7J7J7J7J7J7J7J7fB ": TREATMENT-RADIOTHERAPY TEMPLATE INSTRUCTIONS v. 11/26/2018 The protocol template is a tool to facilitate rapid protocol development. It is not intended to supersede the role of the Principal Investigator in the authoring and scientific development of the protocol. It contains the boilerplate language commonly required. Content may be modified as necessary to meet the scientific aims of the study and development of the protocol. For further details and examples, please refer to the reference document located:  HYPERLINK "/cancer/research/clinical-research-office/protocol-templates" /cancer/research/clinical-research-office/protocol-templates The BLUE text is meant to provide instructions and examples, please delete the BLUE instructions and examples and replace them with protocol specific designs. Please refer to CCCC PRMC website for comprehensive list of definitions and examples for each protocol section.   STUDY NUMBER: CASE XXXX Number will be assigned by Cancer Center at time of PRMC Submission ClinicalTrials.gov NCT #: TBD Protocol Date: STUDY TITLE: Full study title here (600 characters maximum) PRINCIPAL INVESTIGATOR: A study can only have one Principal Investigator. Trials that are being conducted at both University Hospitals and Cleveland Clinic will list the Principal Investigator at the Lead Institution as the overall Principal Investigator for the study. The Co-PI(s) refer to the physician(s) who will lead the study at non-lead institution(s). Example: Joint Protocol with UH Lead PRINCIPAL INVESTIGATOR: Name of Physician, MD Case Comprehensive Cancer Center University Hospitals Cleveland Medical Center Seidman Cancer Center 11100 Euclid Avenue Cleveland, OH 44106 Telephone including area code Email address CO-PI: Name of Physician, MD Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center 9500 Euclid Avenue Cleveland, OH 44195 Telephone including area code Email address CO- INVESTIGATOR: List co-investigators alphabetically by site in the following order: Case Comprehensive Cancer Center, Lead Institution, Main Site Case Comprehensive Cancer Center, Lead Institution, Regional Sites Case Comprehensive Cancer Center, Non-Lead Institution, Main Site Case Comprehensive Cancer Center, Non-Lead Institution, Regional Sites *If this is a multi-institutional study, the protocol title page should include the name of each participating institution, the investigator responsible for the study at that institution, and his/her telephone # and e-mail address. STATISTICIAN: Name of Statistician, degree Case Comprehensive Cancer Center Name of Institution Street Address City, State, Zip code Telephone including area code Email address STUDY COORDINATOR: Name of Lead Study Coordinator Case Comprehensive Cancer Center Name of Institution Street Address City, State, Zip code Telephone including area code Email address SPONSOR: Case Comprehensive Cancer Center SUPPORT/FUNDING: List any support/grants or any funding source (partial or full) here SUPPLIED AGENT(S): Name of supplied agents and supplier, if applicable IND #: If applicable OTHER AGENT(S): Name of other agents Title: Principal Investigator: PRINCIPAL INVESTIGATOR SIGNATURE: ___________________________________ Date: ___________________ SUMMARY OF CHANGES Please provide a list of changes from the previous approved version of the protocol starting at IRB approval. This table will remain blank until initial IRB approval. The list shall be a brief overview. When appropriate, a brief justification for the change should be included. This is a running list for the life of the study. Protocol DateSectionChangeInitial IRB approvalSummarize changes to first protocol amendment STUDY SCHEMA Please provide a visual schema for the study. If preferred, a summary or synopsis may be provided. HYPERLINK "../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE TREATMENT SCHEMAS.doc"EXAMPLE STUDY SCHEMA - hyperlink to separate document Protocol Synopsis: Please refer to  HYPERLINK "http://cancer.case.edu/cancer/media/caseedu/cancer-center/docs/clinical-res-office/protocol-templates/Protocol%20Summary.pdf" PROTOCOL SUMMARY guidance document for examples PROTOCOL SUMMARY Protocol Number/TitleCase CCC assigned number/TitleStudy PhaseStudy phase as defined by clinicaltrials.govBrief Background/Rationale Include: Why doing this study on this population with this drug. Incidence/burdenPrimary Objective Primary Endpoint(s) Endpoints: how it will be measured and at what time point. Do not use end of study or at progression.Secondary Objective(s)Secondary Endpoint(s)Exploratory Objective(s)Exploratory Endpoints (s) This is where exploratory research endpoints will go. For example, gathering preliminary dataCorrelative Objective(s) Correlative Endpoint(s) This is where correlative study objectives will go. Pharmacokinetics, Pharmacodynamics, and biomarkers, etc.Sample SizeNumber expected to accrue Age, genderDisease sites/ConditionsICD terminologyInterventionsAgent X, route, dose, cycle length, number of cyclesAgent Y, route, dose, cycle length, number of cycles ABBREVIATIONS Please update table with relevant abbreviations used in the protocol CCCCCase Comprehensive Cancer CenterCRFCase Report FormDCRUDahms Clinical Research UnitDSTCData Safety and Toxicity CommitteeFDAFood and Drug AdministrationICFInformed Consent FormIRBInstitutional Review BoardPRMCProtocol Review and Monitoring CommitteeSOCStandard of CareCCFCleveland Clinic FoundationUHUniversity Hospitals TABLE OF CONTENTS 1.0 INTRODUCTION 1.1 Background of Study Disease 1.2 Preclinical Data 1.3 Clinical Data to date 1.4 Rationale 1.5 Background and rationale of correlative studies 2.0 OBJECTIVES 2.1 Primary Objective 2.2 Secondary Objective(s) 2.3 Exploratory Objective(s) 3.0 STUDY DESIGN 3.1 Study design, dose escalation, and cohorts 3.2 Number of Subjects 3.3 Replacement of Subjects 3.4 Expected Duration of Treatment and Subject Participation 4.0 SUBJECT SELECTION 4.1 Inclusion Criteria 4.2 Exclusion Criteria 4.3 Inclusion of Women and Minorities 5.0 REGISTRATION 6.0 TREATMENT PLAN 6.1 Radiation Therapy 6.1.1 General Guidelines and Timing 6.1.2 Equipment and Techniques to be Used 6.1.3 Target Volumes 6.1.4 Dose Target and Organs at Risk Constraints 6.2 Name of Investigational Agent X Administration 6.3 Name of Standard of Care Agent(s) Administration 6.4 Phase I Dose Escalation 6.5 Definition of Dose Limiting Toxicity 6.6 General Concomitant Medications and Supportive Care Guidelines 6.7 Criteria for Removal from Study 6.8 Duration of Follow-Up 7.0 DOSE DELAYS / DOSE MODIFICATIONS 8.0 ADVERSE EVENTS AND POTENTIAL RISKS 8.1 Radiation Therapy Adverse Events 8.2 Agent X/Y Adverse events 8.3 Definitions 8.4 Serious Adverse Event Report Form 8.5 Reporting Procedures for Serious Adverse Event 8.6 Serious Adverse Events and OnCore 8.7 Data Safety Toxicity Committee 8.8 Data and Safety Monitoring Plan 9.0 PHARMACEUTICAL INFORMATION 9.1 Investigational Agent(s) 9.2 Commercial Agent(s) 10.0 CORRELATIVE/EXPLORATORY 10.1 Name of Correlative/Exploratory Study #1 10.2 Name of Correlative/Exploratory Study #2 10.3 Name of Correlative/Exploratory Study #3 11.0 STUDY PARAMETERS AND CALENDAR 11.1 Study Parameters 11.2 Calendar 12.0 MEASUREMENT OF EFFECT choose appropriate measurement of effect; ie. RECIST (solid tumors) / hematologic diseases / other response measurement 13.0 RECORDS TO BE KEPT/REGULATORY CONSIDERATIONS 13.1 Data Reporting 13.2 Regulatory Considerations 14.0 STATISTICAL CONSIDERATIONS REFERENCES APPENDICES The investigator may choose from the following commonly used appendices and modify per protocol specifications. The investigator must supply additional appendices as needed including questionnaires and surveys. For further resources, please see reference document ____) APPENDIX __ ECOG / Karnofsky Performance Status Criteria APPENDIX __ Subject Diary (pill, injectable, etc) 1.0 Introduction 1.1 Background Please provide background, incidence, and treatment information on the study disease. Please be specific in the title for disease specific studies. Example: Advanced Biliary Cancers versus Advanced Cancers 1.2 Preclinical Data Provide background and brief information for agent X. Include any animal studies, the explanation of the mechanism of action, and any preclinical data about the agent or treatment. 1.3 Clinical Data to Date Summarize the available clinical study data with relevance to the protocol under development. If none is available, include a statement that there is no available clinical research data to date on the investigational product. 1.4 Rationale Please provide the background and rationale for evaluating this (combination) therapy in this disease. Include the rationale for the proposed starting doses and dose escalation scheme as well as route of administration and dosage period. 1.5 Background and rationale of correlative studies Please provide the background and rationale for correlative studies and exploratory endpoints. 2.0 Objectives Describe the overall objectives and purpose of the study, keeping in mind that objectives must be measurable. Records to be kept should capture the measurement. Study parameters (calendar) should indicate when captured. 2.1 Primary Objective It is preferable to have only one primary objective and primary endpoint. What scientific question are you trying to answer? HYPERLINK "../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.doc"Example: Hyperlink to examples 2.2 Secondary Objective(s) HYPERLINK "../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.doc"Example: Hyperlink to examples 2.3 Exploratory Objectives (s) HYPERLINK "../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.doc"Example: Hyperlink to examples 3.0 Study Design Please provide an overview of the study design and the rationale for this type of design. 3.1 Study design including dose escalation / cohorts This section should include: the type of trial design of the study, stages, cohort information, how subjects will be randomized and if there are plans to use a placebo. Please see guidance document for examples of blinding/unblinding procedures. 3.2 Number of Subjects Provide the number of subjects that will be included in the study using a sentence format. Example: Approximately 50 subjects will be enrolled in this trial. Example if more than one phase: Approximately 50 subjects will be enrolled in this trial. Approximately 15 will be enrolled in the phase I part and 35 in the phase II part. 3.3 Replacement of Subjects The replacement of subjects is protocol specific and needs to be tailored to the trial. Example: If Oral Drug is to be taken 21 out of 21 days and this is not met: Example: If a subject does not take at least 17 doses in the first cycle, the subject will be replaced because he/she has not taken enough drug to confirm safety at that dose level. HYPERLINK "../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OF REPLACEMENT OF SUBJECTS.doc"Example: Hyperlink to further examples 3.4 Expected Duration of Treatment and Subject Participation Please provide a brief summary of the length of treatment period, plus the length of follow up period and any study windows that are applicable. Please provide length of each cycle, minimum and maximum number of cycles. If treatment can continue until disease progression (i.e. no maximum number of cycles), please indicate here. If clinical benefit is not likely until after a certain number of cycles, specify that here. Treatment duration may be modified per section ___. 4.0 Subject Selection Each of the criteria in the sections that follow must be met in order for a subject to be considered eligible for this study. Use the eligibility criteria to confirm a subjects eligibility. For UH lead CASE Studies, please use signature lines below. For CCF lead CASE studies, please remove. Subjects Name _____________________________________________________________ Medical Record # ___________________________________________________________ Research Nurse / Study Coordinator Signature: _________________________________________________ Date __________ Treating Physician [Print] ____________________________________________________ Treating Physician Signature: _________________________________________________ Date __________ Hyperlink to Inclusion/Exclusion tips and examples 4.1 Inclusion Criteria Inclusion Criteria must describe the subject population that you want to include in the study. Each statement must be able to be placed into the form of a question with a positive response received. Create a numbered list of criteria applicable to the protocol that subjects must meet to be eligible for study enrollment. Subjects must meet all of the following inclusion criteria to be eligible for enrollment: Below are common examples: Edit per protocol or see further examples hyperlinked above. 4.1.1 Subjects must have histologically or cytologically confirmed Name of Disease. Please specify eligible disease(s)/stage(s)/prognostic score(s) as well as if staging is pathological or clinical. 4.1.2 Subjects must have received (no, no more than X) prior therapies for this disease. **If applicable, provide guidance on what constitutes a prior line of therapy, how to count prior lines of therapy and breaks in therapy. 4.1.3 Age >18 years. Please state reason for age restriction. If applicable, the following text can be used;  Because no dosing or adverse event data are currently available on the use of ______ in combination with _______ in subjects d"18 years of age, children are excluded from this study. 4.1.4 Performance status _____ [See Appendix __]. Choose one method (not both): Example: ECOG Performance status d" 2 Example: Karnofsky Performance status e" 60% 4.1.5 Life expectancy of e" # weeks/months, in the opinion of and as documented by the investigator. 4.1.6 Subjects must have normal organ and marrow function as defined below: Add time frame if applicable. Please review for relevance to the specific study and modify. 4.1.6.1 Hemoglobin e" 10.0 g/dl 4.1.6.2 Leukocytes e" 3,000/mcL 4.1.6.3 Absolute neutrophil count e" 1,500/mcL 4.1.6.4 Platelet count e" 100,000/mcL 4.1.6.5 Total bilirubin within normal institutional limits 4.1.6.6 AST (SGOT) d" 2.5 X institutional upper limit of normal 4.1.6.7 ALT (SGPT) d" 2.5 X institutional upper limit of normal 4.1.6.8 Serum creatinine within normal institutional limits 4.1.7 Please insert other appropriate eligibility criteria. 4.1.8 Sex (defined as a persons classification as male or female based on biological distinctions) 4.1.9 Gender based (defined as self-representation of gender identity). If eligibility is based on gender, describe gender criteria. 4.1.10 Subjects must have the ability to understand and the willingness to sign a written informed consent document. 4.2 Exclusion Criteria Exclusion Criteria must describe the subject population that you do NOT want to include in the study. Each statement must be able to be placed into the form of a question with a negative response received. Create a numbered list of criteria applicable to the protocol that would exclude a subject from study enrollment. The presence of any of the following will exclude a subject from study enrollment. Below are common examples: Edit per protocol or see further examples hyperlinked above. 4.2.1 Prior treatment toxicities resolved to d" Grade X according to NCI CTCAE Version 4.0 (list exceptions, e.g. alopecia, neuropathy, etc). 4.2.2 Subjects receiving any other investigational agents. 4.2.3 To be included if applicable to protocol. Suggested text is provided below: Subjects with untreated brain metastases/CNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. 4.2.4 History of allergic reactions attributed to compounds of similar chemical or biologic composition to Agent X or other agents used in this study. 4.2.5 Please state appropriate exclusion criteria relating to concomitant medications or substances that have the potential to affect the activity or pharmacokinetics of the study agent(s). 4.2.6 Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 4.2.7 The investigator must state a medical or scientific reason if pregnant or nursing subjects will be excluded from the study. Suggested text is provided below: Pregnant or breastfeeding women are excluded from this study because Agent X is Name of Agent Class agent with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with Agent X, breastfeeding should be discontinued if the mother is treated with Agent X. These potential risks may also apply to other agents used in this study. 4.2.8 The investigator must state a medical or scientific reason if subjects who are HIV-positive will be excluded from the study. Suggested text is provided below: HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with Agent X. In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy. Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated. Also include whether HIV testing is required for this study, or only if a known diagnosis will be excluded. 4.2.9 Insert other appropriate agent-specific exclusion criteria. 4.3 Inclusion of Women and Minorities Make sure you include the appropriate verbiage for the subject population. Suggested text is provided below: Men, women and members of all races and ethnic groups are eligible for this trial. 5.0 Registration All subjects who have been consented are to be registered in the OnCore Database. For those subjects who are consented, but not enrolled, the reason for exclusion must be recorded. All subjects will be registered through [Name of Lead Site] and will be provided a study number by contacting the study coordinator listed on the cover page. Include if a registration form will be required. If the trial is randomized the method of randomization should be stated as well as the proportion of subjects that will be accrued to each dose level. Example: Subjects will be randomized equally to the four dose levels being studied using permuted blocks. 6.0 Treatment Plan Briefly describe the treatment regimen planned. If there are different cohorts, label each cohort and appropriate treatment schedule: Pre-medications allowed/required/suggested (if applicable) Agent(s) (if applicable) Dose(s) (of agents and RT) Route of administration Treatment schedule (including pre-treatment prep) Treatment duration Please provide separate regimen descriptions for different treatment groups of subjects as necessary. The investigator must include the following statement if treatment is required to be administered only on an inpatient basis: Treatment must be administered only on an inpatient basis. Radiation Therapy 6.1.1 General Guidelines and Timing Describe the general rationale for radiation therapy and indications. Describe how radiation will be scheduled relative to chemotherapy administration if applicable. 6.1.2 Equipment and Techniques to be used Provide details of treatment machine(s) (linear accelerator, proton beam, cyberknife, gamma knife) and techniques to be utilized (IMRT, TBI, SBRT, 3D CRT, etc). Describe immobilization, simulation, motion management approach, image fusion, and other techniques. 6.1.3 Target Volumes Provide details on GTV, CTV and PTV and/or other target description as applicable. 6.1.4 Dose to Target and Organs at Risk Constraints Provide details on prescribed dose and fractionation. Include prescription points, coverage goals and dose limits on OARs. 6.2 Name of Investigational Agent X Administration (If applicable, for studies using investigational chemotherapy agents or investigational agent combinations) In addition to a dosing schema, please add a narrative description of the investigational agent administration. Investigational Agent Administration Example: Subjects will receive Agent X ___ mg/m2 on Days 1-3 of each (28 day) cycle. Name of Agent will be administered IV over 2 hours. Example: Subjects will receive Agent Y ___ mg/m2 by IV on Day 1 of each 21-day cycle. Prior to each Name of Agent treatment, pre-hydrate with at least 1000 ml normal saline and use diuretics per institutional guidelines. Example: Subjects will receive Agent Z ____mg/m2 by IV on days 1, 2, and 3 of each 21-day cycle. Please add subsequent sections for additional investigational agents or agent combinations. 6.3 Name of Standard of Care Agent(s) Administration (If applicable, for studies using Standard of Care chemotherapy agents or standard of care agent combinations) In addition to a dosing schema, please add a narrative description of the non-investigational agent administration in the same format as above. SOC Example: Subjects will receive Agent X ___ mg/m2 on Days 1-3 of each (28 day) cycle. Agent X will be administered IV over 2 hours. Example: Subjects will receive Agent Y ___ mg/m2 by IV on Day 1 of each 21-day cycle. Prior to each Agent Y treatment, pre-hydrate with at least 1000 ml normal saline and use diuretics per institutional guidelines. Example: Subjects will receive Agent Z ___ mg/m2 by IV on days 1, 2, and 3 of each 21-day cycle. 6.4 Phase I Dose Escalation (if applicable) Dose escalation will proceed within each cohort according to the following scheme. Dose-limiting toxicity (DLT) is defined in section 6.5. Number of Subjects with DLT at a Given Dose LevelEscalation Decision Rule0 out of 3Enter 3 subjects at the next dose level.1 out of 3Enter at least 3 more subjects at this dose level. If 0 of these 3 subjects experience DLT, proceed to the next dose level. If 1 or more of this group suffer DLT, then dose escalation is stopped, and this dose is declared the maximally administered dose. Three (3) additional subjects will be entered at the next lowest dose level if only 3 subjects were treated previously at that dose.>2Dose escalation will be stopped. This dose level will be declared the maximally administered dose (highest dose administered). Three (3) additional subjects will be entered at the next lowest dose level if only 3 subjects were treated previously at that dose.<1 out of 6 at highest dose level below the maximally administered doseThis is generally the recommended phase 2 dose. At least 6 subjects must be entered at the recommended phase 2 dose. 6.5 Definition of Dose-Limiting Toxicity (Applicable for dose escalation studies only) Dose limiting toxicities must be suspected to be related to the investigational product (please refer to section __ for all other dose modifications). For dose escalation studies, please provide explicit definitions of the type(s), grade(s), and duration(s) of adverse events that will be considered dose-limiting toxicity(s), or provide definitions of other endpoints that will be used to determine dose escalations. Management and dose modifications are outlined in Section 7. 6.6 General Concomitant Medications and Supportive Care Guidelines State guidelines for use of which concomitant medicines/therapies are permitted during the study, and which concomitant medicines/therapies are not permitted during the study (if applicable). Include any additional rescue therapies or supportive care medications or treatments required for administration of each agent in the treatment. Suggestive text, as applicable for supportive care: Subjects should receive full supportive care, including transfusions of blood and blood products, cytokines, antibiotics, antiemetics, etc when appropriate. Example: Because there is a potential for interaction of Name of Agent(s) with other concomitantly administered drugs through the cytochrome P450 system, the case report form must capture the concurrent use of all other drugs, over-the-counter medications, or alternative therapies. The Principal Investigator should be alerted if the subject is taking any agent known to affect or with the potential to affect selected CYP450 isoenzymes. Please refer to Appendix _____ for a complete list. 6.7 Criteria for Removal from Study In the absence of treatment delays due to adverse events, treatment may continue for # cycles or until one of the following criteria applies: Disease progression, Intercurrent illness that prevents further administration of treatment, The investigator considers it, for safety reasons, to be in the best interest of the subject. Unacceptable adverse event(s) [be specific] Example: Unacceptable treatment related toxicity, NCI CTC AE version 4.0 Grade 3 or 4 that fails to recover to baseline or < Grade 3 in the absence of treatment within 4 weeks Example: Any toxicity or other issue that causes a delay of study drug administration by more than 4 weeks General or specific changes in the subjects condition render the subject unacceptable for further treatment in the judgment of the investigator, Subject decision to withdraw from treatment (partial consent) or from the study (full consent), Pregnancy during the course of the study for a child-bearing participant Death, or Sponsor reserves the right to temporarily suspend or prematurely discontinue this study. The date and reason for discontinuation must be documented. Every effort should be made to complete the appropriate assessments. 6.8 Duration of Follow Up Investigators must be sure to match the duration of follow-up with the calendar regardless if survival is the endpoint of a study. Please indicate here if the sponsor-investigator intents to capture information after a patient withdraws from study (per patient agreement). Subjects will be followed for toxicity for 30 days (minimum suggested time frame, follow up time frame should be appropriate to the metabolism of the product) after treatment has been discontinued or until death, whichever occurs first. The clinical course of each event will be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause. [The investigator may want to consider a cut off of 6 months.] Serious adverse events that are still ongoing at the end of the study period will necessitate follow-up to determine the final outcome. Any serious adverse event that occurs after the study period and is considered to be possibly related to the study treatment or study participation will be recorded and reported immediately. 7.0 Dosing Delays/Dose Modifications Treatment modifications/dosing delays and the factors predicating treatment modification should be explicit and clear. If dose modifications or radiation treatment delays are anticipated, please provide a dose de-escalation schema. If you plan to allow dose re-escalation for 1 or more agents, please specify dose re-escalation process in this section. All treatment modifications must be expressed as a specific dose or amount rather than as a percentage of the starting or previous dose. Please consider dosing formulation when calculating dose modifications for ORAL agents. Dose modifications/treatment delays may be presented separately or together as appropriate. Please see examples of dosing delays and modifications in the guidance document. 8.0 Adverse Events and Potential Risks 8.1 Radiation Therapy For RT, please include a comprehensive list of all reported adverse events and any potential risks. 8.2 Agent X/Y For treatment agents, please include a comprehensive list of all reported adverse events and any potential risks for each agent (such as the toxicities seen with another agent of the same class or risks seen in animals administered this agent) as provided by the manufacturer/CAEPR. Please also include the recommended treatment for the commonly occurring events. This information may be provided in tabular format. For a commercial agent, please provide a list of those adverse events most likely to occur on this study, and refer the reader to the package insert(s) for the comprehensive list of adverse events. Please also include the recommended clinical management for the commonly occurring events. This information may be provided in tabular format. 8.3 Definitions 8.3.1 Adverse Event An adverse event (AE) is any unfavorable or unintended event, physical or psychological, associated with a research study, which causes harm or injury to a research participant as a result of the participants involvement in a research study. The event can include abnormal laboratory findings, symptoms, or disease associated with the research study. The event does not necessarily have to have a causal relationship with the research, any risk associated with the research, the research intervention, or the research assessments. Adverse events may be the result of the interventions and interactions used in the research; the collection of identifiable private information in the research; an underlying disease, disorder, or condition of the subject; and/or other circumstances unrelated to the research or any underlying disease, disorder, or condition of the subject. 8.3.2 Serious Adverse Events A serious adverse event (SAE) is any adverse experience occurring at any dose that results in any of the following outcomes: Results in death. Is a life-threatening adverse experience. The term life-threatening in the definition of serious refers to an adverse event in which the subject was at risk of death at the time of the event. It does not refer to an adverse event which hypothetically might have caused death if it were more severe. Requires inpatient hospitalization or prolongation of existing hospitalization. Any adverse event leading to hospitalization or prolongation of hospitalization will be considered as Serious, UNLESS at least one of the following expectations is met: The admission results in a hospital stay of less than 24 hours OR The admission is pre-planned (e.g., elective or scheduled surgery arranged prior to the start of the study) OR The admission is not associated with an adverse event (e.g., social hospitalization for purposes of respite care. However it should be noted that invasive treatment during any hospitalization may fulfill the criteria of medically important and as such may be reportable as a serious adverse event dependant on clinical judgment. In addition where local regulatory authorities specifically require a more stringent definition, the local regulation takes precedent. Results in persistent or significant disability/incapacity. The definition of disability is a substantial disruption of a persons ability to conduct normal lifes functions. Is a congenital anomaly/birth defect. Is an important medical event. Important medical events that may not result death, be life-threatening, or require hospitalization may be considered a serious adverse experience when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood disease or disorders, or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse. The development of a new cancer is always considered an important medical event. Investigators may choose to include exclusions to Serious Adverse Events being reported. Example: For the purpose of this study the following events would not be considered adverse events and would not be recorded in the database: Abnormal laboratory findings considered associated to the original disease 8.3.3 Adverse Event Evaluation The investigator or designee is responsible for ensuring that all adverse events (both serious and non-serious) observed by the clinical team or reported by the subject which occur after the subject has signed the informed consent are fully recorded in the subjects medical records. Source documentation must be available to support all adverse events. A laboratory test abnormality considered clinically relevant (e.g., causing the subject to withdraw from the study, requiring treatment or causing apparent clinical manifestations, result in a delay or dose modification of study treatment, or judged relevant by the investigator), should be reported as an adverse event. The investigator or sub-investigator (treating physician if applicable) will provide the following for all adverse events (both serious and non-serious): Event term (as per CTCAE) Description of the event Date of onset and resolution Expectedness of the toxicity Grade of toxicity Attribution of relatedness to the investigational therapy/agent- (this must be assigned by an investigator, sub-investigator, or treating physician) Action taken as a result of the event, including but not limited to; no changes, dose interrupted, reduced, discontinued, etc. or action taken with regard to the event, i.e. no action, received conmed or other intervention, etc. Outcome of event Descriptions and grading scales found in the NCI Common Terminology Criteria for Adverse Events (CTCAE) version X will be utilized for agent AE reporting. An expected adverse event is an event previously known or anticipated to result from participation in the research study or any underlying disease, disorder, or condition of the subject. The event is usually listed in the Investigator Brochure, consent form or research protocol. An unexpected adverse event is an adverse event not previously known or anticipated to result from the research study or any underlying disease, disorder, or condition of the subject. Attribution is the relationship between an adverse event or serious adverse event and the study drug. Attribution will be assigned as follows: Definite The AE is clearly related to the study drug. Probable The AE is likely related to the study drug. Possible The AE may be related to the study drug. Unlikely The AE is doubtfully related to the study drug. Unrelated The AE is clearly NOT related to the study drug. Protocol must specify if attribution is required for individual components of the treatment regimen or the treatment regimen as a whole. 8.4 SAE Report Form SAEs related to radiation therapy only will be recorded into OnCore and reported to IRB according to local IRB policies and procedures. SAEs related to agent therapy will be recorded on the FDA Form 3500A (MedWatch) but should only be reported as instructed below. The electronic FDA SAE reporting forms should not be used. 8.5 Reporting Procedures for Serious Adverse Events For the purposes of safety reporting, all adverse events will be reported that occur [Please insert appropriate time frame, e.g. on or following first day of RT, on day of registration, etc.] through 30 days after the final dose of study radiation therapy/drug. Adverse events, both serious and non-serious, and deaths that occur during this period will be recorded in the source documents. All SAEs should be monitored until they are resolved or are clearly determined to be due to a subjects stable or chronic condition or intercurrent illness(es). Related AEs will be followed until resolution to baseline or grade 1 or stabilization. 8.5.1 SAE Reporting Requirements Participating investigators (all sites) must report all serious adverse events to the Lead Site Principal Investigator (e.g. Sponsor-Investigator) within 24 hours of discovery or notification of the event. The participating investigator must also provide follow-up information on the SAE until final resolution. Insert Lead Site PIs email/fax number (as applicable). Protocol coordinator can be contacted if applicable. The Lead Site Principal Investigator will review the SAE and report the event to the FDA, external collaborator(s), and IRB as applicable. It is the Sponsor-Investigators responsibility (e.g. lead site PI) to ensure that ALL serious adverse events that occur on the study (e.g. ALL SAEs that occur at each enrolling institution) are reported to all participating sites. Drug Supplier / Manufacturer / Financial Supporter Reporting Requirements: Insert the external entitys reporting Requirements. Please include language that specifies the Sponsor-Investigator (e.g. lead site PI) will be responsible for reporting all SAEs to the external entity. Institutional Review Board Reporting Requirements: Investigative sites will report adverse events to their respective IRB according to the local IRBs policies and procedures in reporting adverse events. 8.6 SAEs and OnCore All SAEs will be entered into OnCore. A copy of the SAE form(s) submitted to the sponsor-investigator is also uploaded into Oncore. 8.7 Data Safety and Toxicity Committee It is the responsibility of each site PI to ensure that ALL SAEs occurring on this trial (internal or external) are reported to the Case Comprehensive Cancer Centers Data and Safety Toxicity Committee. This submission is simultaneous with their submission to the sponsor and/or other regulatory bodies The sponsor-investigator is responsible for submitting an annual report to the DSTC as per CCCC Data and Safety Monitoring Plan. 8.8 Data and Safety Monitoring Plan This protocol will adhere to the policies of the Case Comprehensive Cancer Center Data and Safety Monitoring Plan in accordance with NCI guidelines. 9.0 PHARMACEUTICAL INFORMATION A list of the adverse events and potential risks associated with the investigational or commercial agents administered in this study can be found in Section #. If applicable. Pharmaceutical information must be tailored to the specific protocol. Repeat this section for all pharmaceutical agents being given. If protocol does not include any investigational agents and is RT only, add RT risks in section 9.1. The pharmaceutical section must contain at least the following information, available from the appropriate Investigators Brochure or package insert: 9.1 Investigational Agents 9.1.1 Name of Agent ___________________________ Other Names: ___________________________ Product description: (e.g. doses, tablets, vials, powder, etc- if capsules of varying doses are supplied these should be described) Packaging: (e.g. hard gelatin capsules in bottles, capsule s in blister packs, vials, etc) Solution preparation: (how the agent is to be prepared): Describe in detail all the steps necessary to properly prepare agent. Include reconstitution directions and directions for further dilution, if appropriate. Storage requirements: Include the requirements for the original agent form, reconstituted solution, and final diluted product, as applicable. Stability: Include the stability of the original agent form, reconstituted solution, and final diluted product, as applicable. Route of administration: Include a description of the method to be used and the rate of administration, if applicable. Example: continuous intravenous infusion over 24 hours, short intravenous infusion over 30-60 minutes, intravenous bolus, etc. Describe any precautions required for safe administration. Drug Procurement: Investigational drug may or may not be supplied for a study. Please be sure to make this clear by inserting one of the statements below as applicable: Manufacturer (must specify if the Sponsor-Investigator developed the agent) When drug is not supplied: Agent X must be obtained from commercial sources. Example: Agent X must be obtained from commercial sources and is available in 500 mg/10 ampules and vials, and 1 gm/20 ml, 2.5 gm/50 ml, and 5 gm/100 ml vials. Consider including the following statement while reviewing the template: The cost of this agent will be the subjects responsibility. When drug is supplied: Study Agent X will be supplied for this study by Sponsor/company name. Packaging and labeling: Must specify the contents of the label if the Sponsor-Investigator developed the agent: name of drug, quantity of drug, date of packaging, recommended storage temp, lot number) Drug Accountability: To be included when drug is supplied The investigator or designated study personnel are responsible for maintaining accurate dispensing records of the study drug. All study drugs must be accounted for, including study drug accidentally or deliberately destroyed. Under no circumstances will the investigator allow the investigational drug to be used other than as directed by the protocol. If appropriate, drug storage, drug dispensing, and drug accountability may be delegated to the pharmacy section of the investigative site. Drug Destruction: To be included when drug is supplied This section should note the procedures for final reconciliation of the sites drug or device supply at the end of the study, and whether study drug or device is to be shipped back to a source or destroyed on site. If drug or device is to be shipped back to a source, note the address and contact information here. Suggested language: At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, and drug remaining. This reconciliation will be logged on the drug reconciliation form, signed and dated. Any discrepancies noted will be investigated, resolved, and documented prior to return or destruction of unused study drug. Drug destroyed on site will be documented in the study files. Other Information: Include any other information, e.g., any special handling, any nursing implications, and any subject care implications. Note: if the protocol involves a placebo the sections listed above apply to all components of the protocols treatment regimen (including placebo if applicable) 9.2 Commercial Agent 9.2.1 Name of Agent ___________________________ Other Names: ___________________________ Product description: (e.g. doses, tablets, vials, powder, etc- if capsules of varying doses are supplied these should be described) Solution preparation: (how the agent is to be prepared): Describe in detail all the steps necessary to properly prepare agent. Include reconstitution directions and directions for further dilution, if appropriate. Storage requirements: Include the requirements for the original agent form, reconstituted solution, and final diluted product, as applicable. Stability: Include the stability of the original agent form, reconstituted solution, and final diluted product, as applicable. Route of administration: Include a description of the method to be used and the rate of administration, if applicable. Example: continuous intravenous infusion over 24 hours, short intravenous infusion over 30-60 minutes, intravenous bolus, etc. Describe any precautions required for safe administration. Drug Procurement: Investigational drug may or may not be supplied for a study. Please be sure to make this clear by inserting one of the statements below as applicable: Manufacture (must specify if the Sponsor-Investigator developed the agent) When drug is not supplied: Agent X must be obtained from commercial sources. Example: Agent X must be obtained from commercial sources and is available in 500 mg/10 ampules and vials, and 1 gm/20 ml, 2.5 gm/50 ml, and 5 gm/100 ml vials. Consider including the following statement while reviewing the template: The cost of this agent will be the subjects responsibility. When drug is supplied: Study Agent X will be supplied for this study by Sponsor/company name. Packaging and labeling: Must specify the contents of the label if the Sponsor-Investigator developed the agent: name of drug, quantity of drug, date of packaging, recommended storage temp, lot number) Drug Accountability: To be included when drug is supplied The investigator or designated study personnel are responsible for maintaining accurate dispensing records of the study drug. All study drugs must be accounted for, including study drug accidentally or deliberately destroyed. Under no circumstances will the investigator allow the investigational drug to be used other than as directed by the protocol. If appropriate, drug storage, drug dispensing, and drug accountability may be delegated to the pharmacy section of the investigative site. Drug Destruction: To be included when drug is supplied This section should note the procedures for final reconciliation of the sites drug or device supply at the end of the study, and whether study drug or device is to be shipped back to a source or destroyed on site. If drug or device is to be shipped back to a source, note the address and contact information here. Suggested language: At the completion of the study, there will be a final reconciliation of drug shipped, drug consumed, and drug remaining. This reconciliation will be logged on the drug reconciliation form, signed and dated. Any discrepancies noted will be investigated, resolved, and documented prior to return or destruction of unused study drug. Drug destroyed on site will be documented in the study files. Other Information: Include any other information, e.g., any special handling, any nursing implications, and any subject care implications. Note: if the protocol involves a placebo the sections listed above apply to all components of the protocols treatment regimen (including placebo if applicable) 10.0 CORRELATIVE STUDIES If this trial does not include correlative or special studies, this section should be marked N/A and all instructions as well as the text below deleted. This section should be developed in close collaboration with the Translational Research and Pharmacology Core (TRPC) personnel at an early stage in protocol development. Please refer to guidance document for instructions. 10.1 Name of Correlative study #1 Describe the endpoint of correlative analysis #1. 10.1.1 Background Provide background describing the scientific basis for the correlative endpoint and its relevance to the objectives of the study. 10.1.2 Rationale for Analysis Describe how the analytical data will be analyzed and advance the objectives of the study. Consultation with Biostatistics is recommended for this section. 10.1.3 Collection of Specimens Include the number and specific type of specimens to be acquired from each subject, timepoints (cycles, day) and at what time. This information should also be included in the Study Calendar. You may also create a table that is correlative study procedure specific and add to this section. Please see Correlative study guidance document for exploratory study calendar examples. 10.1.4 Handling of Specimens Describe critical aspects of all processes involved in proper handling of the specimens. Include names and contact information (address, phone number, email, pager, etc.) of laboratories and/or individuals responsible for the acquisition, transportation, storage, tracking, processing, shipping and analyses of all specimens. Also include specific requirements for the handling of the specimens, including transport media, temperature, type of storage vessels (including type and volume of blood draw tubes, (e.g. heparin, EDTA, purple top, red top etc.), and maximal allowable time to complete processing or freezing. Please detail how the samples need to be shipped, when they need to be shipped, when to notify the lab of incoming shipment and any additional time restrictions. 10.1.5 Analytical Laboratory Will the specimens be analyzed at a clinical laboratory, a central reference laboratory, other collaborating laboratory, a Case Comprehensive Cancer Center Core Laboratory, or the Principal Investigators laboratory? Please provide all contact information including the responsible party. 10.1.6 Methods Describe the methods used to measure the endpoint. Provide references or general information on the assay. Please state if a clinically validated assay (CLIA or CAP approved) will be used. In the event that there are more than one correlative/exploratory studies: Please repeat sections as follows, numbering appropriately: Instructions same as above. 10.2.1 Background 10.2.2 Rationale for Analysis 10.2.3 Collection of Specimens 10.2.4 Handling of Specimens 10.2.5 Analytical Laboratory 10.2.6 Methods 11.0 STUDY PARAMETERS AND CALENDAR Be aware of criteria prone to deviations. 11.1 Study Parameters Study parameters are used in conjunction with the study calendar. Please include these common criteria in study parameters: procedures that are not standard of care or are research procedures only, any extra labs or imaging studies that may need to be performed, any demographics or quality of life questionnaires that may be completed, all correlative study instructions. 11.1.1 Screening Evaluation Provide any necessary information that is not captured by the procedures in the study calendar here. Please see guidance document for specific examples. Please include any pre-RT planning in this section. 11.1.2 Treatment Period Provide any necessary information about each cycle/treatment visit that is not captured in the study calendar here. Please note if any procedures need to be completed within a certain timeframe. Be sure to include windows for fiducial placement, labs, visits, imaging, etc in order to avoid having to repeat tests, etc; e.g., labs +/- 3 days. 11.2 Calendar Please thoroughly review calendar guidance document. Consider a window of days, if appropriate for study. Indicate which components of the trial are appropriate for the window. The investigator should be cautious of tight windows (e.g., 24 hours) which may lead to many needless repeat tests or deviations and are almost never necessary. Examples: A visit window of +/- 3 days is allowed for labs (be specific: hematology and/or chemistries). A visit window of +/- 1 day is allowed for treatment. A visit window of +/- 7 days is allowed for 3 month follow-up visits. 12.0 MEASUREMENT OF EFFECT Please provide response criteria. If the criteria for solid tumors in the guidance document are not applicable, the investigator(s) should provide agent or disease-appropriate criteria (e.g., for specific hematologic malignancies, supportive care agents, etc) with references. 13.0 DATA REPORTING / REGULATORY CONSIDERATIONS Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 8.0 (Adverse Events: List and Reporting Requirements). 13.1 Data Reporting The OnCore Database will be utilized, as required by the Case Comprehensive Cancer Center, to provide data collection for both accrual entry and trial data management. OnCore is a Clinical Trials Management System housed on secure servers maintained at Ǹ. OnCore. Access to data through OnCore is restricted by user accounts and assigned roles. Once logged into the OnCore system with a user ID and password, OnCore defines roles for each user which limits access to appropriate data. User information and password can be obtained by contacting the OnCore Administrator at OnCore-registration@case.edu. OnCore is designed with the capability for study setup, activation, tracking, reporting, data monitoring and review, and eligibility verification.This study will utilize electronic Case Report Form completion in the OnCore database. A calendar of events and required forms are available in OnCore. 13.2 Regulatory Considerations The study will be conducted in compliance with ICH guidelines and with all applicable federal (including 21 CFR parts 56 & 50), state or local laws. 13.2.1 Written Informed consent Provision of written informed consent must be obtained prior to any study-related procedures. The Principal Investigator will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risks and benefits of the study as well as the subjects financial responsibility. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and be allowed time to consider the information provided. The original, signed written Informed Consent Form must be kept with the Research Chart in conformance with the institutions standard operating procedures. A copy of the signed written Informed Consent Form must be given to the subject. Additionally, documentation of the consenting process should be located in the research chart. 13.2.2 Subject Data Protection In accordance with the Health Information Portability and Accountability Act (HIPAA), a subject must sign an authorization to release medical information to the sponsor and/or allow the sponsor, a regulatory authority, or Institutional Review Board access to subjects medical information that includes all hospital records relevant to the study, including subjects medical history. 13.2.3 Retention of records The Principal Investigator of The Case Comprehensive Cancer Center supervises the retention of all documentation of adverse events, records of study drug receipt and dispensation, and all IRB correspondence for as long as needed to comply with local, national and international regulations. No records will be destroyed until the Principal Investigator confirms destruction is permitted. 13.2.4 Audits and inspections Authorized representatives of the sponsor, a regulatory authority, an Independent Ethics Committee (IEC) or an Institutional Review Board (IRB) may visit the site to perform audits or inspections, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted, and data were recorded, analysed, and accurately reported according to the protocol, Good Clinical Practice (GCP), guidelines of the International Conference on Harmonization (ICH), and any applicable regulatory requirements. For multi-center studies, participating sites must inform the sponsor-investigator of pending audits. 14.0 STATISTICAL CONSIDERATIONS Investigators must amend a protocol in order to capture additional data. Data can not be collected until the amendment has received IRB approval and will pertain only to data captured from that time period forward. This section should be developed in close collaboration with the study biostatistician: at an early stage in protocol development. SEE GUIDANCE DOCUMENT FOR REFERRALS The outline below is modified from CTEP protocol templates for standard Phase I and II studies (http://ctep.info.nih.gov/protocolDevelopment/default.htm#protocol_development), and is meant to provide a rough guideline as to what information should be included, recognizing that this will depend on the particular protocol and design used. Describe the study design. This includes: the objectives of the trials (primary, secondary and exploratory) the associated endpoint(s) please include time frames for completing associated endpoints the method of dose escalation (e.g. 3+3; accelerated titration; continual reassessment method (CRM)). If the primary goal of the trial is to identify a maximum tolerated dose (or optimal biologic dose, or both) provide a precise definition of it or reference the appropriate protocol section. If the trial is randomized indicate the proportion of subjects to be accrued to each dose level (e.g. equal randomization). Provide a statistical justification for the number of subjects to be enrolled based on the primary goal(s) of the trial. If correlative studies are being performed address the suitability of the proposed sample size to obtain meaningful results (even if the goal of such studies is hypothesis generating). Also include the objectives, endpoints, and any methods not described in correlative research section of the protocol. Describe how the primary and secondary/correlative endpoints will be analyzed (e.g. parametric versus non-parametric methods; one versus two-sided statistical tests; the confidence limits that will be used for estimation). If correlative studies are included, address whether or not adjustments to p-values will be made for multiple comparisons; and if appropriate the method to be used. Provide an estimate of the accrual rate. REFERENCES Please provide the citations for all publications referenced in the text. Publications should be organized as any standard bibliography using AMA style formatting as presented below. Number. Last name followed by initial of first name. Title of article in sentence format. Title of Journal in Abbreviated Title Format. Month Year published;edition or volume:page-page. Example: Hensen, DE, Albores-Savvedra J, Corle D. Carcinoma of the gallbladder, histologic types, stage of disease and survival rates. Cancer 1992;70:1493-1497. APPENDIX I PERFORMANCE STATUS CRITERIA ECOG Performance Status ScaleKarnofsky Performance ScaleGradeDescriptionPercentDescription 0 Normal activity. Full active, able to carry on all pre-disease performance without restriction.  100 Normal, no complaints, no evidence of disease. 90Able to carry on normal activity; minor signs or symptoms of disease. 1Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80Normal activity with effort; some signs or symptoms of disease. 70Cares for self, unable to carry on normal activity or to do active work.  2In bed < 50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% if waking hours. 60Requires occasional assistance, but is able to care for most of his/her needs. 50Requires considerable assistance and frequent medical care. 3In bed > 50% of the time. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and assistance. 30 Severely disabled, hospitalization indicated. Death not imminent. 4100% bedridden. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 20Very sick, hospitalization indicated. Death not imminent.  10Moribund, fatal processes progressing rapidly.5Dead.0Dead APPENDIX II SUBJECT PILL DIARY Revise the areas in red to fit the protocol. Delete #2 under instructions and the second column of pills if only one mg or one agent is used. Add additional columns and rows as needed for multiple agents/longer cycles. Subject Name ________________________Protocol #________________ Subject Study ID __________ Cycle #: _______ Month #: _______ INSTRUCTIONS FOR THE SUBJECT: 1. You will take  FORMTEXT # of  tablets of  FORMTEXT ____ mg  FORMTEXT record agent pills each day. Take the tablets [on an empty stomach / with a full glass (8 ox) of water / before or 2 hours after meals / with or without food, as you wish]. 2. You will take  FORMTEXT # of  tablets of  FORMTEXT ____ mg  FORMTEXT record agent pills each day. Take the tablets [on an empty stomach / with a full glass (8 ox) of water / before or 2 hours after meals / with or without food, as you wish]. 3. Record the date, the number of tablets you took, and what time you took them. 4. If you have any comments please record them in the Comments column below. 5. Please bring your pill bottle and this form to your physician when you come for your next appointment. 6. Please sign your name at the bottom of the diary.DateDay# of  FORMTEXT _____ mg  FORMTEXT record agent pills and time taken # of  FORMTEXT _____ mg  FORMTEXT record agent pills and time takenComments12345678910111213141516171819202122232425262728Add/remove days as neededSubjects Signature: ________________________________________ Date: ___________ APPENDIX III SUBJECT PILL DIARY FOR TWICE DAILY DOSING Add or delete columns and rows and revise the information in red as appropriate for the trial. Subject Name ______________________ Subject Study ID __________ Todays date ___/___/___ Drug _____________________________ Cycle #:_______________________________ INSTRUCTIONS FOR THE SUBJECT: 1. Complete one form every 4 weeks (one treatment cycle). 2. You will take  FORMTEXT record agent tablets twice each day about 12 hours apart. Take the tablets [on an empty stomach / with a full glass (8 ox) of water / before or 2 hours after meals / with or without food, as you wish]. Morning dose: take  FORMTEXT # of   FORMTEXT ____ mg tablet(s) [if applicable, and  FORMTEXT # of   FORMTEXT ____ mg tablet(s)] Evening dose: take  FORMTEXT # of   FORMTEXT ____ mg tablet(s), [if applicable, and  FORMTEXT # of   FORMTEXT ____ mg tablet(s)] 3. Record the date, the number of tablets of each size that you took, and what time you took them. 4. If you have any comments or notice any side effects, please record them in the Comments column. 5. Please bring this form and your bottle(s) of  FORMTEXT record agen to your physician when you return for-0:;<   ` b c ȶȓrarRr?$h&=h&=5B*OJQJaJphh hY`0JOJQJaJ!hY`hY`B*OJQJaJphhY`B*OJQJaJph$jhY`B*OJQJUaJph!h&=h&=B*OJQJaJph"h&=6B*CJOJQJaJph"hv6B*CJOJQJaJph(hN&hN&6B*CJOJQJaJph$h&=h&=5B*OJQJaJphh/5B*OJQJaJph-;< S T d]^gd&=$d]^a$gdN&$d]^a$gd&=   S T    M شv\I88!h&=h&=B*OJQJaJph$h&=h&=>*B*OJQJaJph2jh$5B*OJQJUaJmHnHphu5jh&=h&=B*OJQJUaJmHnHphuhLB*CJOJQJaJph%h&=h&=B*CJOJQJaJph!h&=h&=B*OJQJaJph$h&=h&=5B*OJQJaJph$h&=h&=5B*OJQJaJph'hY`h&=5>*B*OJQJaJph +$ # 8 xHX 0d@&]^`0a$gd&=d]^gd&=  M N l m | } %$ # 8 xHX d]^a$gd&=+$ # 8 xHX pd@&]^p`a$gd&=+$ # 8 xHX 0d@&]^`0a$gd&= M N g h k l m z { | } )ϾyhWFy3y$h&=h&=>*B*OJQJaJph!h&=h&=B*OJQJaJph!h[9jh&=B*OJQJaJph33!h&=h&=B*OJQJaJph!h&=h&=B*OJQJaJph$h&=h&=>*B*OJQJaJph$h&=h,^g>*B*OJQJaJphh,^gB*OJQJaJph!h,^gh,^gB*OJQJaJph!h,^gh,^gB*OJQJaJphh,^g>*B*OJQJaJphh&=>*B*OJQJaJph )+PQ_)$ # 8 xHX d]^`a$gd&=%$ # 8 xHX d]^a$gd&=%$ # 8 xHX d]^a$gd&=)$ # 8 xHX pd]^p`a$gd&= )+OPQi~GSi%(kanr*=>\}p]J]]$h&=h&=>*B*OJQJaJph$h&=h&=>*B*OJQJaJphh&=h&=OJQJaJhN&B*OJQJaJph!h&=h&=B*OJQJaJph!h&=h&=B*OJQJaJph'h&=h&=5>*B*OJQJaJph'h&=h&=5>*B*OJQJaJph* *h&=h&=5>*B*OJQJaJph'h&=h&=56B*OJQJaJph3f:HIi(mn%$ # 8 xHX d]^a$gd&=%$ # 8 xHX  d]^ a$gd&=n2yab*+^%$ # 8 xHX  d]^ a$gd&=($$ # 8 xHX d@&]^a$gd&=%$ # 8 xHX d]^a$gd&=\-<?ݶʌyeRʌye$h&=h&=6B*OJQJaJph'h&=h&=56B*OJQJaJph$h&=h&=5B*OJQJaJph*h&=h&=56>*B*OJQJaJph'h&=h&=56B*OJQJaJph'h&=h&=56B*OJQJaJph3f$h&=h&=>*B*OJQJaJph!h&=h&=B*OJQJaJph!h&=h&=B*OJQJaJph*-d'$ # 8 xHX d@&]^a$gd&=($ 8 HX  Xd]^ `Xa$gd&=%$ # 8 xHX d]^a$gd&=%$ # 8 xHX  d]^ a$gd&= 345678Z[\$a$gdv$d]^a$gd&=($ & 8 xHX d@&]^a$gd&='$ # 8 xHX d@&]^a$gd&=7023acegikmnov}Ƕ}iiUiiiB$h&=h&=>*B*OJQJaJph'h&=h&=B*OJQJ\]aJph'h&=h&=B*OJQJ\]aJph$h&=h&=5B*CJOJQJph$h&=h&=6B*OJQJaJph$h&=h&=6B*OJQJaJph!h&=h&=B*OJQJaJph$h&=h&=5B*OJQJaJphhvB*OJQJaJphhvhvOJQJhvhv5OJQJ $d$If]^a$gd&=$d7$8$H$]^a$gd&=$d]^a$gd&=$a$gdv 0iRRR$d$If]^a$gd&=kd$$Ifl44hF}$ $l t0$    44 laf4ytg0123aE...$d$If]^a$gd&=kd$$Ifl4hF}$ $l  t0$    44 laf4pytgabcdekTTT$d$If]^a$gd&=kd$$Ifl4hF}$ $l t0$    44 laf4ytgefghikTTT$d$If]^a$gd&=kd$$Ifl4hF}$ $l t0$    44 laf4ytgijklmkTTT$d$If]^a$gd&=kdX$$Ifl4hF}$ $l t0$    44 laf4ytgmno}kXXXXX$d]^a$gd&=kd$$Ifl4hF}$ $l t0$    44 laf4ytg} ƶƉ~n]J10jh[9jh[9j5>*B*OJQJUaJph33$h[9jh[9j5B*OJQJaJph33!h[9jh[9jB*OJQJaJph33h[9j5B*OJQJaJphh&=5OJQJaJ$h&=h&=>*B*OJQJaJph3jh&=hv>*B*OJQJUaJphhv>*B*OJQJaJph-jh&=h&=>*B*OJQJUaJph!h&=h&=B*OJQJaJph!h&=h&=B*OJQJaJph'$ # 8 xHX d@&]^a$gdWZ'$ #  xHX d@&]^a$gd[9j'$ # 8 xHX d@&]^a$gdWZ 'GHgL϶wdSBSB1BSBSBS!h{h{B*OJQJaJph33!h[9jh[9jB*OJQJaJph33!h[9jh[9jB*OJQJaJph$h[9jh[9j5B*OJQJaJph$h[9jh[9j5B*OJQJaJph33-jh[9jh[9j5B*OJQJUaJph33(h[9jh[9j0J5B*OJQJaJph330jh[9jh[9j5>*B*OJQJUaJph336jh[9jh[9j5>*B*OJQJUaJph33'h[9jh[9j5>*B*OJQJaJph33HX{kd$$Ifl0 t"u k t0"644 layt7+$ #  xHX d$@&If]^a$gd[9jHIdefgpXXXXXXX+$ #  xHX d$@&If]^a$gd[9j{kd$$Ifl0 t"u k t0"644 layt7LXXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7LMdzXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7z{ XXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7 >?gh  *+CDFGIK\ʺʧ}j$h&=h&=5B*OJQJaJph'h[9jh[9j5>*B*OJQJaJph*h[9jh[9j56>*B*OJQJaJph$h[9jh[9j6B*OJQJaJph33h[9j5B*OJQJaJph$h[9jh[9j5B*OJQJaJph!h[9jh[9jB*OJQJaJph!h[9jh[9jB*OJQJaJph33"  &'?XXXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7XXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7 XX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7  MXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7MNOXX+$ #  xHX d$@&If]^a$gd[9j{kd $$Ifl0 t"u k t0"644 layt7]]]6]'$ #  xHX d@&]^a$gd&='$ #  xHX d@&]^a$gd[9j{kd& $$Ifl0 t"u k t0"644 layt74$ #  xHX d$& #$/@&If]^a$b$gd[9j'$ #  xHX d@&]^a$gd[9j xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd $$Ifl0 t 6 0644 lae4yt7 >xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd;$$Ifl0 t 6 0644 lae4yt7>?DgxDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd$$Ifl0 t 6 0644 lae4yt7ghlxDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd_$$Ifl0 t 6 0644 lae4yt7xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd$$Ifl0 t 6 0644 lae4yt7xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd$$Ifl0 t 6 0644 lae4yt7xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd$$Ifl0 t 6 0644 lae4yt7 xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd$$Ifl0 t 6 0644 lae4yt7  *xDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd9$$Ifl0 t 6 0644 lae4yt7*+.CxDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd$$Ifl0 t 6 0644 lae4yt7CDEFxDD4$ #  xHX d$& #$/@&If]^a$b$gd[9jkd]$$Ifl0 t 6 0644 lae4yt7FGIJ]xQ**'$ #  xHX d@&]^a$gd&='$ #  xHX d@&]^a$gd[9jkd$$Ifl0 t 6 0644 lae4yt7\]r   h y } !!!1!!!!!!!!!ǶǨǨǨǨǶrdh&=B*OJQJaJphhVB*OJQJaJph'h&=h&=56B*OJQJaJph'h&=h&=56B*OJQJaJph3fhB*OJQJaJph!h&=h&=B*OJQJaJph!h&=h&=B*OJQJaJph$h&=h&=5B*OJQJaJph'h&=h&=5>*B*OJQJaJph!]^r   . J g h y !!1!$$  xHX d@&]^a$gd&='$ #  xHX d@&]^a$gd&=1!H!`!!!!!!!!","^""""#Q#u####$$  xHX d@&]^a$gd`a$$  xHX d@&]^a$gd&=!!^"b"""""""""##S#T#w#x####$$ $$$"$#$2$3$X$Y$$$$$$$$$$$$|k!h&=hf$B*OJQJaJphh&=B*OJQJaJph h9hH*!h&=h&=B*OJQJaJphhh1B*OJQJaJph$h&=h&=5B*OJQJaJph!h&=h&=B*OJQJaJph!hh1hh1B*OJQJaJphh`aB*OJQJaJphhh1B*OJQJaJph*###$ $0$V$$$$$$%:%R%S%r%%%&&$&:&H&I&&$$  xHX d@&]^a$gd&=$%R%r%x%%%%%%&$&I&c&d&&&'E'e'f''()) )))))))()ܾ{m{Z$h&=h*~5B*OJQJaJphh&=h&=5OJQJaJh&=hkp5OJQJaJh.8jh2O5OJQJaJhhkp5OJQJaJh5OJQJaJh.8jhkp5OJQJaJh.8jhAuOJQJaJ!h&=h&=B*OJQJaJph!h&=h&=B*OJQJaJph$h&=h&=5B*OJQJaJph &&'#'C'E'e'f'r't''(((((()))$  xHX @&^a$gdh1$$  xHX d@&]^a$gd&=))*)))))******+uuu ]^gdWZ$ h]^a$gdWZ$$   xHX d@&]^a$gd&=$ 8]^a$gdWZ'$ # 8 xHX d@&]^a$gdWZ ()))*)))**********+++++,,,,^-_-ŲťubRbbRbh&=5B*OJQJaJph$h&=h&=5B*OJQJaJphh.8jOJQJaJh&=OJQJaJh&=h&=5OJQJaJh&=h.8j5OJQJaJh.8jhIqOJQJaJ$h&=h&=5B*OJQJaJph!h&=h&=B*OJQJaJph'h&=hkp56B*OJQJaJph3f*h&=h*~h*~5B*OJQJaJph+++,,,^-_-o---N.O.g...$$   xHX d@&]^a$gd9$$  xHX d@&]^a$gd&=$$   xHX d@&]^a$gd&= ]^gdWZ_-o---L.O.g....//////////X0Y0Z0x0y0z0{000051˴ww˴]ww˴3j&h9hv>*B*OJQJUaJph$h9h9>*B*OJQJaJph3jh9hv>*B*OJQJUaJphhv>*B*OJQJaJph-jh9h9>*B*OJQJUaJph!h9h9B*OJQJaJph!h9h9B*OJQJaJph$h9h95B*OJQJaJph.////z0{000W1h111122 3e3f333Z4[4x4 ]^gdWZ$$   xHX d@&]^a$gd9516171U1V1W1h111122 3f3n333Z4[4x4444 5'555λλvccYcEc' *h9h9>*B*OJQJaJphh.8jOJQJaJ$ *h9h9B*OJQJaJph!h9h9B*OJQJaJphh95B*OJQJaJph!h9h9B*OJQJaJph$h9h95B*OJQJaJph$h9h9>*B*OJQJaJph-jh9h9>*B*OJQJUaJph3jh9hv>*B*OJQJUaJphx4445 5556668888899::T:U::d]^gd9$d]^a$gd9$$   xHX d@&]^a$gd9556666666889::U:e:::; ;;1;h;;;;;;;<^==>>>>>6???AA6ؾ蚇vvvvvvvvvv!99*ϴ$995B*ϴ!99*ϴ$99>**ϴ39>**ϴ>**ϴ-99>**ϴ.:::;;;;;;;;;;;;<<<^=_===>>$d]^a$gd$d]^a$gd9d]^gd9>i>>>6???@^@AA6BrBBCCCCDDBEEE$ & F"d]a$gd$d]^a$gd$ & F"d]^`a$gdCPCpCDDDGG(H)H/HdHfHIOIPIUIWIXIII#KwKKLݼrdS@$h9h95B*OJQJaJph!h9hB*OJQJaJphh{B*OJQJaJphh<h{B*OJQJphh<h{OJQJhB*OJQJaJph!hh9B*OJQJaJph!hh9B*OJQJaJphhsB*OJQJaJph$h9h95B*OJQJaJph!h9h9B*OJQJaJph!h9h9B*OJQJaJphEFfFFZGG(H)HeHfHHHPIQI$a$gd{$ & F"hd]^ha$gd<$d]^a$gd<$ & F"d]^`a$gd$d]^a$gd$ & F"d]a$gd QIIIIJJ#K$KwKKKLLMMNNOO$d]^a$gd$ & F#d]^`a$gd$d]^a$gd9$ & F"d]^`a$gdLLLLMNiOpOOSPTPUPVPQQQSSlTmTsVyVVVVV W)W+WMWXWYWWWWWƹݘqݘ]'h9h956B*OJQJaJph3f$h9h95B*OJQJaJph'h9h9>*B*OJQJ]aJph$h9h95B*OJQJaJphh9B*OJQJaJphh9hOJQJaJh9OJQJaJh9h9OJQJaJ!h9h9B*OJQJaJph!h9h9B*OJQJaJph#OUPVPzQ{QQQ!RSSlTmTTsVtVVVV+WMWNWW$d]^a$gd9$d]^a$gd$ & F#d]^`a$gdWWWiXjX Y Y;YZ?ZRZZ[~$ & Fd]a$gdS$d]^a$gdS ]^gdWZ$d]^a$gd9$ d]^a$gd9!  xHX d@&]^gd9WWXXXY YYYY>Z?ZCZQZRZ[Z[,[4[G[s[[\\د鑆{m\N\N\N\@h.8jhS5OJQJaJhSB*OJQJaJph!hShSB*OJQJaJphhyB*OJQJaJphh.8j5OJQJaJh6G5OJQJaJh5OJQJaJ$h9h95B*OJQJaJph* *h9h95>*B*OJQJaJph$h9h95B*OJQJaJph!h9h9B*OJQJaJph!h9h9B*OJQJaJph h9hH*[-[H[`[[[[\\\\\]]]]^ ]^gd`a & F ]^`gdOU ]^gdWZ$d]^a$gdS$d]a$gdS$ & Fd]a$gdS\\\\\]]]]^^^D_J_x___````(`)`K`[`ǶǶǶǶqqaP?!hr95>*B*OJQJaJph!hNlX5>*B*OJQJaJphhNlX5B*OJQJaJph$hshq5B*OJQJaJph$hshq5B*OJQJaJphhqB*OJQJaJph!hh`aB*OJQJaJph!hh`aB*OJQJaJphh`aB*OJQJaJphhqh.8j5OJQJaJhqhF~5OJQJaJhqhU5OJQJaJ^^^B_D_x___`aa.a7aaaabbbbbUccd$d]^a$gdq ]^gdWZ ]^gd`a[`o````aaa,a.a5a6a7aLaaaaaaaa5bbbbbb=cScUccʹp__p__p_QhINB*OJQJaJph!hqhqB*OJQJaJph' *hqhq>*B*OJQJaJph$hqhq5B*OJQJaJph'hqhq5>*B*OJQJaJphhqB*OJQJaJph!hqhqB*OJQJaJph$hshq5B*OJQJaJph!hr95>*B*OJQJaJph!hNlX5>*B*OJQJaJphccccdddddeeee1eeeeeee fMfNfPf̻p`pRBhg5B*OJQJaJphhWB*OJQJaJph *hWB*OJQJaJph$ *hqhqB*OJQJaJph!hqhqB*OJQJaJph$ *hqhqB*OJQJaJph'hqhq5>*B*OJQJaJph!hqhqB*OJQJaJph$hshq5B*OJQJaJph!h>5>*B*OJQJaJphh>5B*OJQJaJphddddeeeeeeMfNfzfgg$ h8d]^a$gdg hd]^gdg$d]^a$gdg$ h]^a$gdK$d]^a$gdqPfQfjfzfggggRgSgggiiij j!jjjjjʹrr]r]rM=h6(5B*OJQJaJphhg5B*OJQJaJph(hghg>*B*EHOJQJaJph%hghgB*EHOJQJaJph(hghg5B*EHOJQJaJphhGwB*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJph$hghg5B*OJQJaJph$hghg5B*OJQJaJphhs5B*OJQJaJphg9gRgSg^ggfK h8d$If]^gdg{kd5$$IflX0 Y! h044 laIytg$ h8d$If]^a$gdggggghihM.. & F 8d$1$If]^gdg h8d$If]^gdg$ h8d$If]^a$gdgykd$$Ifl0 Y! h044 laIytgiiijhM h8d$If]^gdg$ h8d$If]^a$gdgykdG$$Ifl0 Y! h044 laIytgj jhjjhM h8d$If]^gdg$ h8d$If]^a$gdgykd$$Ifl0 Y! h044 laIytgjjjjj8kllmm]msssss\sss$  d]^a$gdg$d]^a$gdgykdO$$Ifl0 Y! h044 laIytg jjjj8klmmmmm]mnnnooooopqrqsqqqqsڹڹ~mWDڨ$hghg5B*OJQJaJph* *hghg5>*B*OJQJaJph!hgh2B*OJQJaJph*hghg5>*B*OJQJ]aJph'hghg5>*B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJphhs5B*OJQJaJph$hghg5B*OJQJaJph$hgh6(5B*OJQJaJph]mnnooooqpqq"r#r:r;rrrrrssss6t7ttt$d7$8$H$]^a$gdg$d]^a$gdgssss sss6tgvivjvvx2yqyzzzzr{|{}}}}}~dzݠ|n[ݠ$hghg5B*OJQJaJphh2B*OJQJaJph'hghg5>*B*OJQJaJphhs5B*OJQJaJph$hghg5B*OJQJaJph'hghg5>*B*OJQJaJph* *hghg5>*B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJpht/u0u{u|uuuufvgvvwwxxsytyzzzD|E|$ d]^a$gdg$0d]^`0a$gdg$d]^a$gdgE|||(})}}}}}~~m$ hd]^a$gdg"$ xHX d@&]^a$gdg'$ #  xHX d@&]^a$gdg$d]^a$gdg 8d]^gdg ~~~~~~ ~|~~QS˸v^I^I^;hghgOJQJ\aJ)hg5B*OJQJ\aJmH phsH /hghg5B*OJQJ\aJmH phsH )hh15B*OJQJ\aJmH phsH h2B*OJQJaJphhgB*OJQJaJph!hghgB*OJQJaJph$hghg6B*OJQJaJph3fhgB*OJQJaJph!hghgB*OJQJaJph*hghg5B*OJQJ\]aJph~~~~~/0RSŃƃ$d7$8$H$]^a$gdg$ d@&]^a$gdg"$ xHX d@&]^a$gdg"$ HX d@&]^a$gdgƃ !>@V[\Džͅ΅υԅK89{|+,1PRSYp !{ҿҿҿҿқҿқҿқққққҿ҈ҿ҈ҿ҈w!hghgB*OJQJaJph$hghg>*B*OJQJaJph'hghg5>*B*OJQJaJphhg5B*OJQJaJph$hghg5B*OJQJaJph!hghgB*OJQJaJphhghgOJQJaJhghg5OJQJ\aJ,ƃ>υ9|,S !{$d7$8$H$]^a$gdg$ & Fd ]a$gdg$d ]^a$gdg$ & Fd ]a$gdg$ & Fd ]a$gdg$d ]^a$gdg{>?TUWXuiq̓Ԕ2345JP_˸˸ܥ˂˥r˥˥_QhxB*OJQJaJph$hghg5B*OJQJaJphhx5B*OJQJaJph$ *hghgB*OJQJaJphhg5B*OJQJaJph$hghg5B*OJQJaJph%hghg@B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJph$ *hghgB*OJQJaJph{ TUuِؐђww_$ & F d1$]a$gdg$ d1$]^a$gdg"$ xHX d@&]^a$gdg$d ]^a$gdg$d7$8$H$]^a$gdg & F hd]gdgd]^gdg ђ$7̓”Ô_`yz34ėŗ$ h8d]^a$gdg$d7$8$H$]^a$gdg$ d1$]^a$gdg$ & F d1$]a$gdg_yy3?ڗ FT}Ękmn *ʚ͚Κz±Ž±raŽVhghgOJQJ!hgh=B*OJQJaJphh>vB*OJQJaJphh=B*OJQJaJphhg5B*OJQJaJph$hghg>*B*OJQJaJph!hghgB*OJQJaJph$hghg5B*OJQJaJphhghgOJQJ\aJhghgOJQJaJhghg5OJQJ\aJ ŗ4hjk ʚ˚%$ # 8 xHX d]^a$gdg$ h8d]^a$gdg$ & F h8d]a$gdgz<D۞IVW ֡ס ?@ɹܨܑ~mZJZhP#Z5B*OJQJaJph$hghg5B*OJQJaJph!hghgB*OJQJaJph$hghg5B*OJQJaJph-hghg56B*OJQJ\]aJph!hghgB*OJQJaJphhP#Z5B*OJQJaJph$hghg5B*OJQJaJph!hghgB*OJQJaJphhghgOJQJhxOJQJ۞Iԟ zWW"$ vHX d@&]^a$gdg & F vX d@&]gdg $ & F FX d@&]a$gdg"$ xHX d@&]^a$gdg"$ xHX d@&]^a$gdg ֡ס ?@hd$ hd]^a$gdg$ & Fdx]a$gdg$d]^a$gdg"$ & F HX d@&]a$gdg$ d1$]^a$gdg & F HX d@&]gdg @BCg?@֥ץ-.ɲxggYgYF$h,Bh,B>*B*OJQJaJphh,BB*OJQJaJph!hghgB*OJQJaJph$hghP#Z5B*OJQJaJph$hghg5B*OJQJaJph&hP#Z5B*OJQJaJmH phsH ,hghg5B*OJQJaJmH phsH !hghgB*OJQJaJph!hP#Z5B*OJQJ\aJph'hghg5B*OJQJ\aJph@֥ץ+,Hyz+,$d]^`a$gdgd]^gdg$d]^a$gdg+,FGO*,67^`uvmo˸˔ˁ˔˔˔˔˔kW'hghg5>*B*OJQJaJph* *hghg5>*B*OJQJaJph%hghgB*OJQJ^JaJph'hghg5>*B*OJQJaJphh,B5B*OJQJaJph$hghg5B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJph$h,Bhg>*B*OJQJaJph"`noLMpq:;ubcd]^gdg$d]^a$gdgKL&'6Xp,.9:Ptucst׳wɶɠɶllɌ$hghg>*B*OJQJaJphhghgOJQJaJ'hghg5>*B*OJQJaJph* *hghg5>*B*OJQJaJph$hghg>*B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJph'hghg5>*B*OJQJaJph#ֳ׳vwxy$d]^`a$gdgd]^gdg$d]^a$gdgĶ/0vy ͺκde˻ )>?۴۴ۣ۴ۣ۴ۣ۴ۣy۴ۣۣfyfۣ$hghg>*B*OJQJaJph'hghg5>*B*OJQJaJph* *hghg5>*B*OJQJaJph!hghgB*OJQJaJph'hghg5>*B*OJQJaJph$hghg5B*OJQJaJph!hghgB*OJQJaJph%hghgB*OJQJ^JaJph'ef()RSz{$d]^a$gdgRh{̻̗p̪]J$hghg5B*OJQJaJph%hghgB*OJQJ^JaJph$hghg>*B*OJQJaJph'hghg5>*B*OJQJaJph$hghg>*B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJph'hghg5>*B*OJQJaJph!hghU1B*OJQJaJphhgB*OJQJaJphstRSu>?_>? |d]^`|gdg$d]^a$gdgd]^gdgRSu?_yz̹ڨڨڨڨڨscPڨڨ$hghg5B*OJQJaJphhU15B*OJQJaJph!hghgB*OJQJaJph$hghg>*B*OJQJaJph!hghgB*OJQJaJph!hghgB*OJQJaJph$hghg5B*OJQJaJphhgB*OJQJaJph!hghgB*OJQJaJph'hghg5>*B*OJQJaJph!"yz d]^gdg$ d]^a$gdg$d]^a$gdg >ijRSTc$d]^a$gdP#Z ]^gdWZd]^gdg>ппбпбЂoаH'##56B*ϴ3$##>**ϴ$#6(5B*ϴ#5B*ϴ!#,*ϴ,*ϴ#*ϴ!##*ϴ!##*ϴ$##5B*ϴ)5Oϴ7:<@mprֲ֟ŲֲֲŲ|hS?'hP#ZhP#Z56B*OJQJaJph3f(hP#ZhP#Z5B*CJ OJQJaJ ph'hP#ZhP#Z5>*B*OJQJaJph$hP#ZhP#Z5B*OJQJaJphh,B5B*OJQJaJph$hP#ZhP#Z>*B*OJQJaJph$hP#ZhP#Z5B*OJQJaJph!hP#ZhP#ZB*OJQJaJph'hP#ZhP#Z5>*B*OJQJaJph* *hP#ZhP#Z5>*B*OJQJaJph%[ 12`a5$$d<@&]^a$gdP#Zd]^gdP#Z$0d]^0`a$gdP#Z$d]^a$gdP#Z dg`aGHst89]^afŴwc'hP#ZhP#ZB*OJQJ\]aJph'hP#ZhP#Z5B*OJQJ\aJph$hP#ZhP#ZB*OJQJ\aJph h9hH*!hP#ZhP#ZB*OJQJaJph!hP#ZhP#ZB*OJQJaJph'hP#ZhP#Z56B*OJQJaJph'hP#ZhP#Z5>*B*OJQJaJph$hP#ZhP#Z5B*OJQJaJph"45=>FZ[ Ӿ꾖r_R_>_>'hP#ZhP#Z5>*B*OJQJaJphhP#ZhP#ZOJQJaJ$hP#ZhP#Z5B*OJQJaJph$hP#ZhP#Z>*B*OJQJaJph!hP#ZhP#ZB*OJQJaJph'hP#ZhP#ZB*OJQJ\]aJph3f'hP#ZhP#ZB*OJQJ\]aJph)hP#ZhP#ZB*OJQJaJmH phsH -hP#ZhP#Z5>*B*OJQJ\]aJph*hP#ZhP#Z>*B*OJQJ\]aJph5O=>[zdd$$d@&]^a$gdP#Z$d7$8$H$]^a$gdP#Z$d]^a$gdP#Z$ d]^a$gdP#Z$d<]^a$gdP#Z$$d<@&]^a$gdP#Z$d]^a$gdP#Z RmQR $a$gdP#Zm$$ & F d]a$gdP#Zm$$ & F d]a$gdP#Zm$$ & F Ld]^`La$gdP#Zm$$d]^a$gdP#Zd]^gdP#Z QRvIs01Ǵn[G'hP#ZhP#Z5B*OJQJ]aJph$hP#ZhP#Z6B*OJQJaJph$hP#ZhP#Z>*B*OJQJaJph!hP#ZhP#ZB*OJQJaJph$hP#ZhP#Z5B*OJQJaJphhP#ZhP#ZB*OJQJph$hP#ZhP#ZB*OJQJ\aJph$ *hP#ZhP#ZB*OJQJaJph'hP#ZhP#Z56B*OJQJaJph!hP#ZhP#ZB*OJQJaJphwad8]^`gdP#Z & F!Ld]^`LgdP#Zm$d]^gdP#Z & F d]gdP#Zm$ ^gdP#Zm$Ld]^`LgdP#Z & F Ld]^`LgdP#Zm$$Ld]^`La$gdP#Z rs012;<$ & Fd]^`a$gdP#Z$d]^a$gdP#Z12:;<fX~fgdeԽl[[[[[[[[[[[[!hP#ZhP#ZB*OJQJaJph'hP#ZhP#Z5>*B*OJQJaJph$hP#ZhP#Z5B*OJQJaJph$hP#ZhP#Z6B*OJQJaJph,hP#ZhP#ZB*OJQJ]aJmHphsH-hP#ZhP#Z5>*B*OJQJ\]aJph0 *hP#ZhP#Z5>*B*OJQJ\]aJph$hP#ZhP#ZB*OJQJ]aJph#;$d$If]^a$gdP#Z$d]^a$gdP#Z$d]^a$gdP#Z;WX^jr~m{kd$$Ifl0H$ t0644 laytP#Z$d$If]^a$gdP#Z~^GG33d$If]^gdP#Z$d$If]^a$gdP#ZkdH$$Ifl\H:$H t0644 laytP#Z.kd$$Ifl4h\H:$``H t0644 laf4ytP#Zd$If]^gdP#Z$d$If]^a$gdP#Z fd$If]^gdP#Z$d$If]^a$gdP#Zfghj !YBB.Bd$If]^gdP#Z$d$If]^a$gdP#Zkd$$Ifl4h\H:$  H t0644 laf4ytP#Z!$defg.kdM $$Ifl4\H:$``H t0644 laf4ytP#Zd$If]^gdP#Z$d$If]^a$gdP#Zghk.kd!$$Ifl4\H:$  H t0644 laf4ytP#Zd$If]^gdP#Z$d$If]^a$gdP#ZVWZd$If]^gdP#Z$d$If]^a$gdP#ZYB.BBd$If]^gdP#Z$d$If]^a$gdP#Zkd!$$Ifl4X\H:$``H t0644 laf4ytP#ZfE..$d$If]^a$gdP#Zkdf"$$Ifl4X\H:$  H t0644 laf4ytP#Zd$If]^gdP#Zfgjk.kd#$$Ifl4\H:$``H t0644 laf4ytP#Zd$If]^gdP#Z$d$If]^a$gdP#Zd$If]^gdP#Z$d$If]^a$gdP#ZRSYBB.Bd$If]^gdP#Z$d$If]^a$gdP#Zkd#$$Ifl4\H:$  H t0644 laf4ytP#ZSV.kd$$$Ifl4\H:$``H t0644 laf4ytP#Zd$If]^gdP#Z$d$If]^a$gdP#Z.kd2%$$Ifl4\H:$  H t0644 laf4ytP#Zd$If]^gdP#Z$d$If]^a$gdP#Z3kd%$$Ifl\H:$H t0644 laytP#Z$d$If]^a$gdP#Zd$If]^gdP#Z> !00d]0^0gdP#Z00d]0^0gdP#Z$d]^a$gdP#Zd]^gdP#Z$d]^a$gdP#Z<=NYiǴtaL9%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph$hP#ZhP#Z6B*OJQJaJph'hP#ZhP#Z56B*OJQJaJph+hP#ZhP#Z56B*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph3f%hP#ZhP#ZB*CJOJQJaJph$hP#ZhP#Z5B*OJQJaJph'hP#ZhP#Z5>*B*OJQJaJph!hP#ZhP#ZB*OJQJaJph ] fO$d$If]^a$gdP#Zmkd)$$Ifl0(* t0*44 lap ytP#Zd$If]^`gdP#Zd$If]^gdP#Z պՆsZE(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph4j'hP#ZhP#ZB*CJOJQJUaJph0hP#ZhP#ZB*CJOJQJaJmHnHphu4j&hP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph.jhP#ZhP#ZB*CJOJQJUaJph ʰʚoTo;o0hP#ZhP#ZB*CJOJQJaJmHnHphu4j(hP#ZhP#ZB*CJOJQJUaJph.jhP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph3hP#ZhP#Z6B*CJOJQJaJmHnHphu1jhP#ZhP#Z6B*CJOJQJUaJph7j'hP#ZhP#Z6B*CJOJQJUaJphԍx_J._7j)hP#ZhP#Z6B*CJOJQJUaJph(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph(hP#ZhP#Z5B*CJOJQJaJph0hP#ZhP#ZB*CJOJQJaJmHnHphu4j(hP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph.jhP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph $\]̷{eP?*(hP#ZhP#Z5B*CJOJQJaJph!hP#ZhP#ZB*OJQJaJph(hP#ZhP#Z5B*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph%hP#ZhP#ZB*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph3hP#ZhP#Z6B*CJOJQJaJmHnHphu ]$d$If]^a$gdP#Z$ Ld$If]^a$gdP#Z$d$If]^a$gdP#Z$Hd$If]^H`a$gdP#Z !"'(,-789EFպs^Bs(s3hP#ZhP#Z6B*CJOJQJaJmHnHphu7j*hP#ZhP#Z6B*CJOJQJUaJph(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph(hP#ZhP#Z5B*CJOJQJaJph0hP#ZhP#ZB*CJOJQJaJmHnHphu4j,*hP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph.jhP#ZhP#ZB*CJOJQJUaJph FGbcmnotuyzԼu\G+\7j+hP#ZhP#Z6B*CJOJQJUaJph(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph0hP#ZhP#ZB*CJOJQJaJmHnHphu4j>+hP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph.jhP#ZhP#ZB*CJOJQJUaJph(hP#ZhP#Z5B*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph  !")*129:ABIJQR̶}}}}}}}}}}}}}}}}}}}}}}!hP#ZhP#ZB*OJQJaJph%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph3hP#ZhP#Z6B*CJOJQJaJmHnHphu12d$If]^gdP#ZkdP,$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd:-$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd.$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd/$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd/$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd0$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd1$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd2$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkdv3$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#ZkdZ4$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd>5$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd"6$$Iflr0l(8   t0*44 lap2ytP#Z d$If]^gdP#Z$Hd$If]^Ha$gdP#Z 2d$If]^gdP#Zkd7$$Iflr0l(8   t0*44 lap2ytP#Z d$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd7$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#Zkd8$$Iflr0l(8   t0*44 lap2ytP#Z !d$If]^gdP#Z$Hd$If]^Ha$gdP#Z!"#2d$If]^gdP#Zkd9$$Iflr0l(8   t0*44 lap2ytP#Z#&'()d$If]^gdP#Z$Hd$If]^Ha$gdP#Z)*+2d$If]^gdP#Zkd:$$Iflr0l(8   t0*44 lap2ytP#Z+./01d$If]^gdP#Z$Hd$If]^Ha$gdP#Z1232d$If]^gdP#Zkdz;$$Iflr0l(8   t0*44 lap2ytP#Z36789d$If]^gdP#Z$Hd$If]^Ha$gdP#Z9:;2d$If]^gdP#Zkd^<$$Iflr0l(8   t0*44 lap2ytP#Z;>?@Ad$If]^gdP#Z$Hd$If]^Ha$gdP#ZABC2d$If]^gdP#ZkdB=$$Iflr0l(8   t0*44 lap2ytP#ZCFGHId$If]^gdP#Z$Hd$If]^Ha$gdP#ZIJK2d$If]^gdP#Zkd&>$$Iflr0l(8   t0*44 lap2ytP#ZKNOPQd$If]^gdP#Z$Hd$If]^Ha$gdP#ZQRS2d$If]^gdP#Zkd ?$$Iflr0l(8   t0*44 lap2ytP#ZSVWXYd$If]^gdP#Z$Hd$If]^Ha$gdP#ZRYZabijqryzƳۏycO'hP#ZhP#Z5>*B*OJQJaJph*hP#ZhP#Z5>*B*OJQJ\aJph+ *hP#ZhP#Z5B*CJOJQJaJph$hP#ZhP#Z5B*OJQJaJph!hP#ZhP#ZB*OJQJaJph3f%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph!hP#ZhP#ZB*OJQJaJph%hP#ZhP#ZB*CJOJQJaJphYZ[2d$If]^gdP#Zkd?$$Iflr0l(8   t0*44 lap2ytP#Z[^_`ad$If]^gdP#Z$Hd$If]^Ha$gdP#Zabc2d$If]^gdP#Zkd@$$Iflr0l(8   t0*44 lap2ytP#Zcfghid$If]^gdP#Z$Hd$If]^Ha$gdP#Zijk2d$If]^gdP#ZkdA$$Iflr0l(8   t0*44 lap2ytP#Zknopqd$If]^gdP#Z$Hd$If]^Ha$gdP#Zqrs2d$If]^gdP#ZkdB$$Iflr0l(8   t0*44 lap2ytP#Zsvwxyd$If]^gdP#Z$Hd$If]^Ha$gdP#Zyz{2d$If]^gdP#Zkd~C$$Iflr0l(8   t0*44 lap2ytP#Z{~d$If]^gdP#Z$Hd$If]^Ha$gdP#Z2d$If]^gdP#ZkdbD$$Iflr0l(8   t0*44 lap2ytP#Zd$If]^gdP#Z$Hd$If]^Ha$gdP#Z2$d$If]^a$gdP#ZkdFE$$Iflr0l(8   t0*44 lap2ytP#Z.9mmm]]F !#00d]0^0gdP#Z00d]0^0gdP#Z$d]^a$gdP#Zd]^gdP#Zokd*F$$Ifl0(* t0*44 lap ytP#Z&.klop#389Wvذ؟ċwwdO<%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph$hP#ZhP#Z6B*OJQJaJph'hP#ZhP#Z56B*OJQJaJph'hP#ZhP#Z56B*OJQJaJph3f!hP#ZhP#ZB*OJQJaJph'hP#ZhP#Z5>*B*OJQJaJph'hP#ZhP#Z56B*OJQJaJph$hP#ZhP#Z5B*OJQJaJph'hP#ZhP#Z5>*B*OJQJaJph9W#NOfmkdK$$Ifl0(* t0*44 lap ytP#Zd$If]^`gdP#Zd$If]^gdP#Z v}ֽr\G(hP#ZhP#Z>*B*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph3hP#ZhP#Z6B*CJOJQJaJmHnHphu7jFhP#ZhP#Z6B*CJOJQJUaJph(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJphպՆpZp?p4jJHhP#ZhP#ZB*CJOJQJUaJph+hP#ZhP#Z56B*CJOJQJaJph3f+hP#ZhP#Z56B*CJOJQJaJph4jGhP#ZhP#ZB*CJOJQJUaJph0hP#ZhP#ZB*CJOJQJaJmHnHphu4jHGhP#ZhP#ZB*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph.jhP#ZhP#ZB*CJOJQJUaJph   '.:;<FGHMNQR\պՋu`ՋE4jLIhP#ZhP#ZB*CJOJQJUaJph(hP#ZhP#Z>**䴳ϴ+##56B*䴳ϴ3+##56B*䴳ϴ0##*䴳ϴԱu4H##*䴳ϴ%##*䴳ϴ.##*䴳ϴʹ͡܋͡ʹ͋͡?ʹ͡4J##*䴳ϴ4ᱷ##*䴳ϴ+##56B*䴳ϴ3+##56B*䴳ϴ%##*䴳ϴ0##*䴳ϴԱu.##*䴳ϴ4I##*䴳ϴíÕÀjQ<(hP#ZhP#Z6B*CJOJQJaJph1jhP#ZhP#Z6B*CJOJQJUaJph+hP#ZhP#Z56B*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph.hP#ZhP#Z56>*B*CJOJQJaJph3f+hP#ZhP#Z56B*CJOJQJaJph%hP#ZhP#ZB*CJOJQJaJph%hP#ZhP#ZB*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph3f MOʰʝu\u@\7jOhP#ZhP#Z5B*CJOJQJUaJph1jhP#ZhP#Z5B*CJOJQJUaJph(hP#ZhP#Z5B*CJOJQJaJph!hP#ZhP#ZB*OJQJaJphU%hP#ZhP#ZB*CJOJQJaJph3hP#ZhP#Z6B*CJOJQJaJmHnHphu1jhP#ZhP#Z6B*CJOJQJUaJph7jPKhP#ZhP#Z6B*CJOJQJUaJph each appointment. 6. Please sign your name at the bottom of the diary.DayDateTime of morning dose# of tablets takenTime of evening dose# of tablets taken Comments FORMTEXT ___ mg FORMTEXT ___ mg FORMTEXT ___ mg FORMTEXT ___ mg12345678910111213141516171819202122232425262728Add/remove days as neededSubjects Signature: ____________________________________________ Date: _____________      EMBED Word.Document.8 \s  EMBED Word.Document.8 \s  EMBED Word.Document.8 \s  PAGE 3 CASE XXXX Page  PAGE 4  COMMENTS "Version date:" \* FirstCap Version date: mm.dd.yyyy OSXhmiR$d$If]^a$gdP#Z$ d$If]^a$gdP#Z$Ld$If]^La$gdP#Z$L(d$If]L^(a$gdP#Z$ `L(d$If]L^(a$gdP#Z$ d$If]^a$gdP#Z$d$If]^a$gdP#Z  $ `d$If]^a$gdP#Z$d$If]^`a$gdP#Z$d$If]^a$gdP#Z$d$If]^a$gdP#ZFfM$d$If]^a$gdP#Z̷̷̢s̢W̢̢7jPhP#ZhP#Z5B*CJOJQJUaJph%hP#ZhP#ZB*CJOJQJaJph7jPhP#ZhP#Z5B*CJOJQJUaJph(hP#ZhP#Z5B*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph1jhP#ZhP#Z5B*CJOJQJUaJph3hP#ZhP#Z5B*CJOJQJaJmHnHphu ()56BCOP\]ijvwʰʛwwwwwwwwwwwwwwwwwwww!hP#ZhP#ZB*OJQJaJph%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph3hP#ZhP#Z5B*CJOJQJaJmHnHphu1jhP#ZhP#Z5B*CJOJQJUaJph7j QhP#ZhP#Z5B*CJOJQJUaJph.   !"FfW$d$If]^a$gdP#ZFfSd$If]^gdP#Z$d$If]^a$gdP#Z"#$%&'()+,-./012345689:;FfN_$d$If]^a$gdP#ZFf5[$d$If]^a$gdP#Z;<=>?@ABCEFGHIJKLMNOPRSTFfg$d$If]^a$gdP#ZFfgc$d$If]^a$gdP#ZTUVWXYZ[\]_`abcdefghijlmFfo$d$If]^a$gdP#ZFfk$d$If]^a$gdP#Zmnopqrstuvwyz{|}~Ffw$d$If]^a$gdP#ZFfs$d$If]^a$gdP#ZFf$d$If]^a$gdP#ZFf{$d$If]^a$gdP#ZFf/$d$If]^a$gdP#Z$d$If]^a$gdP#ZFfa$d$If]^a$gdP#Z$d$If]^a$gdP#ZFfHFf$d$If]^a$gdP#ZFfz$d$If]^a$gdP#Z   FfŜ$ `d$If]^a$gdP#ZFf$d$If]^a$gdP#Z   !"#$%Ff$ `d$If]^a$gdP#ZFfޠ$d$If]^a$gdP#Z+,9:GHUVcdqr~    ۰wswswswsi[jhP#ZCJOJQJUhP#ZCJOJQJhXLjhXLUhg5OJQJaJ$hP#ZhP#Z5B*OJQJaJph%hP#ZhP#ZB*CJOJQJaJph(hP#ZhP#Z5B*CJOJQJaJph+hP#ZhP#Z56B*CJOJQJaJph%hP#ZhP#ZB*CJOJQJaJph!hP#ZhP#ZB*OJQJaJph#%&'()*+,/0123456789:=>?@Ff)$d$If]^a$gdP#ZFf$d$If]^a$gdP#Z@ABCDEFGHKLMNOPQRSTUVYZ[Ff[$d$If]^a$gdP#ZFfB$d$If]^a$gdP#Z[\]^_`abcdghijklmnopqruvFf$d$If]^a$gdP#ZFft$d$If]^a$gdP#Zvwxyz{|}~Ff$d$If]^a$gdP#ZFf$d$If]^a$gdP#Z  hit}}}}}}}}{}r&`#$ ]^gdWZokd$$Iflp0(* t0*44 lap ytP#Z '()+EFGIcdefhijpqrstv|xnhn]nhxQBh&=hP#Z0JCJOJQJhv0JCJOJQJhP#Z0JmHnHu hP#Z0JjhP#Z0JUhP#Zj^hP#ZCJOJQJU*jVP hP#ZB*CJOJQJUVphjhP#ZCJOJQJU*j5VP hP#ZB*CJOJQJUVphjhP#ZCJOJQJUjhP#ZCJOJQJU*jVP hP#ZB*CJOJQJUVphhP#ZCJOJQJtuv ]^gdWZ`$a$gd&= ʵݖ{pf{bWhg5OJQJaJhXLhP#ZCJOJQJhP#Z<CJOJQJhP#ZhP#ZCJOJQJh&=hP#ZCJOJQJ%h&=hP#Z0JB*CJOJQJphh6G0JCJOJQJ(jh&=hP#Z0JCJOJQJU*$hZi0JCJOJQJmHnHu*h&=hP#Z0JCJOJQJ%jh&=hP#Z0JCJOJQJU@ 00&P1F:pQBP/ =!"#$% FR-hʙGn>,Photoshop 3.08BIM,,Ohttp://ns.adobe.com/xap/1.0/ CWRU Inamori black logo image/jpeg Adobe Illustrator CS4 2010-04-22T13:04:06-04:00 2010-04-22T17:04:07Z 2010-04-22T13:04:06-04:00 256 100 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAZAEAAwER AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAAAAAAQFAwIGAQAHCAkKCwEAAgIDAQEBAQEAAAAAAAAA AQACAwQFBgcICQoLEAACAQMDAgQCBgcDBAIGAnMBAgMRBAAFIRIxQVEGE2EicYEUMpGhBxWxQiPB UtHhMxZi8CRygvElQzRTkqKyY3PCNUQnk6OzNhdUZHTD0uIIJoMJChgZhJRFRqS0VtNVKBry4/PE 1OT0ZXWFlaW1xdXl9WZ2hpamtsbW5vY3R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo+Ck5SVlpeYmZ qbnJ2en5KjpKWmp6ipqqusra6voRAAICAQIDBQUEBQYECAMDbQEAAhEDBCESMUEFURNhIgZxgZEy obHwFMHR4SNCFVJicvEzJDRDghaSUyWiY7LCB3PSNeJEgxdUkwgJChgZJjZFGidkdFU38qOzwygp 0+PzhJSktMTU5PRldYWVpbXF1eX1RlZmdoaWprbG1ub2R1dnd4eXp7fH1+f3OEhYaHiImKi4yNjo +DlJWWl5iZmpucnZ6fkqOkpaanqKmqq6ytrq+v/aAAwDAQACEQMRAD8A9U4q7FXYq7FXYq7FXYq7 FXYq7FXhH/OTdnaXmqeSbe8j9a2eXUDLFyZeQWKJqclIYVp2OZuj5S+DiakWYvmiTV9PdW9Py9ZI rHijB74kE9Nzc0J+jM+j3uBxDuQbadey3F4qW3pmzDyXSA0SFUYIas7H9tgoq27EAVJGG0U+h/8A nDf/AKa//t3f9jWYOu6fFzdF1+D6I1iSSLSL6SNikiW8rI42IIQkEZhR5hzTySv8vru6vPIPlq7u 5XnurnSrKW4nkJZ3ke2RndmO5LE1Jw5RUj72OM3Ee5P8gzdirsVdirsVdirsVdirsVdirsVdirsV dirsVdirsVdirsVee3XmvWfNfnDUPKnle7/R1hoYUeYddRUkmE0lQtraLIGjDjiecjKeNKUr1yBA RjxS3vkGkzMpUOnNFX35Y3L2x/R3m7X7LUFBMV2961ynPsZLeQem61/ZHHAM3fEJOLuJTP8ALu58 1zeWY4/Ngrr1rPc211cCMRJOIpnWOeNQqDg8fEggCuQyiN+nknHxV6uababr2j6ndaha2F0lxcaX MLa/jStYpSgfiajf4W7d6jqCMiYkVfVkJA8uiVeYfzD8r6DeNY3k0817FGJ7i2sra4vHhgJ/vZhb pJ6ad6tSvbJRxSkLRLIBsgdS/OD8u9Mt7K6vtVMFrqMSz2Nwba6MUyOOQKOIipO+61qO+SGCZ5Bi c0RzKJ0T8z/I+uatFpGm6iZdRmR5Ird7e5hLLGKsQZY0XYe+CWGURZCY5Yk0Hnf/ADkRCZ/MfkSA Ghln1BAT0BaGIZkaTlL4NOo5x+LxzRfIzpBZ6xZQtPaQsuqWsKxmQySNaQtbwUO7j9ISpb9679cy 5T6fj8Vu4scfX8fi9ki1zRF0zSDprXCQWUEpbVdTB9Vr7UEBBgtVBHqxWvIrzB4cuTFvijXJRNm2 Eo0Kexf84i2wt5vNsYbkGi0iSp8ZYriQj6OWYmt6fFytGOfwe/a5/wAcTUP+Yab/AJNnMKHMOZLk lH5Z/wDkt/Kn/bG0/wD6hY8ll+s+8sMX0j3K/mTzx5V8tvDFrN+tvcXIJt7VEknuJFXqywQLJKVH iFplbYiPLnmny/5ksnvNFvFvII3MU1AyPHIACUkjkCSI1D0ZQcVRGla1perR3Emn3C3CWlxLZ3BT fhPA3GRD7qcVSSP8zvIknmIeXU1aM6sZWtli4SiNp0pyhWcp6JkFfsB+Xtiq29/NLyHZanPpdzqo S+tpfQnhEM78JNjxLLGy1+Id8VZVirsVdirsVdirsVdirsVdirsVdirsVdirsVeFf84yXckd7530 nUDTW4NUM14rn94xZnjc77njIhr8/fM3VjaJHJxNKfqHW3uuYTlsf84+b7Ly95W1TWkZbqSwUxR2 8Z5l7tiEigIU15NI6gjrvlmPGZSAYTnwgl4b+V+rxeUvzej097+e9s/OVnG97d3MM9vXV1BeQ/6R HEzcpS/Gg/3YormZmjxQuvp+5xMR4Z1/O+9knmj/AJWN+XPnvXvOWl6X/iPyrrvozapBGSLm3NtH wB2DMFReR5BSvH7XGgOVw4MkREmiGc+KEjICwUk/NvXvK+t/lB5S1Pyrb8NOGv26wWZAjeKT07hp IWqSFPP3p36ZPDGQyES7mOaQMAR3vXPL2r6/q3mF017yp+iDY2yzaffSyRXTc5maOVI5ogVQ8UXk oNaddsxZxAGxtyYkk7imDfnzI8fnH8u5ENHS8vWUkA7iOEjY7Zfpfpk1Z/qixf8AIj86dN1ZY/JX mW1tLSWQMmmXkESW0LsS0hjdI+CRvyYsjJxBPg1K2ajAR6otWnz36Swb81LS0jvJry3FvNZNygtN WlSe9QRIKLBA8MaabGlGqqxR1Txy/Edvx/a1Zh1/H6npn/OMH/HT80f8wHlz/qAfMXV8h8W/S8z8 Pue3a5/xxNQ/5hpv+TZzEhzDly5JR+Wf/kt/Kn/bG0//AKhY8ll+s+8sMX0j3JH5F+pt+YPnhr4j /EQvIVhWSnMaULaL6uYq/wC6zIZOXHbl13ytsTTz95mtfLHlfV9U0+KOXWX4W9rbxAGWa+uAsVqj KvxM1WU068Rirz38prj/AAt5ti0BrHU7Gw8w2Uchl1SAwerrNpH/AKU8ZLNX6xF8Z91wqjrD1PJa 2mqaVeWnmTyBrGrq9rG4BurKe/uGj52kwqk0YlfetGArQ9TiqK8oWXnebzJ5xk0XU7G00xfMUoub a5tJJ5nYWtqXKSLNGFBSgHwmh3wK9WxV2KuxV2KuxV2KuxV2KuxV2KuxVIfOd15tstGmvfLMNpd3 lqjyvY3ayVmCryCxPGw4vtQBlIPiMsxiJNSYTMgNmLfk3+Yev+f/AC/eazciysxFK9pHawxyu6TK quHkZpRyQhx8IA/1ssz4hA1u14chmLSSL80PzGT81Ivy+1C00m0uJ0M0GpBbmSOWIRmXlHGZIySQ jLxLbEHfJ+DDg4hbHxZcfCaX/m35OXy7c3X5peWb9tI8xWaIl3bhPVt9QEjrEsMkdQeTkqKjqQDT l8WOCfF6DuFzQr1jY/eyFdR/O6605IE0fQ7DUHjVnv5b24lhVmAJUWyQc+S17yFdupyusYPMs7yV yDHrD8sfzAsp9DF3qWm6lp+l6lJrWpNcGeKW7vJwWad+CMq/V2c+kvQ8QTT7K2HNA3sdxTAYpCtx sbRn5reRdV/MJ9EuvLOp6fA+hztcwakZXkkSeo+BRErpSsasSTWo6ZHDkGO+IHdObGZ1XRHafon5 vaTf6ndWUmi3cOryLdy2l1NdotrdeksUnoukLmSJ/TDcWCkdPcgyxkC72SIzBPLdiOs/kV5wn8qa X5X0zUNOhsrG9/TFxeSiYyTX7Bq8YlTjHEnqFVHIkilctjqY8Rkb7muWCVAD3s/srf8ANE61Y3Pm C+0a30GzaSa7XTxdRyykwvGiOZiyemrOHO/VRlBMK2u24Cd71SR/mr5N1nzrqHl298qarpsd9oMs 87C6cyKfVEar8Eay1HwGvLJ4cggDxA7scsDIgxPJg9t+Q35mWtzFc2x8qQ3EDrLDKlm6sjoeSspE GxBFRlx1MP6TSME/6Kj/ANC+/mUJZ5Um8txPchhcelFcxhw9eSlUjUcTXp0w/moea/l5/wBF6B+T X5Z+ZfJt5r13rtzZTvqq2Mdulh6gSNLKOSIKVdEoODqBSvTKM+UTqujdhxGN31eg65/xxNQ/5hpv +TZyiHMN0uSUfln/AOS38qf9sbT/APqFjyWX6z7ywxfSPcq+ZvIvljzJLBPqlqxvbUEWt9byy21z GD1VZoGjfj/k1plbYo6d+W/kzT47NLbT6fUbv9IwO800jm79MxevKzuxlcIaAyVp2piqa6voGk6u bI6hB6zadcx3tk4d42juIq8HDIynoxBB2I2IIxVJLT8rPI1pra6zBp3G5jna7ggM0xtYrl/tTxWp cwJIf5lT5b4qsvPyo8jXeq3Oqy2Vwt9dzfWbl4r6+hR5aAczHFOkfRR+zirLsVdirsVdirsVdirs VdirsVdirsVdirwjyLTyB+fOueUX/daN5pT9IaQvRBKOUgRfAD97H78VzNyevEJdQ4eP0ZDHoWPf m7da1Pr0X5rWB56X5Y1eHSbGJRtLDasxuJy3Qo90WhBB3yzCABwHmRbDMTfGOQNPV9durbzd5x8s aNasJtIsok8zag4Hwuo+DTkr/lys0pUjomY0RwRJ68v1uTI8UgOnP9TyzUtG/LDSP+cgdbtfMGmW 0WgnSY5YLNLV5IVunMHxLDbo3Elee/Gn0nMgGZxCuduOYwGQ2NqTbznpulWX5a2ureQNMnvPJt1r v6T13SIw6ia1t6W8qiMj1BA7WoZlbpWpAXYRxkmdSPqrZlMAQuI9Npv5Y8sfkp+ZLNquhL9Vh425 1XQLYLZj1IGZojPDGB/MRzjND/N1yM55Mex+bKEMc9x8mM23kLyk3/ORV35abT1OhJpYnSx5y8BJ wQ8q8uVak98sOWXhcV7sBjj4tdKWf85Cfl15Q8qfl9pLaXZhHGthRcSUeZYLlLid4PUpzaNXUcQx J9+uDTZZSnv3I1OOMYiu9m/lPQPyM1vzSP8ADmkxm80+1eS4UWkkVs8VwTFwljuEUOdiV+H6e2VT lljHct0I4ydg828l6f8AlBp1z+ZNj5vFhDBZarcQaaJfSF8kMUkqD6nT97yFF/ux165kTMzwmPc0 QEBxCXev1P8AL7VL38hLTWvNgmj80adcQLo11KWFzFZXV5DCkU9fiYL6jugY1XalNxgGQDLUeSnG TjuXNn/5efmFqcOrTflh+ZMaHX40MNneygPb6nbMpADFhRmdO5Hx7hvjBBpy4hXHDl9zdiyG+CfP 702/JfyvoGkDzTNp9jDBN+n9RtklVFDrbxSKEgV6chGvHZa0yGomTV9wZYIAXXeWe65/xxNQ/wCY ab/k2cphzDdLklH5Z/8Akt/Kn/bG0/8A6hY8ll+s+8sMX0j3JNJqfm7zV5n1XTdC1L9A6HoEy2l5 qCQRXF1dXhjWWSOITq8UccaSLVihJPTbK2xT1bVfPXlyxtNFOoW+u+Ydcv8A6nod7Nbi3EcIhMs0 11HDRG9FY3PwceW22KqeuW/5l+VtJl8wp5h/xHHp0bXGp6Pc2dtbrLAgLTfVZLdEkR1TdA5evfFV utfmeln+YvlPTImromuWJkmlp9iS+dRYO/8ALyaF4192xVXuvzDk/wCVy2Hk+3+KxWymW+kp8P16 RBcwx1/mS3gZqeD4qxqz8+ea4tVll/xBb30snmm40aHyzLDbrMbJLxoOULxenLWKMcyzhhtucVWW fn7zXBrvqv5gh1AXHmq40NfK7wW4mWyW7eASwvEI5v3MY5Fn5Dbc4q5fO19P5z8x2Op/mGnl2PTt T+q6fpTQaeTJB6cbD4pojKasxWtcVZLb/mfoumedvNmkeZddtLGCxuLNdKt7l4oWWKWxilkoaKzg yuTVifDFWPan+ZGrXHk6/wBXsfMEdraN5qTTLfWkjtpI4dNkmjUsOaNGwRHLcmBPviqK1Lzfqlh+ X2sazoPnGLzfqFtd6dHbyGO0jjjaW9hjeF/qqRikqSUNdwOlMVT2f8xP0l+XfmbVLAPpfmTQ9PvG vdOnCtPZXkNu8iclYFXXkvJGoVcfSMVSDzb5y8yxat5f06TzCPKmnalpKXMWvyWkE8E+pN1t5XnH pRKqUfanKtARiqfavqXm+PW/K2gx6rFHd6rpWqteXlvDH6TXdvFb+hOiyiWio8rNxrQ9wcVSyb8w 9du/yw0yeykWDzrql1HoQHBD6OprKYbqQxMCtI1ikloRSlMVSzWPOF5H558yaTqP5ir5YttLks47 C1kg05mkWWyhlkk5TxFjWR2708MVeyYq8l/P3yFr+uwaBrvldXHmTRr6NYJIh8SxTuo9Q7HaKRVY 9gvInMrTZALEuRcbUYyaMeYUPNev/lTpnkib8sLzUJILhrQ6daxPY3zNJcoaJKvpwOJGNwA9Vryb xwwjMy46WcoCPAUs/IjzB5a8s6NHpXmfUmsPOOpOiS2upQ3Fo6Q2qC3tLZXuI4oyERajierU65LU RlI2B6Qx08hEUT6l9jc+bLb86tU87L5P1efQ73TV06IKkCXPJTCxcxSyx0HKEjdum/tiRHwxHiFq OLxDKjVMmj8++dIJFvbfyPeQeWxdtDPaCJBqQV0Mr3K28chVg0z70rXc1rlfhR5cXq+xs8SX83ZB +SvKpuvzWv8Azvp+iXPlzR5NO+py291GttLd3byh3l+rAkoioi1LU5Nv44ck6hwk2bRCHr4qoUks Fv5nj/P2Xzg3lrUxoNzajTkn9JC4fgq+o0YfksfJOp7b5PbwuGxbGj4nFRpHf85F6Z5l8y6Rp3l/ QdDvdQntb6HUZrqNUW3EaRSx8A7stXrL0pkdKRE2SupBkKAZP/jnWp9Ztfq/kvVbROMjalf3dvbl hbRRyOkUBgnkLyPNxUKTQVJplfhivqDZ4hvkXnfknyNqOs3HnvRvNvly+02DzjeS31lfNHG624Mk k6h5Ec8WV+BA6MRTL8mQARMTfC0wxk8QkPqR3mEfmKPy4fyJfeXLzVNXspbOK21ay4NaXNnZ3Ecy TFmYFJSkHBkbeu/fBHg4+MHZMuLh4SGb+evIGkfmT5Yt5LiCfSdXiHraVeSp6d3ayg7B1BrxJA5L y9xvQ5TjyHHLvDbkxiY7io/klovmrR/LGoWnmmNhrB1W6lmnYhhceoEb10YUqrmu+HUSiSOHlS4I yA352zTXP+OJqH/MNN/ybOUw5htlySj8s/8AyW/lT/tjaf8A9QseSy/WfeWGL6R7klm0vzh5V8y6 tqegaaNf0XXpVvLvTVuI7a5t7wRrE8kTTlYnjkSNSwLAgjbK2xT1TSPPXmSxtNZksLbQvMOh34vN CspZ/rAeL0jFNDdyw1RfWV3H7uvHb3xVT1qf8zfNWlTeXv8ADo8tw6gjW+paxPe29yI4HHGYWscB Z3d0JClwlOuKoa6/LCfVLrzfbXEJtLO4sNO0zy1dF0ZkFhE0qTDiWZOFy460Pw++KoXTvy/8zWuh eWdUngF55uXXo9a8wurxIaXavDdKCSqcYYHUBVP7Pw4qyj8vfKbaQ2t3d/p8MGo3us6ldQ3NImle 1uLl5ISZE5NRkavEmo7jFWH6X+XvmbQPMFx5x0zTVl1eXWtSW/0/nADd6Te3bSRTRyM4RJog3NeT AlaqfDFUdpFl5w0HzT5ok/wbJq9nq+qfXLS/S6sEAiMUce6TSiQUKE/ZwqyXy/5auYfOXnDUtQs0 NpqdzZyadM/pvzSGxihkNAWZaSIR8QH3YFYpqvk3zRFoN8lppH1yZfOEet2+npLbx+tZRTxy1DSO sa8lQjixB9sVTPzFaeafM3krUNPXys+i3v1vTZILZ7iyf1khvoZpnDQyFF9OOIn4jU9sVVfzT/Lm 98waffah5cuBYeZJrGfT5idob20mRka2uB0qORMb/st7Yq1qA882dpb6ePLMHmbQbjTLaFrBpbeC SC6jQiVZxcnhJE/w7rUrT7Jwqg/KXkLzHot15AjugtxHoVhqsGpXCSKUhe8aB4IUDlXdFCMikL0X fAqvp35dXlv+bl3r7tXy8kbajYW1RxXVb1BbXMgHj6MHI+7/ADxVRkt/Nuj+ePNV9B5Ok12w1eez ms7tLqwiAENjFA44XEquPjQ9sVem4q7FXiP59gf8rJ/KU03OsHf/AKOrHMvT/RP3frcTUfXH3/qT D/nJOHRtV8mxaGireearm7gGg2MPF7kyFx6rcB8Yj9HlyPStK4NLYlf8PVlqaMa69EJ5184/mT+X ll5O0uGfTL8amttpkr3dvcPLFcRRQxSSGRLiMSq7lm+wpHTfJY8cMhJ3ROc4UNmYfpD8ztIvGv8A zDJpN15as7S6ur+TToLiG5VoI+aKFmnmBDb/AGfDKqgdhdttzG5qmOeX/Nv5neYvLNp530e70+6t Z5wJfKsVuzstuJvTdfrfqc/rCp8f2Avt42ShCJ4Tfva4znIcQr3Na156/NCx/NWw8hW02iyrqVm1 9bahNZ3QZUUS/DIiXVOVbc7rt3oOmCOOBgZbrLJMT4dkz1+//OPS/LnmTUry70aFtItVv9PntbaZ o544I53uYZElnZkeix8WFR+NIxGMkDfdlIzAJ22YxZ/mP+a8H5WW35itNpWp2bgy3ulPbTW8scSX DQVhnSZlYmnI8o9u1e9hxQ4+DcNYyz4OLZZpP5xfmJP508raRqC6TbaL5qt4ryw1H6pdBykiFvQK G6KrLzHp1qRurbg0wywQ4SRdhRmnxAbUWffmT5l826RNoFl5W+oS6nrN79TFpfRTS1TgZHnDQyxF UgRCZPhatRSnejFCJsy5BuyykKrqxHyt+YH5seYfOXmTyxDJoMEvl2T02uXs7wrMC7KrBRd/B9mt KnLZ4oRiDvu1wyTlIjbZ6V5Sfze2mSHzWtomqC4lVRYBxAYFIEbKJHkf4gOR5HvmPPhv08m+HFW6 N1z/AI4mof8AMNN/ybOCHMJlySj8s/8AyW/lT/tjaf8A9QseSy/WfeWGL6R7lXzL578s+XJoLbU7 lvr1ype3sLaKW5uXQGhYQwLI/Gv7RFMrbET5a816F5ls5LvR7gzxwyGG4jeOSGWKUAMUkilVHRqM OoxVX0bXtJ1mO6k024W4SyuZbK5K/sTwHjIh+WKu0XXtJ1q2luNMuVuI4JpLafj9qOaFikkbjqGU j+PTFVtv5j0S4fU1S7QfoaT0dTeQNGkL+ks3xO4VaCNwxYGmKsf0/wDNvyLf31vaW15MVvJVgsrx 7S6jtJ5XYIqRXDxrExZjRfi37YqqTfmt5Gi1abSWvLhr63uDaTJHY30iLOG4lDKkDRbE9eVMVVLj 8z/I1tr8mgXOp+hqcUyWsiSQ3CQieRVZI/rDRiDkwcUHPFWU4qxDVfzY8j6Zf3FlPeSzSWbFL+S0 tbm6htmHUTywRyIhHcE1HfFVbV/zP8kaTJZx3d+7tqFsl9Z/VbW6uxJbSGiShraKUcW7VxVG2Pnb y1e31hYw3fG61S2a80+GaOSB5Ykbi/FJVRgy9SpANN8VReqeYtH0q7sLS/uPRuNTkeKxjCSP6jxR mVxVFYLRFJ+KmKsf0v8AN3yFqmqx6VZXtxJfysiLC2n38dDKSE5tJAqoGoaFiBiq/R/zY8i6zfw2 Om3s9xPcSNDEwsb5Yi6kqw9ZoFiFCpFS1MVVdN/NDyLqOsfoe11OuoGeS1SOWC4hR54SyyRxyyxp HIylDsrHFWU4q7FXhf8AzkRa2t358/Ky0u41ltbjVJIriJ/stG9xZK6t7FTmZpjUZe79biakXKPv /Uparomk/ll+efl7VdNt0sPLnmiBtMuYowBFFcVVRQfsBn9Fif8AWPjhEjkxkHmEGIx5ARyKv/zk 3CZrvyLCJHiMurcPVjNHXkYhyUkGjDtjpP4k6r+H3s90/wAu6X5SvL/Uda8xXepWuo2y20cWsSrM UW2S4ubgJxCKytDVivCoCHcg0FBmZ0AK9zcIiJsn5vLvO3kfUPyqgfz/APl3qzRaH6sUmo6DK/q2 0sc8iohiO4dTzUCtWUGobMnHkGT0zG7j5IeH6onZGeedOfWf+ckfKtr9au9KefQS5ntHWK5jIN63 EMVcD+VtsjjPDiPXf9ScgvKOm362X63osXlz8u/POkTa5NrF9eadqepJ9dYNdLA1n6IDEH4lVo6B uKjtTKhLilE1W4DbKPDGQu+bxlrXzdZ/kf5V1Sa9m1XyMbknXvL8UccJW2W8YgfWIwJirOprVqBi uZdxOQjlLvcWpDGDzj1D0z85dE0zzT+VGn+Z/KLIW8vCPUtFmthx4W0QAljRR9j01QMVpsY6Zj4J GMzGXVvzREoAx6Jp+Vmszef9XPn25hMNpZWUel6XA3QXEipNqMyg/wDFnGJW7qmRzR4Bwj3/AKmW I8Z4vx5sJ8i+XH1z85/zGjTV9Q0n0bgH1NMmSFnrIwo5dJKgdsuyT4ccdgWqEbnLch7d5Rs7bTdD ttEivv0jcaNHFZX1yxJdp1hSRmkBZyrOsivx5GgYZh5DZvvcuAoV3IzXP+OJqH/MNN/ybOCHMJly Sj8s/wDyW/lT/tjaf/1Cx5LL9Z95YYvpHuSPyK9mn5g+eIr4geYnvIXh9SnNtKFtELf0q/7rEnqc uP7XXfK2xM/zB81weXvLGq3umCO411zHZWdrDxaV7+5AjtkZRuT8Qah/ZGKvPfyrlfyn5vt9EfSd T0nTPMFlEhk1VIkM2sWcZM0iGOWYf6RFVmrQ8lxVryboOt6VYXvnTyrGbm/Gq6rHrmiciF1C2jv5 uJjqeK3MQ/uz+0PhOFUru9d07XfL/mzWIfUfyzc+adLk1xWRkcaesNqLlJEpyHB1pIPAHFXvRm0r 6lA5eD6k5hFq1U9IsWX0PTP2SS3HhTvSmBXmvkvSfOlzq3me40rzBb6fpi+Yr31bGTTxcu5DIXIn M8fHkNvsbYqxHW59WuvPPmPy1cyQWHlPXvMFtBfas0bSypcxWlrNFbD4lSP6xwCo7A719sKvc9fF +dC1IacSNQNrMLMrs3rem3p09+VMCsc/KGXQD+XOjfocKkEduq3q7CRbxVH1r1x1Evq8i9f1YqkO r2WsX/5o2Y8qavbaVH/hxHjuPqq3sL25u/gWNVlhUL0IYE7Yqlvm/wAoy69+Znl3S9T1BxqlvoN1 PBrNon1d47yG5hKXEcYZwu9fgLEUJGFUJfeZtZufzC8jeXPMsCweZdK1Cd5pogfq95bvZyrHdweA YrR0/ZbFWb+W/wDya/nb/mC0X/iN3gVi/wCRul+cW8o6VeRa9BHoP1q+J0g2AaUqL6cMv1r1h9p6 tX09unvirGvJsuqal5n0zy9q0kFh5fh17U9Y0edUczXl5Z309bUyFgkZTmZCAp5J9OFX0HgV2KvJ tX0/8h/NXm9bXVJptQ8zJLwjtpLrVVkhcvXjHGJFWFQxr8IVRmUPFjHbl8HHIxylvz+Kv+cFl+X9 x5VTybrWrPp984W50W4uWuruVbhWYRt6z+tJJU8lYFi3E7dsGAz4uIBcwjw8JLA9B1Py35zIsfP3 l7UfMms6KFhbVtHuby9tCAOKyNb2syfVpJAnxfuxyIJNDtl8omG8SAD3tMSJbSFkdzItFuP+ccbV JNXjZreSKOW0uRezahOYBdI0UsUiySTRozpVTTISGbl+psj4XNG+VNP/ACN1TWdP0rSdUn1eSyP1 jStFubu+uLWAxrzV44JyYwEX7PL9eRmcoBJFfJMBjJABv5oLXoP+ca5vMNzc61etJrsUrQXE017q xmSRaqY+Xq7U3AUbU6bYY+NW3L4Il4V78/i0kX/OM0em3lNQVLO+Zbe9Bv8AUw03pfEImrL6jKPU rx6d+2z++v8AsX91XP7Sy7yZJ+UGjeVdSl8uX9uPLUC/7kopbye5t4Q3KqtDcyS+kZOZBUKOZ2NT lWQZDIXzbIcAG3JJtF1T8jPL8Eut6Rqo0/R72R4bqwSS5+oPK6At6lm4ZYyUdafCoI6ZOUcstiN2 MTjjuDsjtD/MD8k9I8up5d07X7ax022je3SEzTW0yiSrMyufTlViXLc1Na7g1yMsWQmyN0xnjAoH ZKvLvkT/AJx58xXV9c6GyXt4peW/kj1PUBMRy+OVy1wrspb9vcV75KWTLHn9wYxx4jy+8sy/Ln/l XsGnXen+SJY5bGCcy3RikmnUzS7F/WmLmTl6fUMRtlWXju5NmLhr0sg1z/jiah/zDTf8mzkIcw2S 5JR+Wf8A5Lfyp/2xtP8A+oWPJZfrPvLDF9I9yI8yeSPK3mR4ZNZsFuJ7YFbe6VpIZ4w3UJNC0cqg +AbK2xR038vPJmmxWkdlpcUS2Nyb63+J3P1ooY/XdnZjJJwNAz1IxVNNU0TStV+qHULdZzYXEd5Z sSwMdxFXhIpUg1HIjFV2laRpulWz22nwC3geWW4dFJIMs7mSRviJ+07E4qpWnl7RbSTUnt7SNP0v IZtSSlUmkKCNmZD8PxKoDbb98VSKw/Kb8vLDUIL+00aNJ7WUXFrGZJnghmU1WSK3d2gjZTuCqCmK qk/5W+Q59Ul1WXSwb+ec3UswmnXlMTyLlVkC1r7YqmN55O8s3ltqdtdWEcsGsSrcakjFv3ssaoqP WtVZREtCtOmKpxGixoqLXioCipJNBtuTUnFWK6v+VfkHV7+a/vtJVrm6PK7MUs8CTmlKzxwvGkv+ zU4qrav+W3kjV5LV7/So3axt1s7QRvLCI7dDVYlWJ0AUdhiqOsPKPl3T7myurSzEdxp9s9lZy85G aO3kYOyfExrVlB33xVEahoOk6he2F9eWyS3mlytNYXB2eJ3Qo3Fh2ZWoR0+4YqqW+kadb6neanDA Ev79IY7ucE1kW35CIEE0+H1G6eOKsf0v8rPIWlahFqGn6ULe7gkMsTrNOQrkkk8DIV3JPbFUwk8l eV3sYrFrBPq0F4dSgUM4ZLtpGlMyOGDqxd2Ox74qneKuxV5HoXD/AKGa8yVpz/QENPGnqW9f4ZlS /uR7/wBbjR/vT7mU/mIqnU/JBIBI8xRUP/RheZXi5S/qtmTnH3/oLzWXyr5jXzZ5v87eSLkHzNpO tSQXejs1Yb6y+q20hhZAR8XMuVPc9CGAzI4xwiMuRDTwHiMo87S7UfMEPmH8jPzK1qK2eyF7rSSP aS7PFJw09ZEbpuHBFab+GER4csR5frYGXFjkfP8AUmXm2U+R7jyJ+Z1pC0tmdPt9I8wRQgVkglt1 aF9qVKkdT3VBgh6+KHnsymeDhn81vnfRb3RvKXke5unt7fzZq3m6y1a/muhVEurn1HYSKGR/SgrH GwDDZeoxhK5S/miNLONRj3mSz81rq5k8qWcep3uk6jr4802Et1JYKYrf05I5VtlmYh3/ALuMg1Zi F7kYcI9W11wrmOwur4kmj03RPN0nmubzPff4f846xq9rpBsIFpBaT2yFrWSRXcGZJ2hILn9roMnZ jXDvEC2FCV2akSredNa1m5/Kz8w9J80WtmvmfSLjSra81Wz4iO+rPE0LUAA5rCDUACgNOK0IyMIj jiY8jaZyPBIHmKZl+clrpNrqv5dy2MUEENz5psrmWSBURZCzJWVitAxIp8WVYCSJX/NbcwFx/rJT +e3krRR5q8mT2ATSZdd1FtJ1Z7Wlu1xbXrqZufDjyLeo4YnqW3yWnyHhle9MNRjFitr2e52trbWl tFa2sSQW0CLHDDGoVERRRVVRsABmGTblgUh9cBOi6gBuTbTUH/PM4YcwsuSUflopX8uPKqsKEaPY Ag9QfqseSy/WfexxfSPcyTK2bsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVYB51/LfVb /wA1WPnPyrqaaV5msoTayi4jMtrdW5JPpzKpDD7R+Ie3QgEX48oEeGQsNM8RJ4gaKI0nyl5v1DXt P13zpf2U0ukeo2maXpcUsdsk0qem08jzs8kjhGZVFAF69cEpxAIj171jCRNyPLuZJpXlbyzpFxLc 6TpFlp9xcCk81rbxQPIK8qO0aqW333yszJ5lsEAOQU7zyf5Tvo5o77RrG7juLg3k0dxbxSq1wUWM zFXVhzKIAW64RkkOqmETzCsvlvy+mlLpEem2sekoyumnxwoluGSQTKREoCbSKG6dcHGbu914RVVs p6x5S8q61Mk+s6NY6nNEvCOW8toZ2Va14q0isQKnpjGchyKygDzCV3P5V/lrcIiSeWNNEaElUjtY olqwAJ4xqoJ2G+TGaY6licUO4Kuoflv5D1GSGS+0GzuHt4Baxl4lP7hVCJG38yoAOHKvE7ihwDNI dUnFE8wqJ+XnkJbCPTz5d02SyhdpY7eW1hkRZJKc3o6t8TUFT12x8WV3ZXw41VBfc+Q/I11Fbw3P l3TJ4rRPStI5LO3dYo+RbhGGQhF5Emg74Bkl3lTjiegVdR8meT9TeF9S0LT757aNYbdrm0glMcS7 rGhdG4qK7AbYjJIciUmETzCbRxxxRrHGoSNAFRFACqoFAAB0AyDJdirsVdirsVdirsVdirsVdirs VdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsV dirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVdirsVd irsVdirsVdirsVdirsVdirsVdirsVf/Z converted from application/pdf to <unknown> saved xmp.iid:D27F11740720681191099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:00 Adobe Illustrator CS4 / saved xmp.iid:EF7F117407206811A46CA4519D24356B 2008-05-15T22:53:33-07:00 Adobe Illustrator CS4 / saved xmp.iid:F07F117407206811A46CA4519D24356B 2008-05-15T23:07:07-07:00 Adobe Illustrator CS4 / saved xmp.iid:F77F117407206811BDDDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-07:00 Adobe Illustrator CS4 / saved xmp.iid:FB7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:29:01-07:00 Adobe Illustrator CS4 / saved xmp.iid:FC7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:29:20-07:00 Adobe Illustrator CS4 / saved xmp.iid:FD7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:30:54-07:00 Adobe Illustrator CS4 / saved xmp.iid:FE7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:31:22-07:00 Adobe Illustrator CS4 / saved xmp.iid:B233668C16206811BDDDFD38D0CF24DD 2008-05-16T12:23:46-07:00 Adobe Illustrator CS4 / saved xmp.iid:B333668C16206811BDDDFD38D0CF24DD 2008-05-16T13:27:54-07:00 Adobe Illustrator CS4 / saved xmp.iid:B433668C16206811BDDDFD38D0CF24DD 2008-05-16T13:46:13-07:00 Adobe Illustrator CS4 / saved xmp.iid:F77F11740720681197C1BF14D1759E83 2008-05-16T15:47:57-07:00 Adobe Illustrator CS4 / saved xmp.iid:F87F11740720681197C1BF14D1759E83 2008-05-16T15:51:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:F97F11740720681197C1BF14D1759E83 2008-05-16T15:52:22-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:FA7F117407206811B628E3BF27C8C41B 2008-05-22T13:28:01-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:FF7F117407206811B628E3BF27C8C41B 2008-05-22T16:23:53-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:07C3BD25102DDD1181B594070CEB88D9 2008-05-28T16:45:26-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:F87F1174072068119098B097FDA39BEF 2008-06-02T13:25:25-07:00 Adobe Illustrator CS4 / saved xmp.iid:F77F117407206811BB1DBF8F242B6F84 2008-06-09T14:58:36-07:00 Adobe Illustrator CS4 / saved xmp.iid:F97F117407206811ACAFB8DA80854E76 2008-06-11T14:31:27-07:00 Adobe Illustrator CS4 / saved xmp.iid:0180117407206811834383CD3A8D2303 2008-06-11T22:37:35-07:00 Adobe Illustrator CS4 / saved xmp.iid:F77F117407206811818C85DF6A1A75C3 2008-06-27T14:40:42-07:00 Adobe Illustrator CS4 / saved xmp.iid:5132FB80142B68119E5EBC2C4DFB4C6E 2009-09-03T16:44:46-05:00 Adobe Illustrator CS4 / saved xmp.iid:FC7F11740720681195FE8B4F3464D854 2009-09-08T17:39:14-04:00 Adobe Illustrator CS4 / saved xmp.iid:05801174072068118F62A79AACDA1C39 2009-09-10T10:36:25-04:00 Adobe Illustrator CS4 / saved xmp.iid:07801174072068118F62A79AACDA1C39 2009-09-10T10:42:01-04:00 Adobe Illustrator CS4 / saved xmp.iid:A1DD6DFE182068118F62A79AACDA1C39 2009-09-10T11:44:28-04:00 Adobe Illustrator CS4 / saved xmp.iid:A3DD6DFE182068118F62A79AACDA1C39 2009-09-10T11:48:30-04:00 Adobe Illustrator CS4 / saved xmp.iid:A4DD6DFE182068118F62A79AACDA1C39 2009-09-10T14:25:56-04:00 Adobe Illustrator CS4 / saved xmp.iid:01801174072068118F62822D45AD6E4F 2009-09-11T11:28:28-04:00 Adobe Illustrator CS4 / saved xmp.iid:02801174072068118F62822D45AD6E4F 2009-09-11T14:56:15-04:00 Adobe Illustrator CS4 / saved xmp.iid:0A9FFB180E20681191099B53BFBDA700 2009-10-13T14:03-04:00 Adobe Illustrator CS4 / saved xmp.iid:0B9FFB180E20681191099B53BFBDA700 2009-10-13T14:10:43-04:00 Adobe Illustrator CS4 / saved xmp.iid:0C9FFB180E20681191099B53BFBDA700 2009-10-13T14:40:01-04:00 Adobe Illustrator CS4 / saved xmp.iid:F87F1174072068118F62D97B54CD136D 2009-11-09T17:24:41-05:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:F87F117407206811994CC605C7580E4D 2009-11-10T09:04:52-05:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3A1615431B206811A090F91DBD4E28A9 2009-11-18T13:16:03-05:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6BF9D2DCFD47DF11AA52CDFD4F0D861D 2010-04-14T15:48:26-04:00 Adobe Illustrator CS4 / saved xmp.iid:6DF9D2DCFD47DF11AA52CDFD4F0D861D 2010-04-14T16:11:39-04:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:C7C55601314EDF11B350D57148771925 2010-04-22T13:04:06-04:00 Adobe Illustrator CS4 / xmp.iid:6DF9D2DCFD47DF11AA52CDFD4F0D861D xmp.did:6DF9D2DCFD47DF11AA52CDFD4F0D861D uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf proof:pdf uuid:5D20892493BFDB11914A8590D31508C8 xmp.did:C7C55601314EDF11B350D57148771925 xmp.iid:C7C55601314EDF11B350D57148771925 Print 11.000000 8.499993 Inches 1 False False Cyan Magenta Yellow Black Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 C=100 M=62 Y=12 K=62 2 CMYK PROCESS 100.000000 62.000000 12.000000 62.000000 Grays 1 C=0 M=0 Y=0 K=100 CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 Adobe PDF library 9.00 AdobedC       s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz?Nz=S͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfjҿoQyOM, ??!?4l_~|s /a6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l/Ig&1k2'He_Ŭȟ!Rsٙ(ff͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg5i_÷˼'_͋OτԟsϟY6/?>y90å*~m]kodmoJcE64l~J b0ƒL.&vF9;pna%<]C-E< BkK_ʊG"~_TWV<L(_cIk3ʊGEEym#B,?7?xD^x/ߛTWV<L(_cIk3ʊGEEym#B,?7?xD^x/ߛTWV<L(_cIk3ʊGEEym#n6Si2^ƀ~'7䏞!^Rk oQn^#'7䏞!^Rk oq$mG2E <0@HVlٳf͛6lٳf͛6lٳf͛?ղ-cD ko$3N{3%ٳf͛6lٳf͛6lٳf͛6lٳfA9aKXA?;]K<Ux濯 .%\wgM?\0>&ŮKݲ6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛&ŮKݲ6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛90eʰ.+3$֛??շZǵcBiؿMI<9 )ba~s O}-ɡFpjj9 SP}nF_z}*{1r7\RU:xᯕZҬ! q#{(uΟ DӬ(<BiؿMI<9 )ba~s w迮 ''I[\xu{ ''I[\yf͛|lnaZϩ8aᏖťC/-m*Hgx |-*yynn~)Tmr4_iP 9?Tk(Obb ܷ~k v*.@h{Ar 2 q+ɩf~Q;05cpc1=)H#ٲڟL'c ;`bJ75!]0"iYH䎽# \K1$|dC:k>buBIs״ucd{ <+mmnnucrUTnK@14G(M+5ff4 I'`14G(M+5ff4 IS]Gc8Fb5'hlܯ?)6%_+#yZZ&!MLUd ]>қ}f^gg-*QYи1 oOb'gwI,Ƥ$YfcVc$8UY1,jw$+6lٳf͛?ղ-cD ko$3N{3%ٳf͛6lٳf͛6lٳf͛6lٳfA9aKXA?;]K<Ux濯 .%\wgM?\0>&ŮKXg6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳ$'36b@;e1&Tf[#\ޙ]Ɏ|;v#M u[x^~s6~tWDgc_-A݀Hn?CgrS>wsX3qPQ$Eg>o?~nyFBԞ?QQ̟d 뚕Ѥ*U9ϛߛqЭ䷵'|s'?:?ο1/|ɬZ;ny=O]%_)O-Y²y'~q M쇔+Q$G Vj𬧩I߮\a'żf%qQo)R;չ>?unfߟ쯤?3_ %??unfߟ쯤?3_ᅺW$ϧ]?axqQk[;~#c~8nu?xqQk[;~#c~9#7zqA B헷.яm[z#]ZUT7(i䲼(h?iwYտ.1NR=թUGr_^[Ae[_ay$*?#+H֖T[u\p">;̤^V,1"iD};'6nU9hK"lKb)&f!|}CL ǯ`nl! 0d:4hhu#C1HH?C?3|CqV+@ E_ڴΧ8ysptԜmF>cἳұg<8 ENTVHMVTZ6La)9f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l_zW2<9 )b6''_͋OϞa3۟󉱻uL>fkTLs[EXK=9G*~jߒ*ǪY̿>p9%~[O)[yV |.z\ɯq/yJMkDug6 w׏#,l[<8jp c,S841xvq/yJMkDug6 w׏#,l[<8jrG#4ߔ#<^N;>OOڑܴ>T!eu1PX#)PgiZQU)ci2@E1Jz=Y1FpWqJ ӲV d'҉~@Տv$i4^^nCE .&]\=#w#xg4/|ͯ\jUQ!o j"~SL%İ6lٳf͛6lٰ^[/Lb?mdOO1X?C>2Q͛6lٳf͛6lٳf͛6lٳf͛6l$gQ1%dˁ5_k 2[897{/sxobo9Zdɞņyسf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰΞwד4)0];(RJ 48[1i_duI6Wv숽Y팚xጼ>0yH&N!`:dElOƲZ3z-UZr+i82|k4䷰N >ɫaƟd}k닷QͿ>iTr[\? 0O>bH 5}_g](VPwryo.8|fUg߇2Iy7_'F#́oaeZ|~랅$!(bP;*ԡbXE$HP< 0@(@3C 0ıBH( x6?6?6lٳf͛6lٳg<~_tu)"3(^ 2+7:T%Y>5֟o8&$u>9gЋIVBb ,N̯5~^kJנ$Y_Vuh؁ħq =yɺו/jQ/Sor1Jnd~<&^VԾF8MT*Opwט%旖5$s. ?qpkC_{b.R ?w+zo 5;q@KvUEqAoMXHyf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l_zW2<9 )b6''_͋OϞa3?gZDZg<'`ûO3^| Ng I-4d/Zǘr'NNsӀ} za%(~̊T9uQyk}Vkg=O0syV_L\j߻iFr=]^Ҥk9 -#FCǣˣkT-g;҃7%uֿ;\gZV-~X=oM)ZI#ҴzhCܟzߘ2RGi._`d1/\~~1ɕu,\ͺG%.?axdS<ιcCP$E?Z FY1Ո6XP=a*OV=9Z_f`BUT}տ?-,O-ڀ¦#_F>xcUa[QDݨ *n!R5`Z3ys8J1b#ʚDo 3}SJt]hdϪrKu<Y98u>=3\CŁ'a4D#$ߛjz j5)oiQߝ{]BykMp4=dd6)1t[1MV>; ;<֚i{tɲ:mSbgsa~rٳfp~¼yjrTߘܹ+;c&;̴ʲj2R91״'829?0龰'58Tw=ww?3>pgWU_N:ƬvU]]Ks/&v0ϛ]W};T~7sǟ?u-J%ͺJo4oF~!m>{+ik ˚ENo=ϰo؋x0>#+ik ˚ENo=ϰww6lٳf͛6lٳf͛6lٳf͑?~X5aeh5ycL.6%Qa^)dOq;xc <3̺]g )Etj|H„g;ຏx#IPn>۲x#>ĪaϒPyx#>Īaϋccf͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛ R?EyKI1<+“zwe`O˾p)jϥ$KkSI9v| R rѹa-6tZhTrA5֑0r -O6_0ePdrA5֑0r -O6_#󉶂*Z[{Ezۼ[{ $`?0o;&x+zS $`?0o;&x#rt@66b?mN^F+Wp_^V넬<"Ȟ7@eR ^ε{Jз'7#X]RǢ /f>{:*?ܟԶβ9'󵰘5ǤOJ奼ʭ=>ʳ2ӥx奼ʭ=>ʳ#ߟi%䊥곢˴݈^|ͭ݊3E(ov;<4*3kpiV"U G)]N_9_~R nkm2cSur9QHMd1YҜ._> &K+Q[9_vMd1YҜ._>qyȈXu B1,M?3L  xij43XC&N?;b_;2/U{_?VN?;b_;2ʴxc!V?mdO2cD F{36lٳf͛6lٳf͛6lٳf͛6lٳX?=DǐOwO.''oKo'9rdcq?%FLkr18k#&z;b͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfwHѤ"hIfURB͔̪Uf;s ycIfJT MhLy)עӿ*Oϒ\dr4{RF>!/ SyOϒ\dr4{RF>!~[I};˜Z0ßȯ). 5iٮ_-I>EyIu?0I\+M&Frc|_>9l&g3f͛6lٳf͛6lٳf͛6lٳf͛6lٳFM7Gtn7h $ :!(Οi,r[.6lٳf͛6lٱ;-m幸bIcETAɘ6ic'V j^G;*I Ā ;8٥iX$Qy'3~H[ek`,OoiAYd\@z:o˿ݩjF6ղ%ǓєY_$Zq{A.3vYڟVʄߗNFSƿ<;y;͛6lٳf͛6lٳfH`3f͜_rWiw?1jВ *#Bry-s5uySCK[^Z{2["VcQjߜ^Tז{̖f5kaO# /F?dLJI  ^BF?Sd5O\?dr21g$ .!i~gC 曤ZL@Tv^pic:WpDo3.r|8#XΕ"B? D&4V~c˷rvo;o*:T2PwloZo&;TJA@,O~ɯ>|ȖiSHON۸ =NӳrR~SFԞm2a epQ[sߝ}Ii FC 1&Rք{n'ǐw!X\ُ?F2OϏ!ZCL_u9]!œH-qY _GCª~- i֭GEsfjTGi) L3~\y>R=Vw(੐2EUɿ485 {{{$F y90pyX#mHaù? WDElx<넙\掞?1z1j:} R?JW/~`gk+ԐzVny¼.}݇WK-dl/9Z&u$խ7p _eg&2~lɷ>s {xmua+$Kхnϲ@Cߺ% ^OK0~K0~ӣw:zwM^# Q0?ҋ3yB'yI8F;Pnv9XV@w$'$,5}zD]H.z(O%׸>Mޕw'Qw}c Om`ؼdo3>Mޕw'Qw}c O;5<#w<y͞e&s]4ƐZ_.뚜^g-r KRNu~}GgaLx `v8Gv ` ?No#nmp~Dkk`7NONvP}3 Ym+}:#[[5Eɺrzwd[[<[QIV@0NKZF F,:1Yxt]J5g5`3XC&L;b_;2+U{_?VL;b_;2ʴxc!V?mdO2cD F{36lٳf͛6lٳf͛6lٳf͛6lٳX?=DǐOwO.''oKo'9rdcq?%FLkr18k#&z;b͛6lٳf͛6lٳf͛6lٳf͛6lٳdk>]̺bb1ܴ͛894?/겹2ׯ.ܟ5fqzi 7/#4w+#חlٳKZz5_nTz͛:7,-ssPZ՘hz*|ٳgk5pGJf͛6lٲ1/-f(M$x?lٳVի\{?+͛6o_kgeyfCYVs6lٿu+?ծ=͛;?<ѧ:wROwVPGΠَlٰ6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳZ~d?|_Ǫ hdm?<#$l^x~PRhyN^4~13I$191͛6lٳf͛6lٳf͛6lٳf͛6lٳf:ևktneC-k,lTRUT`}CMm^;Y): F:#WPzaڽwVS3(t$6vZBѬV(HTDUUUbA Pġ"UUQEU`( V!5$Q (l1\~l~lٳf͛6lٳg ]KS+5Cp>?<|4+~yZO*Nծ=;L]?<|4+~yZO*NyOg?6f;Yw)#yu|365-OJ0b!0BkF|365-OJ0b!3 A;:S=b"pzgATnC6lٳf͛6lٳf͞?u;#yZmoj5«$ҟe~Ϲ˚,; 3C3%#cԣS ssuy?4Yv0fg4JG/Cۨ/\-5uo> 'V¯0~Xy/[m:+Y|7Vȧ[8 ?̻*凒&Ӣuh |~ſ(׿-tGWKAiZO|OZ{+Ycó-~%Im'N#<$~R͕m]>k/Ǖ3޲1ʱ⳦%p-61/9_%'?!)=ݟ=})cd9"ռc鰨"Q(η)+6U$(6Xݰ³ĒT8.gUohCGWN4;- `"-(K Qg<-o<~{oqV\Я=6HpmTMC4=}9tm'ݣ= S'Ký!ٔ;%iw9Ȼ!˦i<b >]D='ʤ<#eK *Mf>ҙAFd#b ~;a΃.2XIRl#6 7%Ppǒ[_f 9 L W#y_ә9[pKuĥxUOnp7u=9^J^Js'CKbn3k׊6֔},~_Sb5$PbļmcL~_Sb5$Pa/H0?MѧJ~*/R½xN gNJ{v?5!zz(v>-յ3XI]7O^.yU-}C{Τ[;dD_"Ku?F ./O䏦kE}=E|}더~\_!M3O8叫iؾr<-tQװcɳ^]y'Gm#z|!3Fq 4訣>ׯ.O6v>?#SKןzհ7!|0>Ԓw!O3ԟ'2۳8Ӳ{3K<5=`=yǘ'5I̲64쑯`?w <*͛6l8tO/8PT_fPQ]ӑEY ې?ϟ]ַۮ Bȟ!Rsٙ(ff͛6lٳf͛6lٳf͛6lٳf͛6rZg 2[5yw-?W=Bl9ZdɁ?7F?-s2[dOb"=im6wk|% T(ў˴h5>HՂq\W6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳ ٳg/^[iVGQ0@Her#<~VVT58Vr?qܳ/Ÿ!XOwQ?++sk*dcv}9r))@|SFF1|&KP܈V:e!bmdqE7 4'jZ-F"aK)=ח/>sXMIܓԜ$r;Q$S=N}IңKƟRH#[ZtcLeۥ mh!NG% ( i=dg[iӀQX^-6l̿"rͫju /zrPS!X]ב}fψU@Jxj6*/FC5|#/RM՟W"&REgYe%O 4R:y)i6?1Ct[wQJ(\0 A.w(8 T4SnF;|Kn#IQ%%;.OfOё20!PFfUe*"6fUe*">Zj6T.mhЕÃoxBhhGn #|i2к;%H%7<m[_:0S caZqS ca?z6lٳf͛!??I˯pW&h,Z?TE,M :ud{ϞQ~^JiE[{:T,{7x<.ҋyyyt;5^Yzo*)y3Iٺ}kPˇ' Ɖ:O#BMxթo G^\E+cD'xr&j 406lٳf͛6lٳ4aeyrSK/f'mkO9OM,< g?*ykM??|j^]ӠxX$MFqtMcJJV` АGYl#ţPiH?-t.mHhV ~|8KDo(reX_swqIjk(oxF M+KmBQx7@A?+y_D|}*OMF;isKI Z&b5!Zm^[Rڭ 4R0ĄIBxZE<IWxKhbߘ5MXnI(~$$JZt&aki7e*|SZ4{tЁ9,|өI {Xm1`P`-ĒU+,|өI {Xm1`P`{&*~ijrAytM.ŻI$&!J|}']%>쥇)="J|}']%>>l??!X3PE𻿘 v*iǾMo/`׫@i~2UY9Koxޙ2 z/Fȇs Z1ʝrKu|!F ^؋x XX=5ELvʟj(KA{ڕߡ?} ކ,,΢;eO_ee=Y%-kXiMI ѪRqֳ_`ߒWz^Y_, e3KN?+C̯mdhix}t_/,~Y#>l j /e~}iˑBڔKеB+e`Pt\?G.E jQ/#B>65WZ5MVKB̗31gv>$tp+B[ٞv-,Yf=I{^Ky{3]NťCVbp!1H-縙 C8R *N:(E$i$cEE|$ tQI,HHƊ $0]t .T4K2+yhy q70Rǘt85:{;iۄRN>ѵ<1I-C:S$S u/,yLQӧE$c&jx @ܝZƃS/ʿm'W5)>1ur9aW 'ɉ}WY'ɉ}*eX?C'_Uo$3N{3%ٳf͛6lٳf͛6lٳf͛6lٳfA9aKXA?;]K<Ux濯 .%\wgM?\0>&ŮKXg6lٳf͛6lٳf͛6lٳf͜crs~o#yM4"oO̚xSIg1ύH9f$~RXk?nG&+DEV ~Tf*FF͛>+Z^Ewn!RJ]ω lٰ6lٳf͛6l6Z+ڼj={w7ۜdɡ4#f͓|ٳf͛6lٳ`M_U4VOF .n?J]3f͟7|ë7Zɪ-U~o VMpXI=}9fNlٰ~^<ǡzM"0vnR:\ٳb>-Q ٻjǻ1'6lo6l&:$sf͜q '%Flٳ9f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l؍VvsʹVQKbw'؉䢧1 OA'H-O3EN|/gnWr7Ř~ڇ% sqW`]JѶj;+9 O'z/PDc?JL__n5G+Y4/ҋrޟfEAs˕_F+q YlI :i"h&vhqֹ+?.W_u-gt-$2oꂿ C,I c&)"6YM#17FE*JBA:17FE*JBw=~˗2q<""3!u>tlg= 6lٳf͜7s$o(L^\%\\~`-bTd+9W>EkAy _?z|k<ɠ¶@ƍ=@$S~ C=!;]sSV#Rgc󲵎_Lf_cZ&8S&?'ʰsl?1Yp?ʰsl?1G9"X͛6ٳ͛6ٳ͛6ٳ͛6ٳ5i÷˼'_͋τԟsϟY6/?>90zD##>[70\QkO?o-yj@l#?S{gSɞ ɞlٳ`q VvM@dv݈v=IĄioIi=5,KU@$#Kx0RKIgbXڬO|ykO^}ūFN?\oU#֋SXƑkXͯ2_kJ{{T_?ljB;Ez<F4#ZǬMmy]V;ڢ0g~T>1y32Yz= _WUްwXϳH?@2:?/:`?w%t-SǕP~s#_MIǙ5\^;ʈ+TIfo9^2kO]7N wW>{ڈI5- Q7 ""?7'Z7qoR"ѮycOru~@yWj_^Q(+eIjnoy?lz#|NyBaPN"GSƿژ-ٯwq_) S}B:s<LjdwVtmaLå}h9t5yaM6#y3@P?[HG鿻;|7#P1 o91ɚqܨBkj0W%#cHПh OOɿ2@ΰ6ʰ뗢N36u<e6l?QHj&H~Em 1lٳgX͛6lٳf͛6lٳf͛6lٳf͛6lٳg10?Dy66R_R۰bqKea6lA:Ϟ.'=:S:jS=} )׉݅d?ú_SsZMJg|Fs7D[-f)iӋ}Bv !8<][4žm;tTX>+6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛<79O( 2eؗ [ڽeW9~kw>jicqahN 5ZD<{/}n^}M#Ovn,-tiـ<;(KJݎi L}e wB~y<[hZmVR,Ĝ8%$z(w.heoB>է&ҋ1'̟z9o?/~ƴԀ²%01HotVUҽ;iCXX7 ih_у)Gduuٔqۋ{fqm"M :0e?xϦ>Q%jvܢ*]Ad>S3׺ohzW?OIed^^Z^BRu>v8o;6lٲ+5-Vk+i#t[K 'WڸK?//|i5KpǠx˒bWPv| |5 &IqrQ_lmƟ [^H $xFy2[[+,MVSBGYX 04#%*33eK?4GyQ¤F7S mu4[8~LR^mj01GG:ƓXEi7+ͼ,me$gYK)㹶U&EpC! 677ue6z0y2+>6z03Ο>Qg_02L&Շ1/\Zu<_12'H`Dk {m"Ć}Ifd=6lٳf͛6lٳf͛6lٳf͛6l?,?Ikc'oKo'j%d˜ps9^n_ 18k#&59sxo=? f͛6lٳf͛6lٳf͛uQ= U'6lNTmmrd7M R7lٳ,QG IJ(" Q@f͛6lٳf͛6lٳf͛6lٳf͛6leU,*13f͟9;g7];s &;Z9Y6lMl=:QMg{ \[L9T:0͛6 ͛6lٳa'9h3~`[!Xn؏ؑ6lgW<$׾W=BB?JRf͛9W|#jI7Z=oKqUVdیOS6l]̱i[Fj*V**/hTf͛=1jZ~csݍ -`q$n+-Aff+9yjc?G6l6}R &$]PN'3f͆ߥ-f[۪۟6lߥ-fϤ>27t!&԰yٳٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6,;;³q5o)ڭŬڹ󍾳>9ڰک3Jxhi!Rᘣ#=YH)D*jCSΗ~ MŬNr$zF̠3׾TԆ.X15FH\ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lu`'?.uMm.M)O{;#NF0ξ[梬/dy/|!{q[Da|KEX _B_V <}]A (0;~'bW7Ϙn:x1۳oQT`pG+Nۄ9?!/'#5~CH:ws/ϯ/}j-gҥu&?ߞ'=a.y=8]篮oSe̕dmn9#3?yM3[Ū̧Y7e4hI W;>h=oZ~0?Y,볦o6ٳ͛8㎗^=7͈4)ڠA*؂)ǟʻSy6ڰ슠(Y)aڶDZ>󰪳Ұ.G8ϰSó<['yz^bӦӯSpק8U$_򔑞}cCk-Vnp6aa ? {uXZU{[+20X{2E82[&$bCiX[o|@FiZ?)oOCUobM rM~^jh? Uu <z&H(M>ٴJ3y#ϳ;0ڵ՜ZΣaIo?;’?5덴?:-4'հ<F~iyJHԯ@61V@)uC=~K]ay==SQ 3QJ?5IcwrK[8'*g '򯯩]IJR?+w>C Zs5<6UpGλ !}K*ƹ蹳f͛6lٳf͛6l_zW2<9 )b6''_͋OϞa3#ݣ==cU==cgp<Û6lٳf͝qrڄ^_itvݱRc'YwnW?.Ki4f?k ΉW?.Ki4f? 6\ȳ[̋$2 *6 PsёK$8)Bȟ!Rsٙ(ff͛6lٳf͛6lٳf͛6lٳf͛6rZg 2[5yw-?W=Bl9ZdɁ?7F?-s2[dOb^ZFOH͛>kZ?;[c9T:ٳ`ٳf͛6lٳf͛6lٳf͛6lٳg" ~X]KUӬhn$U̹f"Gh\?2&gɯ9>C-vೳ56@g!5SgҦ!W)uzz^[)˥;V}*bɑ1:fΙ6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͞+7k*O򟬅? ^zc'%y?|J_Pn$Zc\&.9"Ꮿ<>aEk/v7Z-~VPy+~G|/fK\VSWzTk `&~q{^\#Ү$xTs]U{Sk hnO\?/yk˖DzUď :rʻjd{ʿ-_p+EE71Z/Z.dx_by] gkp=hkT(H+Q?ϟ.Zu֟s\O ԏ캕4*MbFF ;mO˺u-ow(#.M=(WnaNq,Hyk24TԼ>q'ru?6߇/95|I?.~~ٟлXǣ>vٳ͛6ٳͅ<ͦjVO@ONHi -[EuF#oؕASO$QʼdPp:ţZjv۷Joj2-aBA|~mw>X?O?Zݿ79|sGܟ9P,O-jiZvڂu*HOFSMI9EjvZ]'X46"&)"a"t}SH{-NKK `|FW=38{i[~_ͧ]OAՠŏXۯ~JcAyYLdjc$;wJ`CU;FOc{W |d&sS$ρ۾޻3f͛>Rgc󲵎_Lf_cZ&8͟(ٳ2#?󾆬)/?󾆬)N,ȴϨ< 2E|z6_Lk0<6lٳf͛6lζ_d?bBjm =~p3~H~aO*rBEISn 4o!vO!b< 3s'uO}D 'x-OX, y"'] 3xT9g? ,'JF^MVeKVrjYB{,=_ }XI%RB4%hzagY*RWq9 /兾$Yt!nezr=z0:qE-<:Y&U*|#圧̿:y2G,źWHNCZtun Gu&qS_ʏ̝<#Mb+Ky]'!sZZRx}hVI%z5~y.aw9H ?0`H`A\0;r$\o&e mOٳg?2r>[QKr1viҋ6lf͛6lٳf͛6lٳf͛6lٳfR`3n,myt>իu 2f͛#z77浥Zg'cZ@mՂ#qlٰo woJo6l-ߝ+O#lٰ>8Ŧ:g'_Rݸv3(3f͊?~I.؞99fϡf͛6l\ji0j6Ff9i5` K T6l?6lٳf́um.V7н-ѣJlٳ/sfDSHTf͛>[,HNe6l?/?M\uH͛8NKoٳgsf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛8LVԼ܅/c!?c&l-lo_* ^ԄJ⏯ٜM~=j ]U3*ZپU<'q%|gu' }GVXe @ɨ6,far>}#r( } 7#%mY]}ZFQ0\*zsԪH*EAH3ԪH*EA^lٳf͛6lٳf͛6lٳf͛6lٳf͛ ߝtg喵,Z2Zi xCq Z#` N]ĨŀoIc@k^XXM$Աڳ$K)W?"Y3ʚ?<\3co띓TY\g(*kuUs~}7*kuUsЮ~DԳOڇf5mVyE5mVy}>Ӥ5ڸ»P07<#n8gZm*{ cc4rrє[ʾn6^8gZm*{ cc4rrєc9B?|0ҮgԴ7P$ՌvRb|IQT즑]ُ]W8 d*~y ӧP/1'%M#T^qTd6lٳf͛6lٳf͛#y4wҼbP& 9 i=U?+bk-VfNNF~s:pj;^c+mh$lj7x7X(\7`ɥj\xPS0,#<"GWg;:q+79?:ec=ཕ(GUaֻAm.lso"ІVn h煊MUe5| ' )4L7U9z|jY6=_ * "7~/e|N p^|gZ\kڿ޿玵_LpM(VN4Bcz\~4Bc>rE͛6lٳf͛6lٳf͛6lٳf͛6lٳfjҿoQyOM, ??!?4l_~|s /aBf/bXRX䥷5,R? g\Gyf͛6lٳf͊A<<MD%YYMUtrI$lRD!І<3A؎E"du4! O/O:uj=$6W`lv΁pj0=VQ }99|9 G]XK}tc&ZG¦ao|Z ̎i(QkS"-#rvSTA-G4d"n^w^[ BWNBHW-Nw0B,\_/GOgJ{F#o_3Ķb9% r~tC5~Q^V5Yt&K4 1 8s^F׃M ~$-EGJbmM /?(I)Z<:m?rE_ǯ(}aI4C `E.o0VC{\.ҳGAԐ`Iwd̻y'w7V:92'';q$}#0єRm  ENL?(ci?1eyF? ,?vvľveqگ!_oLKo&W9V[/Ld*>Bȟ!Rsٙ(ff͛6lٳf͛6lٳf͛6lٳf͛6rZg 2[5yw-?W=Bl9ZdɁ?7F?-s2[dOb[/e[Ҧh継HX&MV|ٳg);|X̶zh 3YGՎv͛6t,ٳf͛6lٳgߑmҴY"ٺ e'.mu\-`M[7s6l˿(yzOљR[vek%Ĥߩ͛6}'1 i /HPLٳbٳf͛6ll,m7]H͛>o$ʲ-"ͧⵛ6Ǐ??+˹54ʎ5-2ٲ'6_ʸ+4*-ݑۣ@ʺɖ hZN g}8CYyjOOyGWY2ۡmY!;X9FBp&Bs?󊟞1jtA ]R8hwR0XA$y)%1?,jx9%s}*2yƿ`;2^ZVZ^ۯ6g?Ľ"}o <&ݻ-s|"Cuů +on#F䞢O97_'Cq*qHF+|z]j R|G&>Y n%N7sx~>/92ww6lٳf͜orɧ?wGcQ?@:'y\iniA>\`=VRаQC ?<=kKuJ Q܏<k,^wÿ> w>X-3ǹ2xN/2ˣԷSu'_%,=0~? G6ߐeYty~{W= YL\GY-Ud4drok\psE) jdi psE) _WJJe^]:%sֿJy;gSTnI+e%,Ҧ*OsZ); ^ɞbMMQ'_:MVMf͛6lٳNV_dtG YiU0g:d+ES%=p9 $u2âéA Ɍ|ex<ń,iwa.>zэĊ["_<x,pv5HO-OUE*ڽ4{YNƩY LS 3>iHo;779XַN~JmONt/&1K/ONt/&3z$Yٳf͛6lٳf 2"E3(FG\h20)QP>Y+N$eap*R|ٳf͛6lٳfjҿoQyOM, ??!?4l_~|s /aD|es}8XڡVܳɦĜNo-m+i8Gv{@HbRz(btyn+l^SMj;srQ~j!FvXu)8WfX9?|T#mfa# t 9?|T#mfa#*OsᷟOX5/DhO<V K'3ʧ7\mSX5/DhKOj_?э>4/'Eݙ&<_QK6m'fOo%h:p&yu_A1{H9_W}? gE#4]dϞLƂ TC@gX㐚Ġ%YN'/w:mznh%O5Z-''xn@h$ liru?'|ocu -KA(Ebu!qm=8ʍ~FUt r$#5eoMZ̞͕N/9M{XOsm1'V_ <%y9;Ixвw+:^rLQEcO"f@xBJsO9[YF&"^u$xD 4˴'p \`ur'ihN4ָO_figMkX.L7/7q5`2L.~`AØh F)h F97&{m U.PZdH_掓l5MvM΀x\#%A#&'j"7 *6~j_|Yo^nbBUWw=rZֵ[R7w$48-B@\FfYGu뗚ֵj1!1Qj.qKԣZ̑D/ZGdeUu$3_;]uDm pF //ci.к Tw9;ugPɗ1ɕͪ/&%c+Ig&2cD m~c!V?mdOϩ9̔g3f͛6lٳf͛6lٳf͛6lٳf͛9I-c3Lyw-MW~v仿ys+!6F?-s2[d؛#-2gav,ٳf͛6lٳf͛6lٳf͛6lٳg!w?1cmRJ\j/¨ʮt ٳg 6l|9%渤տFXPzZe A9uJf͛ -$vl ,.5cAߋY[6l[6l_̟yrГ׾ vk˅)pb3f͒o ռw5t,!$Zنlٳԙf͛6lٳf͛6lO提ޅy?ESo;V>)+6lO.IO$b$+y/ ߧ5.u%sf͞ AbJf͛cuڣ#jrѯ.Xt6l͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳaO|yBUӮ׌PeѺXtZ֋ZlnqGÇ,QGS`-kEu6m7ROi8fSهc/徤Ҳr,ud +-۸i嶯+"FFQҽZ}oCyc-WD~i嶯+"FFQҽZ}o͠{y )`JwdJ9$E6)"He`j# Ft9I"dH2:XFz7rObgK-Uxk₀\IWoO^qkzi^fmEE}XG9?<6iVQ![^߽='ۿQ]20XBuee " s+(e n9yf͛6lٳf͛6lٳf=9 ~_MirG;^CiniҝV>7G掝{gdd_ۖ?, }%Z4Ǡ9ӼlvLZ삑7Xkr^Ե}N{٤oig)$F'ܓoF#njI"fgbjjO9..$i\6椟ϧ^_It-MV PGJC1eYhd5>f,K! (O(_yR`VxTO_>JmV{-Z;>x\Jٸ\ZȓB_cQ]~ҐGbVDx2#>G̶>gƗ GpZ.hڟU>={Əg[syʢ*XnN$HIJ/F^zDJS\/7䯚:ds_7?lүQ в+b:/?ѳ^JD*BȬ_Y׷gdi"y\8.X[G>8ǝ55N(Ƌ5 J{a^v!G&=qɏ;Eka}'jQ9nkos=6lٳf͜rcvzu l=]4jL&M~;_rr8RGf C?7}3Ț5KtC}?%qM+GzȷZi9c݆p?,K?5YXj&n/_8OengD _3_yb_1'+Uq5vFAzGϣ@(6=_,~%usW#iesQf'2i&v=EIHnqM048*N|]M9LNDg՚IiNlZ5ȹ5$՚IiNlZ5'fw_od`AY4zo' ton['-[LzZm以~pܹ=P߆}+\=s6lٳf͉]ww*Akn,B"L`8dwXK#UEI$f$I4rq <G *I(Bj_3yCHg;[eoz,G?75|`XaR @K ԥ _8'汯L @7 Y!gvٳf͛6lٳfjҿoQyOM, ??!?4l_~|s /aG&hZދIsi3Icfb,SC»]il}ek b%E\j$Sv.{yL46}>沵GOO1Fpkb~o?0Xm׊~G?ct_^o ՋUo,նkjaVߺ/7א?ŪW7 ??{E55o\0Xmכkb~om~G?o,նkCjuUCyM[#7 ??{E5?ߑ3V}ȑe7?:en@}W?o\L-H;UjGChh~xb_\yWo?2<ߦ}3hhKW:1Z/Z.dyMofs##C_t9b_\~xCբFG{ʿ-_shh7+EE7Zs##n/}7 VVo*Ե}#CբFG_o?2<3YIep" 1,do9W|qA[2F' /Qˁ<(Ag*75 kxHD>Ye${m"Ć"m~c ,ȟ!Rsٙ(ff͛6lٳf͛6lٳf͛6lٳf͛6rZg 2[5yw-?W=Bl9ZdɁ?7F?-s2[dObi ]"B)왳f~S,! ) R{f͛%Zs=B ~vj7$x͛6tx(8$h(B@͛6;6l_?-[S5.s{+up\y$bƒ=f͓/{FmheY[kXU1v݉&Ěٳalٳf͛6lٳf͛z&7ZFlzmzw6P֕Rv9fUDd2IF_V͛6t<ٳf AbJf͛9?(<_gZh͔2 5(xӓ'GRy 9'〃T I&kvg'GRy 9'〃T I&kb&͛6lBk+x=ȲFUс|N -bIJOPv#3**zK{h%RE"FS23hZI6r5];>>(C/Hڲ/<0YQI_W0Gnhr9~BC3yyjͧNOM1eOKJ.*B ЄzlLr ϗڭrZ+S0S,MD*}>^KjR˿QhNªNK.??1iGCeVHHxSg` W `j?ؚ{bڅ+rOmyO?͞ZU\X/y\Adbi힅懑oHǦ]4冗vj%/L>ڹUմ}>x<_xaxgS? |r|ߴxsߟZ~lEK{fco%v@Nqv<%- pJٰ~^J3txJZHۯΏ[aY<ᤰWp˷gxE_];W77V bvjn )==_k/0kP-qM32%kNzǦ?ojڪIfOQx_l +B6\巙-T#wT61̞ ".A~PQ4}dodXmdi2DS@i?>EnG/ѱvtØ I*IVm 4|Cge+\0(^)bj%X#%Yf͔̪Uf;b@@7$Hhן󓿑 UXmo$ٖ?Cn?8.:vpDtp)G Om5Wà޿HxgZ_10QZ~p$Y@W*YNey}9;Vzߚ-R-np-HDW Ynd=ZשjHku/(j@"yUt]A&kfF!FeuS@öHpIZt":Z]'EifdnI"̀fWU4 ;gi?"Fzsb-L~;0y̾PͶjH|P6?.# '":y`ٶխZ I\=gTgy5#F* ?4/n[ǧ162.#Q5m$|U$JQCCȿoږ ԸGնa9]!unϭMc# {+u&Ov~]My5 -[y/U"?vSDMBKf=bb餋7?1+wzְ:spFpHrϩϿa40$8uUd=(?}y6&s*cM( y_3<ElwbO -,'vfcD#FrMOS?R_okD$3u%₧TtQS$TQdI;/L~?-ywP S„Ώa{[H;+Bbx25;II0rkjHVkۼvWmdjwb"`_?hyex#ΟŦȩ;'i*]flΜbM XwhXBw) vz ħDđHO<ߝ~tܳX1Bonhj9G@=9"a#0zlMMabqU@W{s0J(~S^Kbjm Fʹ///4Z|01C,Σ8ӵ}Ug1)w_ 4HIBGqK)j ;hbROvzo;g`͛6lٳf͛6l_M=+vw|ٱZzAyrSK/f'?0f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͂xc{m"ĆZ}Z'=flٳf͛6lٳf͛6lٳf͛6lٳg %{? .%\ O_אOwO.sy3&ŮKC|cq?%FLv,3ś6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͜'ߘDv>j+c*d*6⛼mҽW 7 J]Ȉk[{(Xr)o;$7 J]Ȉk[{(Xr)omOM7Px.fI#bFykK76uWSFVV*Œ{/-.l洺sn7Uu4`~ ebY=/FyTkB-r*k+vV4A^;㽞+TPC2=j"#S+LzR"CXZB>!ʠ_zg:g_͛6lٳf͛6lf~V[ AL`UU?PG-;F=ViE&hiZP @?VP=X[O8ͬWqq^of5kՅTxC=|-c>f >C^rIU]e9Cе*xڿ#ꮵRм2o疵B.sjXêYH# p_Q.Nj>!w䆕Ʋ.%2"90ԓ=+K䆕Ʋ.%2"93ݹ<f>#'jsIo66?9>IUL)do0&"9Q;kSUSۊ߬.NhڇvĶގCN:qCCu[Aˡڛ_Rt؞Փ= pMNQ՘)%H!# ,S&0kɮuFuѭWbh? ? |l&a4?Dj:Ǖ?.(sDӜ-趂JcZ>,i8o; _>kܯdA,-.T_ O(YRe,Nl9uzP}oƏ^ +Z&SxueO޲ ilO}i?(.^- ~gS'~[Ɓ"AO`,cUY${M'G4m:+J$O8$jG@2IfbmZGR%iV5$RI8g136lٳf͛6lٳ~d@]Z[{TZ̑I(h~S7|y~jԣ56 ۨEE* sl prv4ۯȗ,|J=CSkr,C.PvVZݟ%ȩ$?Fu?hZJvj0sxnKφ4ghG5Χ8 _2iNMFqm`?ٹ;lٳf͛6lٳf͛6ys7o4K=YEjG[i[27cEQ>mKtw,-m:o"N%~Ћ{;lsy 8Vg Ε8D?8q+q0R|%d9.՗L+E辵ٻ+QʲzIJѻٙ>(Į#ǘ鄾ʲzIJѻٙ>(ϛ7Ѵc͛6lٳf͛6bj Ro)^C=&j]ޛt+owC')Q:l7`Ap&j]ޛt+owC')Q:- @׵ P^7mĖмLTT{g]6LKI^@ *=lIG##}$<:fu] \ZJNHiQ{`+{"S$R)+> C*K6 :SPFP$FnY!%IGC)#>yy?`N+Q22Q?=W_sXYl5H +وTd D9.kk: ټ%`;1j<~͛6lٳf͛6S"3E@I̪Tf̪TgΟMP۾5 -)P)ySn&_ܭoNTPH7lW~m>]yKZכq5mzpEʢX=3Yvlam?4 ̰$3"D,˚mr-l mN% LN󷳁ۊSg |6Pq_NG'HZ&'A9 /8%;h~I⹉L2w'cߒd6b_ SVgNZĬ?oכv7__Kk+c-VS7.7?o\^%?Dyt}o'OI$NZk17Ecyh?1y1Ӗ-Mc?=' ?tHށ<^CѵS~4Yrey3F-N_F9-<٭ ˺:=P#B1X W|oPjHY(崯7ԭ=>WEuC~ _M# @If@M2Ad6lٰass"ĕ=EIj:ZޡslL$k*l zvjzvɳM3Zq1cWi:T۩hbX >?<ڷߓme΢?L_IZp(?ڷߓme΢?L_#qpfZIKnfLj?)OȽ8D' x|?"}`&R~#ʟ?zouuq\9,DhTQrE~wyRbit[a ]GͩŪHhICP"?;HM4lJD.iwkymդ[L&H#哸'xh$YarIV#c AFNIeA$BXG|#Kr,fVhC)OW.}X7Te1SLj~s}V˦aW.}X7Te1SLj~Zw<@ŕ.H."JU 4[Ė¡r khq-o獅CG*8#9m+mbYMM@;,Z0$pFSbuYִ`H72y[6?ՕoEoz/ogcI0YMm#X~ދ-:?YoL?Voz/oV/_f7}y[6?՛ދ-:?ՋMm#ŞV͏$5f7}buoz//K-FHj4lw &KYVY! )S] ,,Fg_ol51[}vAmm^HY mVbmΕt˘mX~pBnY'ǐw%{,=?q3ُ?FI4]^O&\?0'j0S;G7#w? 6aYFTCz7q`?-%by=o9ţrC\h55k#D} s  vTTs&W/m>`jplEEG9?ep\_/7HeQ$O:y9*ks1Ob?ΞNv z(>^c.Zj-e)9zlԭ;-[K.,o 1иDzW4Ǥx0juj]qcyю$kҼIv ͛6lٳf͛6lٳf~kk:ֿm갪4(CZjOV/+ǡĞ9 o WA-K~Q5'u N+[—^K@9tP+J=N\~{Tu<*~a]ڟr x>+TYSq+?/o%5ݯ?W7%_?SSp]E/閯шMhrl&G\{h?q 0.Zׄwk?8]]ZykXRP)8ꡅG^pֽ4iw- 2a@Mn`+֘'B󇖵馃HKmi h Xw>q6ٳ͛6ٳ͛6ٳ͜$&<~v仿yp&?^A?;]K<?e#-2`}M_㑏?\3ذ;lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6x?rȿ+B>w$ (7+?xί-Q/MU~eatX}>!k9uWQ&?q<线|#J> 'sl|1zGG̟RnWPtKPG?>d-䲕u՚LG_9ڳ9f͛6lٳf͛6l R?} Z 'ƟsCIzáWz|ppU(oPy}6_?H~"/Xt3OqSq`q,וjfW'aq_חYt#) b~xsMCQ?۝q_חYt#) b~yaW6lٳf͛6lٳLOQpu.̏}gq^2WB&wNo0sVOz !*|<)>Q-uz' x$HWF 8FzΕ~.[u )e ('Vhws_KVH"|H# 3g]dk]&LiV%Is#DƑʴ䆟N|?2hWq[N]cYUݱBh88.L!*25Iƞ9ɢë\Ym9ugyUv O$^&н[t?PB:}a ߝ?M BpfGy6W3eokTc,ă(cC'No;ƵI&?ʒj\lJFO+E#&_(Z-P}hC=3d7[;DޣIXZmn/qpEBCGWjl= |ySDQZ[FR*Ƕ#urmE_uMMFil YH^io3=| }jb LvV6lni'zcm oWj%-s}pjOA*3/s̟3I\HI*]wcs>R9mc>`^ zՑm߂@V@>Z'm!<ڝW0^V2l2GQdn~ִ?O(BTy;Rad?u'~I^[m6CZ\[^\.t /)ݰLX֕ {iVDP!_pO^~I~^O HecbFg;?Gfx%QQ@cM |y+K35՘([Ȩhj"zMcP^F6AUd·ےɿe"W@{"zMcP^F6AUd·ےɿ&_i6Tj)"?zcsb=y 19 M_3ȚN7aXϨ^-cy u!1c-WaG?T(xS.O[kyn 4ب':&8~"ymj6?rWi?rˤ4hڻ8o.zr]%ʫ.ѣwXc#j BV?2k?1??Hj~A*KXc欁>`vv׺&u $ (+'kqL5#K%m<=Y ƃ}^ETnJy?"m.O+d,*ޓ~ɭ|p ސ$ܡolxg|hz}=A9hj~9[W'=dz 姓vq$W̾QmXX R|;6 u%K.F ͦFNVp=ocgyyP@ZKGPx8Ww<`~|鑽 4z}eH>@cw CFr.WH󿘼+}{A0^@hjc2G(ZH}"^]V-OLҸfS: H8e1j^b}+e;HO@*4m1WMSMfx=>!AJ!/%ᐎOFGqu؏Py+z_􄾳`ZWB:?u4- ٳf͛6lٳf#?,|.i2*5SM AvGhya{NǝܤFQAX)61ihFq0=cE nRI#z(,xKN>ܷ];n!ϱg2mܱ+ǾzOΣ&ⲵˆY-N԰;0ᩑVu6ٳ͛6ٳ͛6ٳ͜$&<~v仿yp&?^A?;]K<?e#-2`}M_㑏?\3ذ;lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٱKKGTZV!ToMlٱٳf͛6lٳf͛6lٳf͛6llR,I,NE"E!AlAff͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6q"?+-m6q_BRCs-t'+%uIˏz`>(!%IIo}*Rasy"6bXcJNwWtLǕ|_'d8m~6$&.J)? 俙?Cy_>-z -9,祳f͛6lٳf͛|?(y;V% zmʑIO {$e_ <ͮAhڴ)i:+3khZ= ZDΪi"r|м?U KsU7U97Fּs^٭Q&Ě G #ʂsznyV[A6{!L?i4LK 31y5 _JJa\Okߢ[` TG=9oo2~Rip+m%=6J4W)oo2~Rip+m%=6J4Wzk_ 'M?OR_ꀊ7.@n a#?`{V' WPxt^)a)c7`{V' WPxt^)gCNNlٳg54ȭ1ӁJlCL:)d/.`T ="vg3w|ٳfϘu#Ҽiq'wj*;Gl_xeitV#90٥"KkU, ?]Nkk/ڡ^$uF\KV㕜oA$d$I)GYyחݘ+g%?Za^vS~5Įםo|[0;)ʎYgl>Fi?:6׎02mO$#/f”2 EoWՓaY#v?/LmJzW6lٲ1yw_c_)k;!̞z*;?njmޗ闩X%,.Qe9I'^H̞U26UI{]w/ xfOF*./1[mZ:^V^C( y-d+l!J90\+ph~hY 3o4@zϣ g3f͛<9yE[Emn>[F(EgKQ80z~Rsz..QEXY@ˉ s:'A@Ǝ=sz..QEXY@ˉ sgCrG?yȾc^g"gb"AhPG%j|P5ϙo-jZl%M!;|RH$FhGQ؏Y6Z-KMD=QpoA?,3<帵JHK#ֶ(ta'INхُ!$1FߤIMB‹slMՇTaW:Q@eI6lq]33KkXU64(E9fΓ6lٳf:~Fy1-qfP/byy)xW?g6lͿu4ա=͛m>is(Bn!'ZI͛:o/ 5Y|w) {>GLl=8lٳG$rƲFpH*Tlٱٳf3wLȟZ,4mcx今&hVF%|9f"k~hM'Ddī ڒ=j}ٳfí+s]G_WJFH H6l?.$-|u̚F1?Q"KFZ>fΫ6lٳf{yyF; ,X4j|Yf6iիC{+͛6o_?hyeyfCV?6lٿu4ա=͛=gy2yB85K(n#2į*`.Ulٰ\E/ M.އ3nUK*+6lo)^Y0kWKAnG4Uv ݎlٳD~n6_ZGtSЊQlٳg)VHW6l:jf͛WOZ#^lٳiիC{+͛6{S6lٳf͛1-Mn8b2hbURD= 3 c&)xePH$CЫ ~c>j~dy:ɾy|5Hmݺp9hI#yA@%Hh⍾ n ˶yͺ *EDǫDm#O4<.c&hjp9$E6)"b5b@j6#$HF$BlAO]8|-hWֽ_"Kw:ӵ$SOjgtYHq~?I-f@waϾzɾ`O0ygOՔw]G̟ {dq\9͛6lٳf+i`Qt"ɻSRBۥf܃I/9z /-iwzұ!b>XW\})q?3YynK>3~^ 4w: )[hfI%|Wc:W">IoXoraKv/䯕WJx}gY"y Bة-<.DV7,-Im䤐7p8MQ҈<->=3 .n>vp8MQ҈<->=3#ʹ.)-,34z2sƺ7׳ݞ'#Չ볧5ԝQw5B%91[/lȑǴ+!-'2IJ]ʋ0ԑp̳>㦳ٰȯ5>Jq;<Na=ì6lٳf͛6G&\pRiq3B8ǩr83 U'|&٩K`8i6z:7L*ʾ_^M}%X0 t4<506lٳf͛6lٳ4aeyrSK/f'mkO9OM,< gO~PU/A/ 2GeCY/A/ 2k [$f͛6lٳf͛6l[c&d;iJOFީosw_| y)cQ)y[R}#cm[GϦf͛6lٳf͛6lٳf͛ (07?e[Ml?`-o8 79aC`TB/ NzC3f͛6lr&+_Ο5E@9[Ns$?: 3+D{(5s$?: 3+U,h7$"@'`}LXmiR$Y5_gaP&s?ߔ9GqP}e%2Ec_`v==K,uY4 {$Rlݪ(= m$)҄/kO^G~մʲȵްڇ\䍶ٺ=VUzϱSz:څE%7\[G8#>gҞ͛6ٳ͛6ٳ͛6ٳ͛6ٳA9K?;]K<Ux濯 .%\wgM?\0>&ŮKXg6lٳf͛6lٳf͛6lٳf͌ x$EUW!UQEYo6lG䎣.VK?*GXJ,veSe6lR=y@i^^ŵk$= [ H_lٳVOaOXͮݯڸ“ސc6l+3~h}'RFN-͛9.5Xd˳\yzsձ?G12uY<3f͞[ΤvZ/m)/@U o6l=6lٳf2GIh7>LU J:ǫk1ݫFGf;^WyX{}.X%KK) KT>fR/pJ9<=ǘ/ ͭmA%""Si7fΉg:iQ2@7o6l/ }2M-Ο3I+R0͛6yq̿+u_/CF6I%c"[` b6l?6n'Y3"D5YV1YmA=T/ƃ@nf͛͞6x/r'n,3f͝C?q/.S+w4)Eo16lk󅟗PMGL5̍ H?36l3\yiZҫ2tjarRhU>DfV)mjqޅNփ鄺I$g7pV59f6l&:$sf͞fu&VkboR7W6l?ɯffB5,6lٿP&f͛:ח-?[:WnL#qZi6lK͟k?s&[6lS,VS6l6lٳf͛6lٳf͞ ۫ ?Lٳg?Dgq6l깳fm}(Lfi5MOQ\Iui~m0Lb_Oэ͛6u?ɯffB5,6l+JTK=N]XI Zn*f6l&:$sf͞,*krڅx]#{ٳg'84̯/vΖڽUtj.z24OOlٲ}6lٳf͛6lٳfd܇Vvlٳgk6G7n9f6lߙV=H^d4t) ?-6l.vSMQ>*I6g'ٰ$O.$԰+<?*lٳd_#q7_f/ux:$)֍6l?/)ly[O/3hwoUb xȷ2WQff͛>De1!Ue*=EBYCSpB+ރ6lٳgm[:_͛6}?g# ٳg ?2[˳SirDrOM,ٳg QwVONbDj1}1lٳٳf͛6lٳfC9IMp5e \5* =e ٳg/즏_;z60Vyx!͛>f͛߬gP&?¿,q|*/*קuy"OaOMRmxpy/9k. 떀0J8ᦋ>/9k. 떀0J83vٳfiZ;8d$Q)wcPN%wuW#YT@YK1 J KYG49言<_!Z鸻5O~ @ڦynRpe+k_ٍB|!@׷vQ;n01J?٭f5 =C1 BG*(8$hP(:(8$hPNgh~qOLaIe'ݕFq/o/ӵM*хZ4dw[__uk/2;ےU?2 p.uGJ>kE$jc/'7WRaƋ7(# Gy|Ƌ}HՒ_^OoHgY9f͞i4-+vRmM;^ /5[r//2zmzIxY`3jzF|M?_^d4//t_J3HgcB u1"GĶv!No1,I̔՟7DJroqL~ s!o?Y5y:BFTnM):fΙ6lٳf͞@_79#aQ{ ֑0Vr<-GBIy[0MQ2?)]O< (G'7K1':VKNKf͛/< ?5yJS?1_G9wJ1BFBDn6nL&'#n '6ox/8mhܙhMjOSg<ٳfϞ~Cw~FF-(×d^ߺr<婴8FT[k7XQ 08<揖|}R-oޔRbF7QD6D_U/aD v0;v_F853:/f wK-ZGqIs^~w1ǥ~uP 0T#zNԴN:++F{ hdrh:0= H*ziwkyoͤqo(0t`{xlٳf͛6lٳf͛6lٳg5i_÷˼'_͋OτԟsϟY6/?>90ϣ(_43_@_@$H3͛6ٳ͛6ٳM?9s3ӳ|S߬)+>S,VSGʷ"!oIM3%_͛6ٳ<6w9ǨCxb;VUxhfеϬ~KaōiC`M 0D6}cU]Uw,kOzx3͛6l*gɖZqoo6qtՀ4l F3Yr[ DgB/ S +S39 jl_5Xo8Pp'#ڷҫ\9~[]y䈝E;RR#nQC_]iO {aGْ~sz#lf]R>kfJ{-랔ST>f͛8Iߞ10~3~z/s_0Yȏۮ;CS|Gq?JLE:&OXZ*_No{"]MgF&(@$~t02)(?rES΍MigP-ʁH;xx'H'&),N :2byHFE)"e`hAJAb:RD%]ЂB2W_3Ci.^!5<"1Ƅ~R~N SznIMwVص̖Nÿ'yTdţ4[RhG]պ}.Ah33B(R'-~Dn*z>f|ɤũi38G 1$f9,I&'H6k6lVU` q1D7?,Fo9S&?k'FySS caYp?^ySS ca?z6lٳf͛6lٳf͛6lٳf͛6lٳf͛9I-c3Lyw-MW~v仿ys+!6F?-s2[d؛#-2gav,ٳf͛6lٳf͛6lٳf͛6ysV}7N7 J1sH܈ )-Hf͛9/2=<2UħtV>'#p6l}V$"DDAEUQ@ ٳbf͛6lٳf1ysE&uv{' GPA*wV͛6f͛9wO{ie jlFaYg*N͛#6a6ٳ>ռynҬǸ鳧ʜٳg=5+JC5zwǥٳ럳ӽRʼGs͛͞6ٳ?2no;6ٳ䣛ڷ?jٳ͛6;4=h$-*0͞ԧӿ7lٳ͛87Viw[o麌& iZ9 ͛6qËm7$Iy\ r~f͛͞6q_W?i9f8mroe\sf͛͞6lٳf͛6lٳaW?LlٳYDlٳlٳf͛6lٳf͛<9aW fO.B6lsf͞5BPsf͝pP wڧ͛6z+6lٳf͛6lٳf͜Wr$ZĎlٳȿ?}$Z^$$ ="߱9x6l^e応~bdu6Fe 0SI =#Sqsf͞?10*&%DZG6l5͛6lٳf͛6xs'&?ʶf͛;_J9s&͛6wLٳg7QO+6w*{Њ͛$a-N?hb+I6llٳf͛Dhz^69T12ImdZbT2͛> vmf;zRiw -8 ͛6f͛6lٳ_w7o'+.@!` T\$Pe9fΧ8eѾOڐ݅D?J_'`j!q$3**|ű?/t/!CI8BpD{oc z\[BM~Uǧn#jN!9翙Ff="ά^Et/W\'1;]KYǵ e?_]טJK|M=6H)[#wW:8qV:R[m mZAO97Fy^[EjՊm[ŷ?.pf7^WQu닏>eVX.Vջ-[sR=iZfk!;{hD%(L[Cil;{x(PtT@G*P((L[Cil;{x(PtT@G r\ٳf͛6l>Zpȯi 'oؿ?8OWvNgnrXs^ɦ,aT!:;|kEe3 dmYa"1޾,Otw^& k%5|$a徹/]_R`R, "n誣T綳u͛6l~m~Th[m/Q${yi$j؀DwI<ۤ+\EVQV> ռG|3ͺIUk;hi3?m_l%mo#\ d4a GbrnjpDozo mn,ՊSiV¹r26lٳf͛6lٳf͞+ɧ.ϟY6/?>k_R?Y>Bielؿ_>JY~^ ?;/Y~^ ?\b ͛6lٳf͛6lٳfϚߛ4mK$#SMW}7wM~G/5Uåt.xJqL/oEg|S9@ipԯ1 ^$|7U) Y✠4jWޙO=+5?vo/I TOgfO7RG7 eXyN'fo/I T5O0jE֝ =K#Krn&EqB* ZQ RkM/M]=RZyL*,a[ͬV8"jyrTKWOy֞S+aJ V;pFc9"wE\ OĤım~CW('5R}%#%ί9f͛ (07?e[Ml?`-o8 79aC`TB/ NzC3XtMj+YHSogIc_wDv =VNFyrKҮ)Z#A}QEYC@٭j8WESYs)Lw:ꪇfXAzrڽAe Pf8WESYs)Lw:ꪇfXAzrڽGmF KjYmA} JwEF|u/5\/!0iPD=oטpTBPDJ;v_˯˿.ypZ׿`͑?v)06/ȏۮ;볢읿<9#8*o7yRd+^z1ZWm~U~Y505dZڨ\*ŀ|RӽZKۜkɮ葁"@W, 19"JHXAFpFF(૩!GPFM\QWRC) ~S~jkߗgVӉZGicZc A:j~SЙ-ދyfMX=zvTbR[KwS G5?) }hLE&,~̽U|3<:yv^nDS: !)VwH -+TZ/o.̧gGi{0= 1$f~|z˾bҼEvtq׳XVU` q1D7?,Fo9S&?k'FySS caYp?^ySS ca?z6lٳf͛6lٳf͛6lٳf͛6lٳf͛9I-c3Lyw-MW~v仿ys+!6F?-s2[d؛#-2gav,ٳf͛6lٳf͛6lٳf͛6|Lj^;؞JD6l䯒w妉] unWI-|x{(͛6N3f͛6lٳf͛6lٳf͛6l/4˪~i.W@jʋQSlٳ2-/ .G!њ%Q'͛6wٳf͛6lٳf͛6lٳae(j\ԭv߄R V,ٳgTԼ-J c4kėh}Ky*~|hsf͟M༳i,M⎡6lضlٳ54jjyG.pkXsgDf_Ϳˏ%ZyWPUokM̵DHnbՇf͛=8eXܲ<-`PF nsʌ3^P]Ν9B0oZ>(kgNՁVUer+9!ʭRh$T 2†# 6|WCaagmX?¿Oa/ϘA*~7wv5l?Ռ1+Vtz .w疹_yebT'6JGpK{|+r8wc~,ͨҰ/v5ݛ6lٳf͛6lJ|03?_?O9^pȯi '5g#yȟ wڶKFZUbVEЏP3пBv*Jh3Ɉl^7x1пBv*Jh3Ɉ'3=~Ḱ_ʖ`_O@kS \G?["ѴH~~a䶥lCI.g%yb?J`C_H,M(a\cvL(~K_]֒E ?ػ:}37^OZV]0DRf))ۜlO|&nogJrC 25;rRéGr}s?ˍmi779!)=ì&lٳf͛6Z4tvGOyאfSXve U4Z+hdQH*+;;6H H8U4Z+hdQH*+;;ygKpQ?{n*]0Yu,sԼĦ-0h4 jswZ; ?q9BA^ybSqt r56jva[Kg{n'9fFVV[]D\Dx U;-eeba...$จ*w Ft8V%c/Lz)ٔmm3ݱܟ֣;oyo]+:u럈6Bz'o 65b ԟߚw73vc$8׮~"@ O잽3yp;.lٳf͛6lٳg5i_÷˼'_͋OτԟsϟY6/?>y90ϣ(l_43_h_@dA_h_@d$H3f͛6lٳf͛6lٳM?9sR3w_|S߬)m+>];k9wqnuHg$謧؃L !o2 !CѕPMPX> !o2 !CѕP}ʁN Ւ?g\ Ւ?8+3*҈E?ܛEZErGN?R~T^rmi}g6W>M5([K]l&h&HWD#("^}zDwq4#D 끯4q < (*H4KϿY@4(&B$y#cH4=qo_@5jxcR&/Ey1OǏF5/?i3Yp:lٳaW?L0ɳTag>1:/ݍwi䯳㷡#ծVOגW<ǩjmSFee7>/; cM{a1Zy{$Q}D fAR_ɟO!7f}npL ?;\sxڌdSޓ=Xy5ko[b[Q{c?$Ylh%#ŽĊF"$9-hՖC+QʎH. UyhyuG?5yv kpm5er)md[[>K/5~Xy{W^"f[{@-ŷeGg/ּ-DS,_}J{dQ-oޔ?1X_kiy;KZ0UXveɮHql͛6lٳg5s1֟#P&ps_@e?Yk89_7 /s{uohjo9cI߆f͛<98wmyQӣ-ꁻ8[,]ae489]Z_%_ޭf~9gB .VQv~ş/_Hȥ$BUс  #8 #pUԐE## ǮpFF(૩!GPFN'75o2 Fη:]#t$уʟGBrI?<>-4x:N?f͛6lٳf͛6lٳf͛6lٳf͛>u~~$ߜly^(qQOlٳg"q +iz}G)Lsf͓ٳf͛6lٳf͛6lٳf͛6|޷SAuRñ]f͛=W+a dZU:lٳޟ?QڞHUoRMb_$ƞfOyO#bib,A(I j?FlٳrG,k$l7ԂH ͛u M7Ood%"Ksf͟5Cξv<:Ϫ\2^BxFv͛6{_y2Byg*hLrw3Ot Zbo:/Ȝ]~̟ ϙ?C%jZנv5"s~~WWpuA7M 'R$Sjxg?roo-7 (<#ޘiz6Go~g:X!{85KV 5M6723:"!;򿯨]tvY6\VFꡧ,[r6_~gs+ߘJh #oUda^gtlf͛6l/%Vx%6I qq{rĿKx=^2}XYCTIU[wǿ!|YiK۱a׃'X0eH9ó>ϗ)%Ӧ%'pW$z׽/ǎҴWðy/z׽/ǎҴWߜN~_Նo~ԭHKOl4CF?do_ZRڕ)ri풌9p6lٳf͛6lٳk`f"㵤4s 5bT?_?O9jGWwI/+ &\'7K1'$ow9?Jv vlٳaryk˩ɮ&fԠ,]0 qlFj+e$Jr?zc}89A_..ڊ@5=÷^c/6lٳf͛6lٳf͛ ߚML:ŰS j.a=@+o 9/!hk1ݢo}Xmi?h>ҩ#C^)Ѷ%?,&ְҹ%̧?>u+麟AZ;ʹ-،_[°:jm:2"\#<.C*2)# HeIbbІSPA 6#pp)dT&),lMe5lcS$h~`a]JQT`z1usz$ٳfRJ$R)Y#`YXP莌 Tv ELDtdu e"yA퍮v 8#)ȬjKtL:}6poD@RG " )=ИtHl'4I rNlٳaW?L0ɳTag>`g1:8`n#:W4`#__E0HazC _>@>z4XS/b"ȥeo,2yJOkvOgG!Uq ^ِ}'tַh-_>u::;#WRC) 甙YXv 甙YXv wGUu%ITԝʷDf;oϘCC~VP{J>' tYxOoQ8>_$"h?IRgeL칳f͛6l/?M\uH>_gaP&sW'6Ds1Ĥڛ"?nRg3vٳf͛6l|?SUXQ|K}OPuO[_HWj?}_u.ԴRB?yk=m~TS횏m~|tXe4e;Gc P8O P9%95O0jzUt:G]Tߡ?jQ=hN!ol:EIQ*S֌οho=BW[\NzG^ve=3Җz֛hRfO q&óX凚ZԴلuø~Jm1~^sl?1_\?מbBc>r͛6ٳ͛6ٳ͛6ٳ͛6ٳA9K?;]K<Ux濯 .%\wgM?\0>&ŮKXg6lٳf͛6lٳf͛6lbh)(R#lٳgcNе6SJCKo!C͛6}0k/-iz N~>*Ԛٳlٳ͛6ٳ͛6ٳ͛<9?K~t륖eCq6lǘ&CqI6r1?#*f͛:lٳf͛6lٳf͛6lٱ+{;Yd[[+}D6lZ`Fc6}=Џrw͛>ySH:7m6Ё{͛ ?%k ]̢A"͛<8Ϣ[V<ҚVW6l6l9|<[[GI?܎Ac1M(ex͛=K8W卵̼O/0A5fEm=v149f_?>Y98іSNo=,ٳg TeCGK[\֖_`6lٳg_-/S%kt@=3f͞?M~PyVL)j-fM0͛'fd܇VvlٳdqSRkeѾ=7p2cM\ٳgfutxj &yxdp;͛'>趿Sm6^i:}Ɯa4I%hABۉS3f͂3f͛6l/?M\uH͛8WMɿs'a͛6{6lٳf͛6lٳfͅ^l[Y2ٳfϜgڶ?fϦf͛6lٳf͛6l_N_0Y2f͛=?8'?}u ٳgU͛6xskS Ce͛6t_@5j6lٳf͛6lٳf͛6q_W?i9f8mroe\sf͛͞6lٳg$\ʐIQmz>`Ž]6yG_hMSO,=WKbU."SAT͛>y#]mOe8jxqlٳ?7!U6l Qm[5lٳf͛6lٳf͛6lٳk?k-K am+VaFlٳb|67RXXhM0|3f͟@?%y5/ }f fɾlٳ嶭[/L͛>?ʳlٰVlٳٳgOο$&~fkz,i7:u:}Z.5͛6{g.#󾵏sڀD',ٳg#|-ծ"԰eӶ$;gsf͞d?WNi lRh .Biؓ6lf͛6lD˛6l_+5_n\lٳ͛6lٳf͛6lٳf͛6lٳf͛6'umoum-b[yѢ&Yqe>d4/ )zaBf AM SBʡJHV |uǓ|nj2ۻu{ws2Fn.;&Jk)17}(A&3'ol7tt12TYHV(BGaXeIsxMYMAw 7YbA0u 6 ?96/-YC (S E D{yΑ H%*< n},zyΑ H%*< DHf5w2s{lBL/<|c F Ïڙ)`@>zɞ]˾YVH#L풼:p6lٳf͛#?~PCLԢ'o(~%s I%_6 N4 }kZt,!'~(p3椱IRHث Ђ=Ȯ૩!Ar4Ayu$2#bN?%1G<2")I+JFH/|p$?f09#P$ $5h?Ÿ'>X%ϛ5qåJ󰪵ñ}yAI({3ymnz;_\1n%bbUq/_pzdG7V&!W緳8w͛6lٳf͛6lٳf oSOg ֑0(SEkHi?y9#ϡ_$&sԟ._'|i_#z%ދϝ+%'%ٳf͛6lٳf͛6lٳf͛6lٳf͛6l&iʭNƧQ#mNz|JW _xCmG z]Y#SMW}'YD!oIoECo'W>gK͛6lٳf͛6lٳf͛6l*gɖZqoo6qtՀ4l F3Yr[ DgB/ S +S39 .ѲϴW'_&լ9=ٿ#`6lĿ0&DX˨Z{ͿR矞'B W?g݆swUUG 󃮃XldmofʽWrseP==^ܿ%9seP==^z;gq͛6lٳf͛6ls/&u]*!Av4*?̿ߛ?Rk4E^̑RGN+4#;|ߛ?Rk4E^̑_2VYMN A#b A#btO]k$SwMJjZuhjT ?fDɆDZ!PȠϥvE^C؁wnu!PȠϥvE^C؂OPS ca/ߗ_LgH9f͛6lٳf͛6lٳf͛6lٳf͛6l?,?Ikc'oKo'j%d˜ps9^n_ 18k#&59sxo=? f͛6lٳf͛6lٳf͛6lٳ??h?Khy}R|)y 2=o ٳdpfKf q{ԍɒk|Ao ٳgsf͛6lٳf͛6lٳf͛6lu ME>"겷(yfU8o8ɤj0pi RD31;<9칳ftٳf͛6lٳf͛6lٳg-?6-*?4kz|oB?o>f8}73e2ZXǜ|=6lٳ߹f5n랏x;^nΙfȏ&:1)=^uE͛6{ 6l,/.Ni=O,k@K5*)VOٳg<|kgq' / i@+?/^lٰSRNze}CKުmY H?͛6zqec}=_YruTz17q*TvbٳfΫ6l/^/+mEG]6]a"&lٳkKv&]+Q*CqHf͛;lٳ?7!U6l Qm[5lٳf͛6lٳf͛6lٳ;ugPɛ6lH,.3f͞vO[޷)2FᵼjOI7t ٳdq#ґ?.w!fć +vޫFlٳf͛6l&:$sf͜+p&ʹ͛=6lٳf͛6lٳf¯6- lٳgOm[LٳgLٳf͛6lٳf͛6x/r'n,3f͞\>lٳ͛l{_մJ*Ƌ4ȕ<[;ٳa4?6yM״Kshm՛r('هlٳ_(6l MܓҙfU/ɽaֿJ\r SNP /X6lA Aҙf͛6lٳfgEjmQ$=]d(-}͛6u02W֮ 5?ka.Yf6lmV39fϧOr6l6lٳf3jy#:.;d| xX6lɿ#?9^\$^hQ@e͛!_~LοZ7 {V*;WԁLٳgX(8$h(B@͛6;6lٳf͞5BPsf͝/p%fmˏ͛6wٳf͛6lٳf͛6lٳf͛6lٳf͛6l淑h7cٿ^;R9RO#8'b6?wx1a^؜[[XyWW/Y%_2~cu=7*fnJ/Q:'?Kyj3'+M!Dc;TB> Ms̏-?#[̓Q9Zi '5ڢ_{=yٳf͛6lٳf͛6lד?z8Tm|+pO<6_o g8<K|?zO?`ou8}+}=C){I g)VV{q_O)#ER@x Cј'<ɖJo537 /Д?2pLҵRG'~,eLnz¸K%̜9y9͛6lٳf͛6lٳfm^BVĊ+՜r[̺m#V|XƘO_sC+yMrϙy+<眧 ux~ Kɸ'==98I׍y) L? lcNz{rq7Γ-یS2ii6lٳf͞yּ:/u9Zi/.%[Ħ4V*A#~Y CG4*KKy^($;31^X6*jHmkiU䖗4 QH8($vfcSJyG.~ /'!O־9=k/)sm`Yɪ;W7$5'@\yNvWkk2_pMQޢ/ğ-JmzɾdԧmK'Gq8]1#k3GyMN}VYݝ>81'QP=z;vn͛6lٳfO_,ʟ4_]:koڞ -;r d{ TLVs3Hb);M#>ga-R 3Z+Y!L46|д]C\֬tm:3-"5 L1X6lٳf͞Ľ[D1cg%ikr$-!$ 5<s_7_=1^zusgя{'|,et45M =[k:O- ӠH}rEbA=[k:O- ӠH}ry\_$f͛6lٳf͛6l3/0||2]jөZЉ.]+ n|Ѭ\fҏ3r]AUXR }s #f;W|x,٢^1mf%Vޝt)ž\ =>ʄq qoi!BOO@w{$Lٳf͛6lٳf6hߘg7|.܏*ifxSw6ɺ9%_KBY-9 V%z.KeJ+Ij $^v>i}7K?Q%G>!*įC㞓η9?~w||%Um܁u;a_V6wO& bw I0W+kZ;ߧ3^y#Y_QAߠ^D#i+2o/2EYs^@ޣ97"Cm,Ygf͛ i>`o4]^n70?FS7q4SOOOir9n8#I M2T\h?=|ֿ-֓ʝLoMXFyzcӦ%o)::N^ٽ; _-X itklNӓ/ψzQ$<}!k;epy~eoco̥KHzky[7=|8#LѐL~O~e.p4-Z^:Ev;[>wi+(e!U5pF A6l枧]GyO%.F霿r#򍕭Gqz1ˀ5W?9G+ZRXc9-1^b`:0ŹxE&l~ܶayȠ6ב{r'8rMJlïA3awٳf͛6lٳf͛6l7 םm]OYbGvG}G93y@bX2QRKNYWA{ 7o0Vy/P{_7R4;g Œ-sSik(l<,uYzB~T4uxyY<렲: 2}&[d=m6lٳf͛6lٳf͛6lٳf͛6lٳf͜r$&<~v仿yp&?^A?;]K<?e#-2`}M_㑏?\3ذ;lٳf͛6lٳf͛6lٳf͛#?7|yPqIǩkr^Nf#;͛>|^l{ڂc b,WmPh=AЂ3f͞5x4o>G@)5͛6-I,ᕅA6ئٰ&AX.ݐ{=͛<9ho~wLch½ϖ\Zl%OalٳETko=4L Gc(i&Aui#KҌ>͛=cyB FQTd_Of͛ 3f͔I#D7$6l_>So^ c<ۧ'vCa6l0y \PMZvv#rNʈ=Tv6lɿʽ3i2ϩND3NE(GP}=I͛6Nf͞)eX605ď#}yfΫ8]OˍKUuMSRpm"Lٳgsf͉[so-k,#G,N*(ٳgo#\y0c&!p5{P9foO̽3L>ՙϱ6͛6f͛67.ʵkf͛#ܵЙ83մٳ_͛f9ܑOGFٳgο=y7toYӥYlbzה70VGQ6lPVu_2ia( ޝ3f͝C6l/?M\uH͛8WMɿs'a͛6{6lٳf͛6lٳfͅ^l[Y2ٳfϜgڶ?fϦf͛6lٳf͛6l_N_0Y2f͛=?8'?}u ٳgU͛6xskS Ce͛6t_@5j6lٳf͛6lٳf͛6q_W?i9f8mroe\sf͛͞6lٳf͛6lٳg%[bP9U`Q}_Czf͞M͛6{p%չP͛;lٳGgGFM+^iOOgbk\ٳg;6yn*R qI#'HzBif6l!|]g7ik"$&%6|N6lΚ O*8 +A nw6l䷒$W妋([3vc,H_sf͓|ٳgm[:_͛6}?g# ٳ`ٳf͛6yʖmv˚v$$ Flٳ}ՍōfYfI#b0lٳH=kη1isR[ڃ͛6z6lٳf͛6l_ͯO/e6l Vjܸ;Lٳg͛6lٳf͛6lٳf͛6lٳf͛6lٳfw -}nۢ\%U@Z4+e_6 w0x }~`֡9\}?*QW>k\A5[΍G,l(hAAyb))WC 9 A؎<,RE#"6*v!>9y_Cq SUrZ~yzqN zZI}}Dk.{^[o1yL*M?vGhcp8spz ֭s m/5iIg. s""*"E*@Y*U(l#Y*U(lyf͛6lٳfn,3]#c$=GO"Gs4'=GO"Gr Ͽo,I%瘭n@xi/K*[(ַ"&yXgF' FHS ?ʻ#Zg4aE[ڰB|)!Og5?0o<}C̷}^;חo+NyΞhbOI%!  *ǹ8Gupn'i;yΞhbOI%!  *ǹ9鯩nn3R$`FU&3!¿!Uwt7W7wpA0f ` 眬.u(kOIadQеXWK*ZQԩ~k QyM=D,|s 麾8`43<-Q+ ~~ Z_ZH9lhUquu?"!%AI# FƅYHd~SXyG[-TeA}kH SSaf"{Z kH-O)>#OTmc;QݤtyI,&Az*jIߘߙ7pckm&j=I)T4t‹`q}O  6`j֮ԒC@Lߐw~[o4Zt)YA2w4^9e>O01p$JXڰFlas2E|΋9e>O01p$JXڰFlasauٳf.mieHaAWFx4,CWX]܅{I4Pd8vw!@?T[v xi-øc,22A#ϩCq:ٖiYH_Db_ i#Wsdg_f> KfYfZ!! WϩeGFj_lGu۝^o$/µD~(iy[۶y̺ο^Z@WabxYctC6+8ytI$7'^ ,JnkLߓߚV~%6$Wd$5hޕ+A鹭0L#=O Qo^Ҵ;)$g Q!F_MiqE};RЈaN޹7:x4[5Y  lE'n=h\%$ԝ=I:Iܞ 3΄jw'͛6zhVa&ԭHBPSdUY;>9 ljd]Ċq qUZP=sI5H)'NeXlO}yWs##x1Z/Z.dxsGP~+6o-.#?e&sS(i"~fr2WmΩЏ/;`akSX趶^J5IEcTϓ|wAʮ!V b91_5ۑmkh<?֚yx`(܍ZM˗aҞ65{]AMr@J0CB~jnF5{Km?8y|`v:&M,Q-o Y@}?R1)c!} Ckd՞t 1~]=-tTi[^є-VSЬP$j.u$[V8UU=H˱mTʴ5?pλ ^}jЧJJ9 v?vxr~ey lb{}JGL]s!YA!KP`|~nb{dh%h ;6M^}fPTR4kv#EY+Ghaطȯ域u!N-zTb62wTM6jK3]yk"hkA$N8WeӨ |k-yW_S$M h$J{_8[{P_O-QB9S |nS)Xַ̧V+QZY?ƇJh?MI-u8b-kp {.Ei:H@tmՔ#$He=]]C) Pqyf͛6lٳf͛<9#85!uO%R4xW}\k~<^`X_7[i4#;_[{22Q_5Ym2|?u=V3O9$1yD1ڵ:}mG#/6R;VO2]&z6lٳf͛6lٳf͛6lٳf͛6lٳf͛9I-c3Lyw-MW~v仿ys+!6F?-s2[d؛#-2gav,ٳf͛6lٳf͛6lٳf͛6lٳd[>ѿE Vv-4SU=͛6xqOKqB|ˣY&__ -j\ct͛6sm~}zMVkH,͛$sC~tKv UH }@lٲ.yκj^c[dV3CW6l?hե*2{($rGrYfef͛6lٰ><Ť\hݜwmQP{X 6lg瘴٦Y\f͛:lٳƿ_h_.lٳXZ̈́mŤny2A+ƥJo6l,W^o&o6lٿŞj$5f͛3K.G&zdq)VSp nlٳlٳ^䚹O͛6po*NÛ6llٳf͛6lٳf͛6lٳɟf>xm2zD+]K\?߈> ifJ9s&͛6wLٳg>?3uˋ́-d|$|)Il.LgvIý{%'./2/̷wqG'Yְ:s/Ώ-7=5.4VUHu/ B}A@r!iYle9Q'3F^-Zb6dCh{=sOg<~1NqM_s,BVO?b[ź:)s|yFfa^q4_}〟XVLomM*_DxJsoN؏Zׯ<0oϏ>bٱ#^G"ϒ}o؆6+@³ҸV8:ɰڵ?:ɰڵ93񱹳<#+;%vbh1퉟̩ĺ39U-z*~;z|&72+T Iz?*|ˤϥ_X^}( MZpeީӫeso)Dk" }U 2oՃ.OΝ^[+}NLr#Y/HS4o ^˫:\[Ҥpcrׁ֕@O K_̟,\=2zo3Y;\N%bH<OaVk勇tBWOMk'`R6kT~z8 Սl=8N'GM./GS$)0ǍRM>G'GM./GS$)0V9hFiViܭ֟9kt@|ɘ~ksʣ֟9kt@|ɘ~|9{]2A/\7I[=?K_M }is2H~Q_ggq_M }is2H~QL4V+2(neNJt ;;d;yc&=j0bROB7,lmx-h:0eȗ>ܾ:͜6"71,#ޢ?ڳ7ʹPj!G<3u+Z]Ds1 +{8sW:RKO0 (x0#8'?uTeh d >̵ǰr٭^9#ؼ0#r<Sg2?oUҵxCcbȼI!U%Q`ݹ@w±kY(~΍w?  \Yd _O9"(I]8'[e,}}d6lٳf͛"_WGK;QqɒРrO5uxa|e iw>L^@@aOK6$ ֣+/5iKX!Rb J< |Y 1 ޱ1&~_ Z4:ĸhփLZ4:ĸ&5)It>\#LV?o!y + UrƏf?8CJrW88TA~[Q*~Rw*O Go~ 'EHܩ?'5x8L_GoO1P~F~^x#󉟗Y>;Sդ[Ḗݑ7P}8"jW7䇕bTilrEYxƆqi6J+=TքߒW5=RJf^gl·s͛6r/_%f-J A蠍J!] /]WYU(4s\i1ف4SѐO4O̺캽r̨ E9K<`gC%Ÿ˅a|IJ򸿒,[ĸZs?%+J4m&ߔWb8P~F~^yCx??Tߗ9?)dt.>?o"!<%{4o\ُ?N>?o"!<%{4o\[kY-)*+?﫟_?OQ^A}\1)'0Sr~C ]Oot{3ӈ0 [8cO /5HRܓnHp_N,[DGF=}#b2?! q;o` .} OՁqʥw_* бk:-g`wyoʽ4,~T待6=]]]i]TPaOy3ZO,t_ZOVi*]@B6*;h%MMI=ri%i>RdI}i=Yvj (d7Ο>D󇛵3ZqTBAɏ-kޱ}wz]3GĨ8 J|Q8\Lһ5Z)ycZw_]ެl*nz/6jQT<_ʃ7G'S+86o~ 7mShb+ b$w3"X~Ey W$s19?'#ԠQ5~Cy ]OogӌoN":,%l ?<^kk. $|v1?3DGF=}#b2?! =ge6UW^д[2].$qzkHֹ,_Hnb# SԽ><'Ec|[wb"B])q6eFoȏ!OT\~TJX%0K8Z%ge9GF=?!/]h#]/,|=;VKqi$SOi nWdzZ%Ff͛ X2;CVSUa?w6lXiva_ k  ٳ`ٳf͛6lٳf͛6lٳb7+vݡD$x3f͑?*,$s$Ovfӭ 'ܘf͆O< iM)JZ[ԥ?vf͛ f͛6lٳf͛6lٳf͛6lٳf͛6l^4wEѵ(k F -c Iw9fVv6pYZDZƐ»*GEE3f͋f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛1͛6y_-t;agi{w%ɴi,ʞvlٳalٳf͛,QME*,8AA͛#sW~YJY[Hu1sf͇Z^iWҬ-~I WXŒٳ`ٳf͛6lٳf͛6lٳf͛6lٳf͛6F:\R&D !=A6l͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛65Y 4=Q +IiEPYkđƘ;/<9QiVv,77SBF:?<\۽k?=YEm-:3K_G ̥N#`~l*΃MNe/}`*32I8Ho08M%lVk00 TD2 L~^ Z>alἌq5zWÐ41r :RNg dSѫҾў|V- #Y̑<[C]Om>).ߣbп;U,^j^qj6Z_ZH\J]M 9,K2؂Va8}՝Զq401IbqFVA!~fyȚ7NKia'm!FO,_Ү H2۵ZR nQdѴף>=<*6q= 3q -5+^sdd6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳX?=DǐOwO.''oKo'9rdcq?%FLkr18k#&z;b͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfM9Qf?,g4t r$c#B?:-ĿZR A"WފO  C~t[.6ZE9L&g39D~uU\rF-e?A,E=0V'#'NQgB+a衅@ұ9ϡlgf͛6lٳf͛<9{Qo{yBU҂GfOӫBoIKK.+{y4 }'ڽhu}q?=|%\VhOl0,l u4GE 8bMm?󚿕u^=ieXMC bT[5k0K-GEAUUɽzdk_.Q1_ R,CPh C}-ũiωaOǦi>AԤX9X-[:\BȳA*X22VE,rƲDHUH*A@*7ɔR,k$N$QԂ k:VͩqXqh/&mYįI//KkXdV RTsLtE,*įI//KkXdV RTsL"-ݣHR/I~_C_'MOK\b0թ2 ,ξN`ź/a%yɗ5:P1KGQ@hu+l4ů~ 7`{U8ul:ʃyiZjGSzvZ\zW:de7&AZ~6ݚ^NȥX*:.Ԃpæ7vi{m:Kg"K`PܺSl~~Mػ$lrp+`Y \b Qk5* \b QIXV^sV_l]?7ы9 12sO5فZQĨ~E8_/%O2ơdݣcy.>.j~Q=3O6ҵyxŒR?̯!W\Ggܿ~)Wn+Z~#jb(oҿ*/7_lr\/#G'?w-􉝺F.Hkv21.]iyW-n} ^~P AǢ u\Aqoqo*M Fb*0)b:ȍ]H AT7XA$N#}R?"1Lvlv\~ay PM&o7 9 d F0;adi7RZMYu -Ē);0=LuREp_4f-&լ⺄II՘2Y*#Ek:D,*eCQC%u?HtH_[XUBʆڇҿG/[_\ߥlF'/h nK3}zZ#_w-ÛjKW5aM 5.^mъvާ(>Iru hܦS9z/|OqYjZ7Igq!ylkͧ6$AC2ʒP9p&s$9!XH4i捨,z}P̶9T\ x56lٳf̈́ _]IiZ Cyn&Tr_e"ag?XRn"+*ZS94#pS埬ImZ\)`7 Պe-Pj)0k–QAd6l*=OM.ĬQ `~ bVE?gv"IZ­&OVNR r2t@D%,^l&oEog[t:/vq/NxڕZ7)K_J )׌i_Fz0?N)K_J )׌i_Ki_OG7%YDks~ҿ7׬?5//h oWA#G7%e-ħnR72O֞ld=[R9Hydu`>d=ڸR9ႿW=ǘȲ9鰭t<|wq_2r#Iu[8+FvݱxY|ˑKiZ5Ki?ڮyMu [;n$n ]"fIĬ{쬵kKjc 㕛,h@ [w`"V%g+GeeZ]]S0OAc@NHlٳf͛6lٳf͛6lٳf͛6lٳf͛6l$gQ1%dˁ5_k 2[897{/sxobo9Zdɞņyسf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳHO`bȏKk1'j_!D6]_?<2A͛6lٳf͛6lٳfϚ_?m3XֵBw4["?7둯MBW&aK"?7둯MBW&a[km2N1.犨$T04 J^YX$h:c@`@U 22CV 9TѴ5 ,0D[Zt-4i%(~o4 OLBHʠ}=iL,4C;x$w1R~g׿ ,g뉙) ƿbH Z.Imo-ettY9`94{f$e'ABY jG@Ne6yq&+yzG~$1.egˢb+քy*)FUҝ}iFRJ 4m*!>y56?崳j±ɰ2.V,>/ʞ;ڱ*󚲵ƼLTb7׶VH$լ@'Z+;ϳղن)$=ЮʵԳ氿Yѷ.5y?=?3ʚ?<\ߢ_sʚ?<\.Կ:4fۅcO^ID3[O^`[U&]vRcDϐMCN4۹,Y"46E>  ]Z]ZNP*qVA`Tr5uiui;[BQX3Dz{&*3xZ[Asq4PV>DĎh}Y~g Q|m:X"#$syp:G/W>`f1o,ҵxEfu4 ]/˚D'cwyAܜNy3#۹>o2~%5)8ȋdpkrzip) V!k0Ë'I]^->/~bZ8>5a.` }?3~n9&î:hjhXӐb]_J JAJU7_./1?UhnR Tzԏ|3W_̭3}15-,Y6xD? B)Ppo俚u?zS\/ʼnHT:1p8*c}7+ڽo俚u?zS\/ʼnHT:1p97ySGg/|i:poE*áu[n4/irʪx(8s4I,m=ޓq_{KUS,}Ay*xza9D RyNԮX$_2h;)98Q][K>I%7g7ߘ?C눬%_VL7V w*|者ѥba,ꅹN/ڑ+451[(Μ㎈)ƞΘDzAՉ+P󾞅tڠH9e*R@'Hdu; 0#9 [[yt븛Ȭ;0Op*1YuAeݺs]dTgEaـ~s5Vn|uT1⬼c*gA翘%HuFG#?ɇӃmyЁ0ǣgA翘%HuFG#?ɇӝ_P[uHx@*:Ң8㇜?/-UIWY`ƋIne 3y]F\jP 5jUՎƾ zly÷g26h4@kԫG][|A#圓  f͝'q\f5YtfDOZAeP:o>g҆of4p  d0\GT:{MP5-F U!1v䷓-_7RMIs5ܢF"E@v_Y:YI;$GZP(@>׆ٰ䳾ӭZ$צ'ʳ%EI9":ҁ2\$͛68m²RPuѴԧx᳢9ɳZ{gET5q[r=P3\:B͛6E5Hu_3iq>rbI oAȊK]:=G:śoRRgD/JJ|NQfԴ4 wu>7GL)!4υhjM)v ^VI?-yCRiKogќvHٳf͛6l?,4\tl:KRo]JQ+p}OIԴ'=i-]':4nUn,ңxJnDЊ~I:-%k$Fʲ ŀ=d<#9Mq[ Oo-[*@^}yͲ^k7qK5H:F98&[ {6~s]krF?IfC(g>΃8E)%'eE{= F#tW ,[qG㶑nϫjӶUjT\_Dk$rQ8[ڻi=Z'=[ s͛6#{ei}g=)qisCq$VFS -โK{X&S8)#3b'qo[F2UH=A2.O=*_[-ؒZKeRj q7iNѲbcRZJ҅0H~"Y~U4_o'~h[G^]Y1-JiBƙgf͛<9Cuqj+sH'71:>?9SY.CxG*0aPe~߁ iv9Q3Ź%>礿C1~iQuhڴ8eH:juZO[UQi?w76lٳf͞hV];>Sf֥iLDє=?hWC /i>7]V?dV̿bB\8QZ휇_ MgD}AoH YYP~-+6Jm ;g#BΝe\3!h I#aB p|cP:w!/p̆9$ Ơ%#vL3ɛ6l$?%:yV\?50O0 =_ }:m͟O0hj6c2E"4ѠD;}lh l~l_yEQ.c)QZ'9"6g[jͽoke@Y$< RrqG 6!FO*j6塸U'r,?Q.44}~U7ߞeV: ֏#i4xK mlj=sߙJ>U۰fc2Ot;|r?kyݶ>w|6D'⌓*g+SDfXo̡E*!'zE&zqUI{=[+Π26nA@>?tGer^9FBR Yf͛6lٳf͛6l{zn"خ2Өsa*fjyVMxHDUGåxlfǞk~(WXEQJ??'//VETĖ{j^t$>ВڈGĀ࿵߹ݴȐ_#oձ!򳾂9?ge%mOu)M/|(:Z>~{X|Z-lSӆ1=ٙ3X9Gm2 7OCilcNijHAѴ}?F t64|K1Iܜ56l^'̌GZ4dWjqmmP HBe80jqmmP HBg˜E? rOc"'D{"[$?h?QϢ꼐f͛6lٳf͛6lٱ+ŽӑDzW&ɤZWs@O2i=(d३A\kuu=WdY\grY3i'InRݏvcRr.I$ssM$I4YXjNz?p6>cּu(GO hkP/M&uǽ~ m[Pfp|5=\{j`yY2Y6l/?M\uH>_gaP&s¹"7g)/':kWhhy?㵫4s= f͛6lٳf͛6lٳf͛6ys^?z<ƼZ]9 (XIK"A)?/և29˿!cS ?iuQh%'#.?a6y=8C(:3q8&DO8]_bcyLes6lٳf͛>dKIϘ KX;2jQm(?ɎVQ5:Dg5[(+(XKo,E,L7!Hp'9Q$H`$GQ y#2DϪ g3J~]9Z^5\vyhV *0yFs rӫukAV< ]P}RJ1Gsyl=Kf͛6lٳf͛6A;H?i{э)_LVObyyw7ڂOBzZ_HWw1 gڥr7Q(j n= =}i~#]&+~]2#o"4.-'٩qo*bΜt.%C1?_ [iV2*G8䷕MogNv:Hסܯ-=ٞlٳg?({yoaɓѷBń/0r?bU k{(cPɞG[ɥ5VcH+4x3͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfA9aKXA?;]K<Ux濯 .%\wgM?\0>&ŮKݲ6ٳ͛6ٳ͛6ٳ͛6[2gش6Vڙ¢*ۏeʱ67ԫq,^[;Z+G<9 ٳg ֿ22|rF J&iu5#+bf|iڄN*^2$;͛|2DmA"g#͛6zsxt?ڥݚS׃dd$fOf͛6lٳf͛6lٳO`,.t4eַ btf\ٳdCpߤ+w?l`?q6lflٳf͛6lٳf͛("4>5dRPe6lYf8aX+~IZ/S|HmOlٳ7?o*_6l7?o*_6l7?o*_6l~t~lɩZFnYhՔIB A6l[6l%5kA5-m?PkUr({V}lٳ7?o*_6l^EAoiCٳdʿ_zTдG&m[@}6͛6z?:ti}OA4UېFOF_lٳd6lٳf͛6lٳf͛6lٳf͛6lO<~۫[Zq;ن jw;(Flٳ>4?/*qڋdz4Q6ȯe,bе ө[n-~ BTf͛<+sWf+sWf+sWf+sWfyR7ڗ嗕{ۭ6[X,rI͛6Qmg`nf͛<89 7.nK^vey!$`OQ'~͛6{F9#56ARTGPsf͎͛6lٳf͛6lٳg g|@t!Z3'#q%Hڠٳd'qek뗺:i(nyU_׍yBFlٳxW.dhnm`  vVR:EFlٳ_J͛7_J͛7_J͛7_J͛7_J͛>DS'~Aw}3~I_;5A9)w̌~iшP;{I(WFiYc/-P:ԓ=siug mk1""@G@3iug mk13f͛6lٰ.'@7co~Xq"sx"<?9|1lX}HGXOOL^Hsyf͛6lٳf͛6lوEA؃ҙPQ13Guo8^BiRB5{wft%e>`+K;dhn`q$2+)#с#Z]Ewk#Cs! YMAO/4}~H6#crcyoOE]ni~b+ M[Psұя($K_Sd!a.y=8C(:3q8&DO8]_bcyLes6lٳf͛>e~`jv|ɪ[, AIև4^E{m^Xon&%fF؏Pr-f(8 (A!_^\_~fZ9a D3Wm{1z1͛6|?^Loi[|?V}p+~ec98Ӆ6^#F.Y@>G<,NsxzRxg?I"dH2:XFE:`hA8n:]*AVЃG'/4|7EjJ(8Mj?z~e_1ZS$ONɷj{ۤE:笼Uu2At< vɞ6lٳf͞4+?(YBOZ)ٯ'Ph{J*S ?ho@WԸVDpX2揮[}5}K:EhJ};w7."mbQ̣ҌqܳR_VT{u^=GpvoڭG}=3R_VT{u^=Gsdd6lٳ=F?O0r?b SDg9dmPg*^^}5_ʱd_[Q#`EY+1\?<~͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg %{? .%\ O_אOwO.sy3&ŮKC|cq?%FLv,3ś6lٳf͛6lٳf͛6lٳf¿3G΁{k3}7O;}[Sm *3f͟F]20XBlٲf͛6lٳf͟=$v3Pf͛O~n럖d7:]]0 4`첧7Мٳg_+s-Q:0٣eG͛6͛6lٳf͛?0/f͟:/??l%3f͟M3f͛6l ;.4MMOZUd79fZ1mlm_]\us+ 47Ef͛=e8?,[w(̚HnQnvp:rE6lVoi vG Jx*f͛<C&ٛDZ-j0͛=6?1?<ٳ`_m'J?_$y}nyJW6l🕿cH9fY6lcʞWRA-?9fLٳg %{?6lOū;;m&`h/ E*+"Ȫ#6l _ZҮޭN6l?Mt& _Hm"cKPOѱ>7Ed ͛iB-x#7 'zlٳ9f9jɩf͜7q Zhomiw,#E$fhVkFi͛6o🕿cH9fY6le Ck1ƀ*f6- lٳg ٳg"&yiZOٶOc_fc#3f͛6lٳf͛6l_ͯ@4/j6l >&,ٳg$9chP**E 6lYY6lUƙxFbB͛6|ҀmRPgzf͛>VkFi͛6o🕿cH9fDDDTE U6lOMm'f͛6vBN,#0NlٳVkFi͛6o🕿cH9f-i{}.5X]O`ٳalٳkc9fȯVjb8,bx@է0iZf͛=1~W[4wVҦW$@0>͛<98i>ռǒ"ϩXɖΦ12N=)6?yCղǦ0>pB:9)66ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳHO`bȏKѤ1'!ƶ6]_?<x5>#NZ=AI)˿2c x|,O7Ӓ+){ds7g."򕎢/yE?lNNI6lٳf͛6lٰ.'@7co~Xq"sx"<~JvGR^f /f;K/:WrY!UE^ɕ.f4Pw'$?^u.X-4HB9]7_H7_lr\<>oɿ<(!No0Ks'#Ȉ]#Uܵ9w/ߌȈ]#Uܵ9w7.\KjZl#)V5Z' #r/Fr\Wڥ)*۲'9P }xfr^'pTGuJkK<̜ϯ$A;d2=syz<w+,CVrJ>5+љֱ$G#ߐ7ջ7r45$#3<ҹ0:lٳgζ-wo-֤]Xg˜{O0ƒXFXn-{x0`gc7#9夞au%-Zxg.-緞K{b"ue4*hAyXFThBUс lAB4"ub))Q WF2 b:nlnwʿ:OӼZQ@y w10?Jɟ^a8Zt~5H~<:U*,O>LT-OCx\~_h+Ϻy$`?wu ߑې;3ZMБ53G_Cmou Xھ+}ܼ//yn::6^w6lٳf͜Wr$ZĎs_@e?YzϿ=b`g<+n,vw?7_^c`mn,H$bWa-HRT:o^i&{ rL WE RE6jjG,1Rs?(oҿ*/띗Ve#m?򰼍W/z mӉ"Aa8 Zw_FFd- ;/#\ߟL<{&_Ia9a9cfgQ;P37u#/uuxrܢiupðP-,Yb  ;{^^a.y=8C(:3q8&DO8]_bcyLes6lٳG{i>Rtk͚M,D7ԢQ䐃Tzۯ9ɱ#OK!58;~j7 m›~962lt=.HwHc! ~(tz}??sZ5x4}KF("4Oª;|jZvmh O@rvXGY@3Njisw)DI==/aiIY.Ũ}VG8"TՎUͪQnANe6KmmK[~_yGJ*fn׷Hҿ  ٳf94ZEP앜ݬ!d7>rc>[Y+u5d#>- ^ߜP>(s|yc`JiMYm ?ϋq>¹ѿ󆟘|}۹ii! v/ģd A_Tnt ސj v> ?׏"0F+BNϺgWG5w>w86lM?4XyWʺeTsp)`4U0k6.{ܟӓ 5c&bn+<'Xo5O_?aɓѷBŜ!x!y?Jךnm8c "'bPsϞK\3kVq $m2 $^ZcU(Txg|%.86VXEzg J?#G'vxX~FO녗󑟒P4yP@LKx~k$~SmFE}P~U8_##k18#TlߙdX[;- P#jxP9 <Ϧ][!,0%\)Yi`Ω-B Io.̐b dҬ439;lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg %{? .%\ O_אOwO.sy3&ŮKC|cq?%FLv,3ś6lٳf͛6lٳf͛6lٳfd~d _"ET v{V!&lٱߓ} iZ-^rQ @O깳f_͛6lٳf͛6lٲUŒpA͛6^lٳf͛6lٲ7֭_LIc׆}͛<-EyJI'~r[0͛6G_?4/ᴄCj:r *LO0 :-3f͞a 9 m#Vdo&QQkݔ͛:lٳf͛6lٳN4x,ٳdqSп0<=e}sLftiTA;ֻ6l~K~s럖2^_uN:zWeGC]b6l.yE&khIy'8'N;)ٔ6le6lٳf/@|l|ٳgίOm[LٳgLٳ`mSR۽JA2\\z,q)woFlٳߟyʻSZ xAASS6l'OדHŨ*M] RoU5nfΓ6lٳf͛6lٳf(ʂ^,Fhsf͗6l?1?<ٳf96lVlٳf͛6lٳf͛9I-c3Lyf5'?C>lٳޙf͛6l~n/J䢔Z6lʒ]:&XR:ֹfNlٳf͛6lٳf͛6lٳoLwǼ0J_Eљ4"6߽V6l//_/yj:jKc{k'y'H]6wٳf͛6lٳf͛6S*EApj?ٳe͛8_OJ8m&͛6qOo*NÛ6llٳf͛6lٳf͛ (07?ef͟6|ck 1-ޣiD9'Eu$Pf^mbߝo\?P"qMt=n76l_?oe%i³%g1?4㳴[͛6ٳ͛<9(mQP͛9/Dś6lVlٳf͛ʼlٳ[/Lf͛>͛6ٳ͛Z 0Y9NGS}E:co!#~DMOy5(NkY)$ݑ;νZ΂҉'W=j4?:{hR7: pzsJ$K)_=m ͛6lٳf͛6տy$Fo9MOx?N|_Εhך47ʱR#7u%()ٰQOt%뱷כ&>ձvGg!W̿?'&?7ιY3͛6ٳ=3O=A/.#ҽCM/Եܴ7(/|ٳ90.QɉJ/1><ߔ~cӯt>=BeVy+"}7Ma[6V\%ԋ#v˂/VTPMk#fjP.YΠ\9ёG'ftq Oo5z},>Qqc\vDHYZGثx!^j-o>mx4֠Y#uHRjjX6#.y ~ ]ֿ7Zy_ɶqGe s@~kC0 (yo6h1|RJ9+3:d x+˹s>Pߖ4m.&-mcIXrVg?Zt~{6lٳf́-:SӮw-J:JkK[#E28Ae XUXPc][ZMipK{hCёH9SQo-ɦ4i!"?2H["Bu"zے7dBa?iv"Bu"zے7d.uCB֬u:OJN;wx045 7P-[ͬ4MRxcvfSQ`]3Pu mBո\ȳD!}.򇙬<}36SKZԡa#O]ZY7,:$|J}ժIaed^+е{mgF-o"YTu*HT7^"ܑʧM [xg 88[n)U`. vLEȤڭ "~_1]Q#*ۙ-'+~WvgJ]k[Dc|tN##E_gU)wuQnF#;t'6lٳf͛<9Gct|/Lc, ?Fy&NF r\t-OXдY| +v7bxN5Eiʙt 6kQ.p<}E J\2Fg_s韐m֣]C xڸ?sUB\#T~oB{Wku]#\ԥE,򤖬Sۑ`=Gq0c]^k_fǟ0 =mv*"uxK{~dd?qNl/k{I5n`QH.U#)-n-4k+9baFW[iAq5YuՅ{8CIkqk[\\@Q 2J?#Lzg6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳX?=DǐOwO.''oKo'9rdcq?%FLkr18k#&z;b͛6lٳf͛6lٳf͛6b@@7$lٳ/5_[nO&{=.Y "3f͟F/|z% 6(e+J4yL<͛6͛6lٳf͛6lٳf͛6lٳf͛6lٳƿ?Tei'|ח Sf͛'Au:K]n-`o޲I0S6l9u/ֱ36lvlٳf͛6lٳN4x,ٳgIy[0MQ2͛8Y;6X.»EݮaQC6l";O]pK,_0vXA" b6l] ]u"X.MKms`(|ٳ`ٳa>U>ٳWY٦lٳ馱ٳVɭ(߄5(a͛6ʱJ3$ǫJVX͛=6ٳ͛6ٳ͛6ٳ͛6?1?<ٳg:v?,?nKO}[tS6lvV-WfCjuU͛6yorFo Y{V%f!7b˱D2սԣٳ^՟V++fϥu%o66ٳ͛6ٳdߘlj##͟=.<<_GQ+:yralٳtqkj4Q@f͛6lٳf͛6lٳf͛6lٳf9jɩf͞e.&ZwlRڈs#llٳП;^@[\ٳfX_͛7א?ŪW6lki{xPBʊPW|ٳaw?LlٳYDlٳEuTo?~ᔍՔ7q6l?w侯kOҵ"{&#a*!͛;?Zp7pD:3lGD~ѱT͛6z6lٳf͞uBisf͜pSwGb͛6{+6lٳf́uo^ ?6lIg&3f͟Rsf͛6lٳf͞ ɹٳfoo*~_/.z]wNf|e Ȇfא?ŪW6lٿvV-Wf?_-iUJ5̆$f/lٳ͛<9(:o36lW'6lٳք*v6l?"?[QǗ<ǩf%2/$(JPw46l㷑|F"-RCc`=φlٳFlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg5%Dő͟zcO&Կ)~Clֿy3yo#;|ir]KFɗ:o_7dL} Rd=I6lYl"IORPK[c 8^vQ3/H[9N۫V77+7eI~>˗Z62K0!<7Fy\Y1+0aԱRmIoI52~g)^& SCA~J]S'b=w5ӡyL q 2|1MG'`~/$kB^9d$cI AҙpA=n"pzٳf͛6lٳfr?W')b7cϖ<~@/EOc)1#aEI,>?$~E3y!U͛6մ}SJnG+{%PRd(|QXcx~R9N7֑^Y\ZJ+oT Vaoɪ~gi$CÂp gιN> J؅FPܹ֔uݴWy|xP΋ٳf͛6lٳfmm嶺'JMP+TGcfXdee;A،"402,H v M'SI pӵMF cOOȻ+Œm.fӘ=v~pHF-9?"K,qݛNcH\ϱ$Nj7nk%-fR#Np+m/!{{[ ppё*è9ïl,n崼n2 *}Ĭ.༳Ym猕t%ea eqS YMAw2R#oq=@xCFVSPAϣ}z|E챘u]BxKA1#=_?32yZTj Sڍ3c+9{tsC0'Fu1ݨ <_nܾ93- &:$s~z/3}( 9\vgҿ?`a?㵫4s OeT~?9ݳf͛!V?Q>F%)$!Qzql*-=][s#Q o#NwA,<3~C_i2yvJҧvc#4qI?!/ vݾy? TkĿI{}}?<~Auc>9 +HKXxWeHP(z~kxAc( 2@(  6[8!E(EUP>ئ6ٳ͛<9Gct|/Lc, ?Fy&NF r\_@|lL? M.Ix_՞G[ɥ3lٳg-::33t ~f_=r奜_G12K1<u-Ӯ /~䧈C";Y f6"1Ǔ`cεޥuΥ<<ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfA9aKXA?;]K<Ux濯 .%\wgM?\0>&ŮKXg6lٳf͛6lٳf͛6lVU` sf͟1/tQQJlٳlٳf͛6lٳf͛6lٳf͛6lٳf͛ ?ʞU<~tw.R8ԟڑE9fϜ|E_k~cޟu%Y򯲌ٳg/,~˾^Ӵ-=xCV5 Olٰ]ōk5O,*UԏfϚ}ֺ3]_KVģz6B?!?>u?˭UtA7yk56?mh{͛=ݦjz~:uwv7q10dtaPFlٰ P2*6lS,VS6l6ĺ7#9f͛93G+[RGt*;03f͛͞6lٳf͛6lٳf͛6lٳf͛6yWsz؞lٳ~EE7C~zk׭AǏZ͛:+ٳfy6l6Z6/k~OL˅+6lLٳg %{?6lm'Y{/4%x%PË$eXTf͆ߘ~mZ28PGlٲAOO͟4M͵oj m ߷PEc6lkfsH֣Ɖ6_v 6u\ٳf͛6lٳf͛6lٳg3Hyѷ*ӏӿ6l39݁Q_fϠyf͛6lٳf͛6lٳf͛6lٳf9jɩf͞Z?\-%סLÇ_S,ٳgoy6l#ܯ3f͛colٳԶ}^9rcXR3fͅl[Y2ٳfϜgڶ?fϦfŸ4[BVu떫w]#nˣuWS6lmgvGfm+T*zlKf͝qr-sm8TGҶ l1w#~C}6z_6l_ͯ@4/j6l >&,ٳgf͛6lVU` sf͟04xc6l'6lٳf͛6l̟*N͛6lߔ?<?ĿIQ="/SN9fɯ+ٳfy6l~S,ʿ󽟚?O>/&%9͛;lٳc9f)~>>/72׈'*ҹfWטe;gaڲѲ3ϱ39͛'f=zSvTܨ&=>oV Kg*s6r_\ž9-9-͛6lٳfr?W')b7cϖ<~@/EOc)1#aEI,>?$~E3y!U͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6p6yNt e!i(6BLVs?![kz$Ťau}:3!e 7QfeQ9]b0]Ĩ~眳]zɿĩV?⡝qz^_(? 8X/W?.]۟uFgV/?M\uH>_gaP&s¹"7g)/':kWhhy?㵫4s= f͛6lٳf͛6lٳf͛6p_W-9'v_ҋLO5?0.QɉY%>g?/C&s:WIYݿ㋫Lo=)s dɺyn HLS/"~g-|i;%eQ^ !Yhۣ¿3`o42 VͽB nE!0j|osގ{Zyj7}zwV4S') 96QЌViƟxլi= gu(O/tD]O?eЕoc\е]VŸZ F^H9pʲ'S\е]VŸZ F^H9oȾtk1i/0Z"AxeI ?Cߘ,<[j-Xn+VG4ml2MȝWo`ѭ[7 R#6Sa? f͛6lٰϞRo-PC[K!Ӕ|QIWy7~_~`G-[ǧ:ٳfNlٳf͛6lٳf͛6lٳf͛6lٳ?[9~;5T)u+o8g *ٳg-|u?4K; mB9#K#iG"d<^f͝kbҾ6l;^~\\ٳg)οu:;uzJőHTlٳZ䛹iMRv0&A$ 7 ٳgf͛6lrG'o,:($ٳLA'Ʊ]^Zwk"mqj|5͛6+6lٳf͛6lٳf͛6lٳf9jɩf͜Sp&ʹ͛=6lٳf͛6lٳf¯6- lٳgOm[LٳgLٳf͛6zuvZuSH_,MC5ٳg?6?*ks_5՗JRx"Dۚc'f͞lP[;ͷT c5HzٳmT4f8K)lQ1f͛=6lٳfr?6lV3fϩ9f͛6lٳfd܇VvlٳguC5m1!6lYf͛6lٳf͛6l_Zlٲ!8u~zѵHƟgi-H04=clٳi~^kwgw) 'PܵbHGF6lo(0 $Q}!R-M6e"ܨ.:7#6lsf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳN\zgmt^§ j€#_ふ3K~ 2/s6e?\F>~g?_Γ8蟝U,ATnҀ>r[Nʿz)b\T |9-e_=z*|LN} R=K6lٳf͜ȟ__J?SQOiŰ,}NQȿ_>Ny]DYb{Oֶth|KQ+6~>U v^IGsʹ_> /7Rf e-AzU? ,g:s Y+ 1ѧ3BN fuO/2=zCh?J=3f͛6lٳ`][9WOo+d1D\Ey?tOO)`ߠ4ݕI9&e_?hdTT@d_dɕ|@YQSA>2C͛6lٳf͛6l^p0o#\Y]jR[qNnn:.׿14:%{C*i kϓ)*}<ױp%ޔ"4Ȯi-G!T3Hc^|OQS/4kY"3Ǥ\_< BM)@Mh[0YWL/'C"XrуB$.T~8PZ!\>u4IȖ6ܴ`а ߎD&94մ>a ݄ YUהrjF:? 6Yd =0r ٷK,SBp>~ż&{YOl¨vmv΃ٳf͛6lD9:8* Ue*2){LUeaFS 9U/-Էy#SKآ(Qxb.`:i4(n"E =8yMS5Au 5Kux\!-.:kVT:K՗oΏ˧폘tj6K|SBSa~be_Z1rΏ˧폘tj6K|SBSg6p__S]yyWUu]J!Vj;KB O*jfoX >t(Q Mo|~VaIMXt-vne#=zYZ^Ayg2\Z\Ʋ Jb5{yḂ;eUj*#|`5psqw:)YXTGb1l~l~lٳf͛6xs|oH?:- /R>-yg?>|?qk0%-U: OθM[J'_>~|c`J[jt xs09I,O5.pw1$:FZG A짨j{(hYzycV著$N,uDhYzycV著$NF?^[t =ig[Dnj9I4M2R H$YOo)qh|kZrһg/-ZS԰juaS[c[h/]>_WZ$ajJ§$oalٳf͛6D4?2_˿,5xf# ~ fsd]~qv]rKaH͝vTtRq+pHjp>nIc2)\yN܊NyG̶gƙHe-g $UqQˉeеxuT7Ȗh㒁mx1%d ;B4{=R(o"YJH|ٳf͛6lٳf͛6lٳf͛6lٳf͜r$&<~v仿yp&?^A?;]K<?e#-2`}M_㑏?\3ذ;lٳf͛6lٳf͛6lٳf͛<9e5k>*Y\؝&oi^6l!W/5yDR%j`sf͞Q9f͛6lٳf͛6lJ[R hy"" 31RNlٱ\ٳbֶ7ג,6<1qgb|͛>ʲ<*I\[̐G@ Ԫu9fXcq| ~+uojODAQ@#3f͆(_}Im3f͛kY-lٰ.8}W.y KtIMH5*<3f͞:]gɾpbFմ+$Ko%$У ٳgҟ/kz{sԭ㹷cׄ+BB\-tjewN6lWE~0kcT#c\FU_]$oW6l׳f͛6lٳf͛6lؓڥV2-KNeW T͛͛6yWsz؞lٳ mn͛6z6lٳf͛6lٳf͜r$&<ٳgv6lO"hy5E+*N2t⣡9fϞZ;g35]+G4g`C*>$u 6lɿ;ɶ\ϗ'u=[y~(fZ `XŖ"656l'im/S [5(,l>.ܖSfG,4]BboWP\ 27cwfɏ/Dś6lVlٳf͛ʼlٳ[/Lf͛>͛6ٳ͛pwGN=??m}bO C32Kkrvma[riLyGTM'V!6Q<>@?-q[iw wo(ꉤJd4'G}-Hd2:T:B A$shd` 5v^lٳf͛6l9z||4bAՋy|s>V>_ļl) ^xS5F_ygpX]:!xm0u*7ӯtkVsk"M x2¿vGduuٔ>:蹵&>1Ȭ垸޻khvzWq)ZqVd hVE¿#g<kaVl}Ձ{X2͛6laj?er5A"k)"7P=2֦_tEi(+#E`O2֦_tEi(+#9H'# + #=yoq,2xCUe;(! {.`x$YaC")F-f3f͛">✷޷𱊶ٖ$Ҟ$+< : duycSbS] w={VРyuFt7Ƨ+~ZyCr̗0V,q[ѷe]'#ĜQf%*p;Α8ΡkVQd"8uYoJ"GN(""!Z?8?)yWF9W;Gd5+[ 254FY<'yZ\?։%?3.kisɹ{g Pn6Ɣ 7^_*C{9}hX?>Eetm=qʾcPADZ"B9} /Y]*;:1-F{AzPeu j$(MTSX_pLΡ U_/͛6lߟߛg.buo3jq<:M &)j?7;v~XХHXF~%,(eoN'l xXQowJxJXP N y#X|gqA) *y3Qw1kvUY㒟 q#{(;xyV4zsǗoŭiVKYgoJ|1>܍>yC Eӣt#N#Pݍ*Os]3NkKߊ o{4XQvUFzKmt:O^֑Q/~()'sͿhʚ'RE7׷_!Bo,;_}B0Gi:]E|938]JI~&nT!u#4\}f.r"YA>p|'qZ~ַ$VRYC$*X#ޛ($gC֭t:n]cP{x݈䮂ǁ]QQ3Z|au=Bv W |6z?3f͍X8vw!Trr5.Vc@>79Nv1IM9'hwizguc, TMҝ#]t+] $P4j]0B+ToB<N,"J[@EJVzsR7|qW͵s5Ifc$Tȳ{'y5RZ1s$y+ D$!NC5Ij.z;Fgh&mk.^ \Z,(xcEsO g֠Jѣp$Q<ށ[@*#9A%ƕF᥀Ispycgs^q?lٯyzyIqjӔL1SgqX[Դ+B MnZ=OцZ,K$gG<z#{RXA?iUG 3yp;lٳf͛6yrqMBk6ڷToUZ;㿚?u$疢%朿IxGx~K5 32>.>8I6娫py/j^+߶& ̍I#pUЫ txݣJ:(AA’4;gtxݣJ:(AA89uYcy.3~^Kcj:}ޡ7w[tYmF|Olwe#䩄_΍]7]+VgC3Gt?H>5=;Utۘ,.Ios *l-Wv$(xVSJH*wgl-/mb'C4d2eٳf͜?MWI?SS_^?YGZ?Y1+,}h@S/{gAğ1̟,{cr}b֊>Ab:Gʙ?PUҰ饆민y <٪PP\\9c_Ҫ27w(G | Ox6j'aoC&%qz?(^I]:xޱT5V_cuO#i)Oedh)#$t%t;™/mnT6"4Q [VFZ3d6lٰZ748}gTbQȽ(<9\ kNPiXdF5]sL kNPiXdFxroL L!QIǵ3~p~aYM KYc5oSl6pS[XzV~htlXB=iTE _gHM6w%ߴk6P?Ĝ"DUX?G--4 0cflٳf͛6lٳf͛6lٳf͛6lٳg %{? .%\ O_אOwO.sy3&ŮKC|cq?%FLv,3ś6lٳf͛6lٳf͛6lٳf:扥Eޏۭ֝}Csdof͛<~[",Xq5\PQes p6l,md|N}r0(yJ ٳg|a昑1Y?KAfT "yo R%yP_4۾lٳr3H&֣/P|6:Yr;C]lٳɿn-KJZ/CZ͛=6l󗿘A ^[G1C-$4ob xf͛8/ϐ4-on#yx FU3)|_6l<ٳf͛6lٳf͛6xwr_̏ӖӼQETKeU͛6uO??~.֊I\5]@$X͛6z;6lrG'o.1^MQb+H6D>f6lٳg9͛ <,:ŦUܫ}kDW56l]7_͛6o]7_͛69?:?)u<ݥ3 .'`fɞlٳX?=DǛ6lWN#0^3͛=6l?ߓg\hѠ=&2Ƃuffn?FlٳߒzϜc.sK}bOoR3'юlٳvjuN6$ >`͛͛6lٳf͛6lٳf͛"?zq]J@ <%JVwfyͿ>g:n v%eB O\ٳgx:ORM_P@V/S6l_2(V]}$Q~(\Flٰ4@2O4qR* \Jf͛9G*,< iw_MPTGo`^f͛8/?7<rpp_Um[Vr:n}ٳfo͛8_OJ8m&͛6p/_2˿뺄en"2,iͤj 6l]7_͛6o]7_͛6o]7_͛6KtFRtE& # + #6l ͟k?s&[6lS,VS6l6lٳf͛6lٳf͑_̯ˏ/`yb} XN<;;Pe}#'aClٳg_˿1̓hZUxT+47$|b倛So@.8?1/WBCqrGˊ*>Y|oϿ:ϫy˚*Y%c8֤Gih*vkZ/ou&4Nk** xX瓜|T kEڦ8eEU!TpUU ?J~nԡ,ʼXKLoԮ/ *?b/19'?6 Åć^w 9F_$~kENu!~fINҤ򾥩hֺy4ʱ`܀L|Ϳ-ZEd5݄c0Z\U~H`j RBzL:Vrc8~mj+&Ѯ#a⨣R@;P3?ΝkCkmM fbKu-B9dL^Rh2(dpBDzTiЌij^Z&U 7WsӖzC:Y͛6l󒟕?c|4Т"zQ;B?7<|{hzug0#( Z爬'1a>L)6< d &z/qa4Mv_#pu=M.G? WԧA:@έeӵ'm5fvKS@?"? fߑ~v];R.PnVld8Nw8;s>St\ߓ p"ߔBV8S~;Ws̯1:NcG%eubX[]O8/iɷUtHt;Lߘ%$zR;;g3Fؽ *Y+6vs\B37&8]FQ~ʪiǛb/4dαr lܘ U?Io?FtH_?#?:ՃRInǔ5`TO 1e(a_PF_Ԯ/Y/hW;,?=b z"jc;־4Z o̫dojp^1>Lrߨ 6NʶNf uJ&?)3ZQ#s'#˟1&k`K ˟1&kZ8B%#%~ ˞}e-wꬭ2pAc Rz^,/M8@)y^ɦ#+A ? 3z6&t+4lo:Q&&idL'xXoj:谋[c*2s.+_|1ѭ]u*)j)ZVu+In2'2B>ϰ--c۰o1γұԤ6<q4<$RCᤈX~G;:u֟r "jƇ"OygϞkrRUu!mm.-;a|*i%!Ylg^qr~OZsXT\wNa75'Y# &D0&ҭOdi}ķc[ƤTd/ȝ|FUL"xW/̯Fݠҭ,4nBX6uL-WQQLIܰO~Z1YAmޢd#!) )W~kkk-$7KtΰUd <;yݬr&jͪ]KS+kwtMz2?y7u7k jemRJ糿(?&i^v V*-Oֻ(js:Otw(GEQ}sigQws;zŒtUQ]߇k?0Yϫ]X4Z|\HJʻQy4^ |׭Oy~TկU)juNܪvJb ̯EZD_MlR+W,ꝃTmֿ$ ;r#.RQqgc9uͯȈ|֊2;KZ{$%?64o"#MZ+׌k ;G.zd T.{%jWrZO~Q~j-жtfSuv 4 Dk2it/p*yήF|mfQʔCUY-*?b/1R|qoWy醑^AE$nvUE *0c:$ _*h"K UUE@1)9 }_ށ2O/gZY&ca9F@~Ŀsc$|mŬ5i_;z@.}lewPp; <"ntDDWÒN\ycE:a-稯%/5C_:M4?z[LZ}g?$[qYgY%Y'f`A 3/(F? ENye{ dPVH+!&TSjË${m5j5d$#C"zm^!"g˞Dӕ֢-:e YY殡 &婭UDkqq"ЂW޸W+1殡 &婭UDkqq"ЂW޹-?:NR|,e{!g=y5֏Ou3si ײ1fBrJ>Q&)nsM5vQʔCUY3U{"_fy^ȗOmQkl5͵xN̯.'OFԡ"y+ hs k`?.'OFԡ"y+ hs%[:95}z]t=;OSNbռ5gLB`5T·~iji,Z&3=?i^r u?(ZՋi:5Z&;*u.jj5ZMuKf(OQSa"G+İ_ \fմ;-Jkv!$RPp1lٳg2|{NaDiAf:^ 2?,Fl#6.>{k> '9Wⲵ3/q<ůO,$VC:jԥΝWnV01Oɏ:hooRT֕gPswQT~d-JiVz ~xCw_Imb,BGKt'?KNը |5y:顶fqܫzd=>:*тAqk?x gqg^?>yN9LW?J ZyFִ{w_F% xVW:|{; 2^HȒ t5V:fcijW2zt`}# 0V;g?#?-նlM_iQF+V~2BwY\濔46o0D<$0Q1]@=}?)ɣhmb&Tasd+S+QxIZ g*de',i_{O5?@W: %yJм"%[~$Mw_i*t@q9O6uU Ǒ.|,RY/<.x?iT+0N:K1GK%Ox%?JoVmq]ǧy$q%p(È8y(je-c&eAGrbcPAbAy(je-c&eAGrb>gr͛6ٳ͛6ٳ͛6ٳ͛6ٳA9K?;]K<Ux濯 .%\wgM?\0>&ŮKݲ6ٳ͛6ٳ͛6ٳ͛6tN}?϶LӢ6o7ᖛ,ɴ:+Ʊٳz$ݻeQ<@27lٲ:ߘ/VRh#[ :͛&XfZhm[syOFsf͞G$RLZteec#V?͛;lٳ_?^~ǿ-<&%E[Flٳ9f~v?nyK_4Mz]챽О̎>%#6䟖-ʳoM)ߜr-<8,6l7͛6lٳf͛6lٳ`mOLM>Nm㻱C# `sf͞4=毖-$e[FCy psf͛͞6lٳf͛6D0+|8YyL-o>*g|8}6۲津jZѻ͛9=Hy=ҳҾ,ȕ͛6%մʲ+,͛6V٦汷ܽ"֥,P"ٳVVowx8.&5龱ٳ+,f?Q6+,f:yq<+Nf{͛9'|KCuKm+R(#94PN6l"5|a>r}jZ tAsV l3f͛͞6lٳg;?'|g?E1lٳf͛6lٳf͛6lٲY_.>'u'u$Pe9#PsJч6p#?~g5 WvY1+$1$zmЂ3f͛͞6lٳ`}B)&1I"tETfi?P1*;״@ ;\f͛=6lٳf͛6lo?1b<}N]> ?m!<ҙfOBR?iQ6l+,efBR?iQ6l~P=~py/֯}[LYn>e' ExG;f͛=6lt΁y[N#qgw,)AhY3f̈́󊿕-V:;Rѽ{iRKJssf͛͞64-FOn,x.`qUxRxsf͞%wu/W}:ZDAf7xƆ͛6w!韜o+)yI6]Վx.dk-nH~D^nTSCٳgh͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfS~N?i #˚ܥT U?dwOC;~s M\61SJ\ /_xa.gK۝<&5sM+Qr\/Hni~*9$E6)"He`j#:`hA8n:7Gd`JUt ?<&Ω:0.%\F;~=%Sհ.h]U?5//Zmxi@Ē0c m`yBtkJ$Ȱ$di!?'ُbI@Pߖ^Af,t;jSE }P}.7嗐YڤHp8aPWi t*L3[G$y /l\=fUŽ3#j(>4*ȾMp-H VC ; 0t6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰWkeu)"^~/JS񤂇Ƽqa^~/JS񤂇ȍc7_E%>" zjcĚͺĿF߫?,9%;a^r_hZF[h=k*Uv$Nt6L +Z({8qht{:e6/aZEkާ'/+D.m.k˭=[ 9dM8Y1uӴnvD0%NFS"1"`{;O akVm,MѳT`3f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛9I-c3Lyw-MW~v仿ys+!6F?-s2[d؛#-2gav,ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6%skmu $Ur(e0e4=Քsf͊͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6nHn$#rQIٳfsf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛ z%扬-ޛ}:YHH&XjtuB{K,g=;d$B*UҬ5m:}:!=3us_宻K@btP u*yR>9?齦:ٱ%;~cԼϦԯ=󴡴]챫5ڱQ#Ѻms/شDZڰ!)#8S-g6գ$*;.oɲQ&ӲW6)69հղɴ0Nխ<0G V0_7O)NJч~sd6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛9I-c3Lyw-MW~v仿ys+!6F?-s2[d؛#-2gav,ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lߟ!4WOo!IsgpU*%*:[>_}?NUW+r߾v3:lٳa_WM֩i6GR-fVKH_#Z/nm%duRUvscefXّy0]^iV6dV:*o3W>{YS~CI.,44RS9e][^T N:yҿg"̺y ykjC4=#ߓsO3C~>׌ߧ?oC~>׌f`ƊS$ycr8Iy^3~?ῳ,G@];/?叚Vٯ.+HlUyf ,h{ WYmvrV$S6Ƨawk"鋉ff$qMW+צ 5l wYd1W]U$URl6wx@ngz@k 7ybJH^6.?* .4CLYh,*US/!K_YNoŦ\yVc;cE[ O:>`Wնl`H#K?׈iߟmYyR+Xp\I^"Kp54 6mK8.V$s`<O ^1ߧ?o?1x= ҳe$y=0bv[˿0gڞ/=̖$qHȏ yo zj>yoB?^6OJ]]W(뇴?ٍr:RWre>Bɇ䆿Yy{M3Ma$#0 zaΧ0a%v[u4ߊPӎz兤q(2$.r;%:HpY~'.r;%:Hpєq"/2M;))rFX}-VyNSDlLi#f9` IXS:O??4<C~>׌ӟG7`cs %@@m~^CZEM>^s)̵^CZEM>^9 =[Gt]eҹ!XX]ZWׄ>t(r≭[w'&`V2 7ܹ|95זuh5AYbBRh~C YSW' EwAwtRVEZ6 3 G' EwAwtRVEZ6a)f͜{rSɤFu1.( }bj?IPr HuY~մl#J5 z6Q|A#14.<{1lqzs! VsQ}s /?~[(Gd?v3) ݊$#C???;󝴃_Jј(? Tg\'>[T{ku qi% rGik@}+xiOιO}JJ4>na<wӼukps/GU J^p_̏?j^R6 iB)Jz|h*ԯ>-qdRk,쳢US㴡եyγտrP-/A/"#ῳ!rߧ?ow?18ǦtJ$-4&5"$<9? !\lzC _oȻV/G.OW#rʹ|"\vYϖZGeKw`H=6 o8Ahp< 4AfXd <6W ԃCͨ܉AZ}[k>-.Y,Mu s@dϕn}{$?za_h#x$*"I! E&GyTſwRCբFG_?+EE7Zs##n/}7 VVo*Ե}#CբFG_o?24%U:1`X\K)'8m |]Kα4 >OM$?(@UcNEXVt˯1Z^ᄶlj}aBȊ0矕YRF.Z4OoTmkyW{>yco#i-@V'@KKHHeeaPAFttttWF V "ttttWF V v^lٳfOwzzSehD^כ1_[j {׿wFR,tTXA1f#Ɗps_1KFmV+Hn.pM+EY+-=Id$im1 Qi$r~ 4@DO|0ntLٳf͛6lٳfo,e;I"4ƨ4-&J2=?Ӭ$(2%;ǫ/<9/j^-#tP 9ĴE pjiNYe^W:V]G ĢJߧVю2.q9g喝{\T oZ+Mu`**6~,M=89^6LuK$b~ͰRI4s_@r~~] tGӤ3>?)?5b5s6WkO˧U2ªpA j8 jٳf͛6yrA ǜm[&w{yX%+Jzeϖeע#l^3$4H2OBz` ^63#&<\f]z(=F2NI#*T,'pƟ"i^rѵՠ[3NQqTDR4GՕKwcE-P}'_UUasul 5* L?^Z щb{mUV7Zkk{X# B jG@g"(cXE$HP`P  P k(Ăbw}i%Wv2΋$lfVeͭouOXx5L6P=I< cүYo-纅:QʬTRI\[jW$xr Zʲ#0 &qom\\ da2# j}?c8Gœ8SMNbkӠƜxjSI)NX?M}:zt8ӏmJvcf͛8嶡ZMCyr]\P̳ D]18|~xYCUif+N@$~ֿ̢́ 7VP9Z{ӐbF4l.eFaPd'Ĭ?f럔ڿ$Ě%wZ0Fn6&2;ֻNwGWGm:8ӍU$lT5w~rPOqQ?FN+N!Uh:0 ]߾|ὴ{IGAR1SuİIvFuİIvF8s:jb_3i˩EcD Ҽl ^TGNc2\WOy."J/J̵F䛻yOIۊIWSnK)rE|-OQIk?>ItM%yP56䲗$W.~hyOm>KK%5"wHȏ>uc-jt"K[vSC@2WB2]J7U"?}ՏYЉ-m M )_=7ORӂL;AdQۉA-!ll#]?巐'vd& Fч> 5.#Nxݾфp(\?tAQҔvH12}\"ѝ즃<h~et%&=Lg⌟~W%^Y|XjQru,MVL<,u_<_[ՠgd4Z1IvhIL<,u_<_[ՠgd4Z1k_L3yKOD;f.~9ޮ,qMTLMS af†%?Vw?!\FcCU=SFT>,\yɲ.g:\xb @̋J oZg,Ѵu{H>+)6D^6U{ka$Hw?2&m:]k@yC͑:^}cAmmKFչs qe?Ѓsڕ{mu њ Gá*áJMwh?xB?$2V䈱jPZj[%GWlߛ^YQu w/c^d=X7LY\blg.޾j:K{ ao?t@kKK=J;dZGEk?5<'<$QoYZJozcu onJSOO8I+I=oGaV(ޙ$~`hiZ̲Kg)SbdbFRY'p˯.9[Yj$r-Zm=pqt՛8?חbGg^O9~6؞Gm; " > vѬHP> a-v(DSdxQmӬ4e("{ ~o~GyO Gk –#@ VrFz:yDMK}Tm@~c~B+;\uFsy^P6?1HGC޿Fyq@h3h׈`{K>결#Vγ$Գ̾,'Ŭ!< XYrlhGk9䑹ӿ1LSze41gs8w.fD48ZEmϨ/ 3,4F tѨϻ𲵧R:vO_q˳Zj4,0DzG5=9լ&J۲ˮXA䢣|ɝ(&}2%EA濟ȭxI)}/爳IwϢ?p?TDllOlj"C/'$:x_Olj"C/':JpFJsf͛6lٳf͛6lٳ?ѧh^%hf-wkZ46mh#4`yO?՚Sg?!sA6hE6bH?H9ֿ,:`AIeau%e~FOM (07?e[Ml?`-o8 79S^Z|ͬţhR9H WuZb##5܋#ޔm+ Hȥ$BUс  #:21G]I P:1Sc:21G]I P:3󑩤]ץذszE!?=:t 3f͛9I/4&,lֿy06KdGg%޵ɞ|&.1i:/9wj|רIK`>4pE#9jרK>4sٹ;lٳ,?ʻ<1ɕ-WYL7qE;R޲VAQ&14EJpW.?VɿVW䚩+_c9lg3P~^,d@)SF9Pue\qXkPx[r: ā/˾A85(M0sd)Q*YB2פw@ aS`yoʖzyPL;(:&/LJ͞:13ÑkڿEW'6uo?\v)0CS|Vs{uo=i s͛6lٳf͛6xrjˏ?2u7XT{c_:,Xm8`n#~E}O?H{~E}O{=! yܨkk$H)*`GɱH,紘V+)ުT)2=~F+9&7@w?ϖ< vU"Q18^執OtγҲѸ0dٳ3vɖJ۱%=#$*Ѱ޴w*m:< e4ȿ+i?WCSi]쉏I`sޥS;?}ΓyfzAN ~-=zun'õ7ȝ徍iI ɋ[= '?gsd8_OJ8m&o(4BLqsAgθIuϥ_+<l=7\y#Pٶa2IiGzm?`#F̖fm-=d>/`ƕg>5/8vTz@ڸ&A)@d ˺Z0Q(j &0-\~g1cxW# XϝYL3"|GPO~M/H秿&[hsQRUɦ ɦI򖙯OmuEJƁe3`S(-F_iS-lQ\]" j}FPoéO/hvzƩke:"pHcS@' ?_v~dp6>*UH\j/3y}巌~V q F\BHMdgWy-cnnПWӞ CFy3yƏ+]3^|71+V4O%-YQkt(1chp]'zcd``;a|Dr9/PciMNU7VO4ǺGv%+̟Kܬo5nEJڦƵFs*Vj3n]ڕ8 IywX zU<ɸf2J7B+qQ@tEtuӬ"XmNWf;;Qim!AQ`?Y=Ip84g6Lb[ (װ8?Nlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg %{? .%\ O_אOwO.sy3&ŮKC|cq?%FLv,3ś6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l2Qm[o56sA`cs~ п?&\_3_ ??9)>0_5ҿ(l_43^ ?V_$?՝wPm ` yQmg`n`-o8 78OZqoo6s¿=GO7~Me-/D盿&dsPyry6<ƀɨр@vץkT.AueWap/Yޭf~:_B .VQv~ş/_Hȥ$BUс  #8 #pUԐE## ǮpFF(૩!GPFzqr9-s l`5yMc[\1C쟔 ˚D)~{,Rni)n쟔 ˚D)~{,Rnz;nmk9#K?"??.L Rw8g >&,_3ShDqR}K`jgwٳfXC&y&%c+Z!1/\;tyPϛK&%c-J{SVo/?L{=/|Dtdu e"YJHpA͙YJHpAϜߝ~B#~c"![ZY= `xSPys͗r[b޵Mҟ1= O#Pys͗r[b޵Mҟ1O\:]̜42E[|ɏJ7[H KZ_,[JBl=Go7Gg3ՀYgnuo2]Ǧ۴4%?1IW3k}BU;rsƟ윁eQ_y]t ^zۓ4d o|u_Ͷ+kK OMwFp]{:ff&0}̟Ni<ߎp]{:ff&0}̟N{=#ٳfϘ>zţE  b{Hü6;n1ƿ'nID?)./cKpQQA-Դ28 䁞?`-yV]J?ngm= c|ITʰy_˖Tdr!CR@X! 4|j[Jѽ{*0h=9Lfjn .0Go-5ײ3FӚ4ϟW7sYvo*tu4ee4 ay-#hI6 )RU؃ay-#hI6 ο7<4E#rѮI0=Z2>(d_am\i՚RLfJ'wC$JhOvc5PFH9o#~bBRyO] ?fT+߼5F#bJ/ 9QOw&~doQed R:.JFJf͛8_OJ8m&o(4BLqsAgθIuϥ_+<l=7\y#Pٶa2IiGzm?d\:͛6l~gIr1(0B\~g1c>ug2;T.B==5G/_#mEKW&+&f͛6lrOQSgU?JTY(nI`uLߗDq' k^[;  JJWߗDq' k^[; `HUddjUApvPIT`Z8;(`Œ* 3ן^Kǜ'OBolF C;ߗ.^{u'm"{3Kg],빳f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l?,?Ikc'oKo'j%d˜ps9^n_ 18k#&59sxo=? f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6p̟pVMMPh6XyG1$p&,_3ShDqR}K`jgwٳfXC&y&%c+Z!1/\;tyPϛK&%c-J{SVo/?L{=/|ٳf;d~_򍟛{?zTns=ϥ-)r+wB]+qpGSo)OO~o0{79_A[Ӹ#ҧGsK$R1I#`hCPAJU# uJU#>ʲ?<~^` ܱuqmɇ0<Yỷ?+XwONGɷ{to랲'~V* oscsOyM5-T)[Fi?~gҗw}+f#u??i9z/-)wzұ!b>Y?/,m..co <^4X=&_V%xt+'Л:el r|M2e=o^OYWK°} ̜y8y8͛6lJ͞:13Ñkڿ?䭯ޱcKV7?YP=Z\%ݵ$)FVRZmWVmk2+0emtΞCvekqpv40BYIjs>2A͛6lOo3я?2u6XT{c_:,YO4| QvUawGVC2/ħ!+yfNQ}Spֻ{bSŇ:2Cjz֕ >,a/bz*ߋdUXo/f`}:[n;ڽ/&Prb@$444[٬N[īzac-=>c֧G.K]JS I7msIO1yV$V!bfp\kͅwۮ؄`:~3Bs#LRy̶vڶ" 3^l+v|~Z~Py+mIBw=Z*P禼O/yVǦ[KM%<[Z >ݾ禼䰿/ǦðډKM%<[Z lٳg/~4my 5^1j(%(qU0ñ ~7>_D-A@%]]܊N?C|_MÏhKPP Wnc~dN,X;qխ%=!?F|/1Z㎥o[VjC{Ze'k9ƿgp6 ~V[՚V~%rkuuisդos !&)":+)H=f h$hG"7HAЌ i&Fh4r!*pTƯ S[X/!O Yiws?_Bj a׭GG_c:nfԿށ0/|5vW Aqk֣߱;N9jɩ~  \~Ph6gsW?J&M8H/@mLZg<(^lO0*ìWf͛ &0-\~g1cxW# XϝYL3"|GPO~M/H秿&[hsQRUɦ ɦlٳf͛6ycsEOKʺ-5ՔIbE$19 QQ5.iOSqȽ=xh> t08}S򥢊,#}y˞ȳ$;SA-j'̒%͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳA9K?;]K<Ux濯 .%\wgM?\0>&ŮKݲ6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳ͛6ٳd䣇ڶ1$:?7?!&<넙\+o&UX0g$V_,?~'͛6lٳf͛6lٳfm}(L!' fD rR}7`k%?QCVhg]B( H:C5- *gɖZqoo6qtՀ4l?{ygqnɓB˄Z_/7~Me称==6lV^M 2TB hTooɿ6)&i#?knڎVhGwɿ6)&i#?kn=! b C+P0;ejqЂ3C\럒|#ͫZ$F5Gfɉc?g3{͛6lh֏{j:[\Qhv8P,.,nm ה讌p>aX/;Ű?>ޱV\<@ꦱ?ɑqsȚsWU휭=9~̴ahx۪g5E֯t9Z"zr.=h;WO杗5MgȃGRG? s^o8п#oj^('[i?_Qt74B @΅K}P DV=nd IŒy'M7zenQ##$BByz(tNww m,cZI; &QI")X{P )AgPlA6lٳf͟0|)V1?yZv&o8r37yo;W790Yέ8%&jonRg3v.<^ky].PЖh}Xi0-jzX~:?緗[RjP)=VeO gHY#b! V:wGd`JUt 4u;0t%]H*Ђ:s>|uߪWU~ 6iنz1֚GրoT~ f$vw{u?g/|i}hFGarq<[$yˮ=-;!m- z,ZT8t+WS!dM,A>_Oy`S|ZuJl6~afK8Po}A@A^Yree :RPLsLu=C+TJKk{yWH+؃ʬX8խݼQ$bV~So=qBfɄ%zʹ :p6lٲo͟%w:1 _r1(0՞TyS=8'?}u Km*\?Ďz{k%G?.u\`f͛6lٳg5CcLGZ=?r>8/>]5Ę=̓~LyQӠkⒺs?+_茽~vSqs?+_茽~vSy))͛6lٳf͛6lٳfm}(L!' fD rR}7`k%?QCVhg]B( H:C5- $v~H ܟ闒Maw&Xoo"@p"i|EϠy ?Pf͛6lٳg?%W7>vuu@ Ɠrq w_-|e`P{M̱?kԷRӹxGwȿ7*Z ؠc~ϯ GQ+ 3g 'e &+ީunO:Ԅy:l{?E?.??gQz7_MOv'Y{C=9ٳfU⡩;8oDߩߝRb!MLin!H7 7TSS[|?8t~x}ZNr&&fyZc&&ci`Ғ-TSE3if~10KnҟG)Mzo6lٳf͛<9i~yw@iکQ@ZCB\^X,|3izG-~Zսg>? YfPZ&?5< 3a^q|?yыl%RqAC_e֧J]jF2BOh 2IQ.˭N[DżdjqL~tٳf͛6lI<ϫȄ2=+X3:+k̦Gp\b__c:+k̦Gp\碿dAy2~6e^+ EP==^nQ?u_6Q~#`_מsf͛8OGיyA$#,dAϝߝל4H->xۉٰ"Weו<-kIOxO'FV. l3XL|OB:7Ќ4o/l5Ixyk\) 1m\{ˌo/=-kV~:FV;NH6I~Bombmߡ7?}8mE{׏HJpI)/VlRXUXn9`APwazX@ ο4]?:Zϥ_N@Ph~y-f}7~UVK+iqde1m ꌧ<Ϧoj esm Q!1?t=kM4{-cL\iŴH⢣=;PԬ-Ʋ *>Ga:+9;PԬ-Ʋ *>`3H<~Jy}3B._GSߝ2#mGqӅߞ*`mGԥ҂:ͣj?/uS+W?S~QȒ~Uy9DӔⶱA#2uD*KOgJ ֣?K0üٳfw9 q俚ZFRʑ3 iʑ~_kl|Gp>@η4H/>9<{qV&c^^sy4Fg%fY?.tbkmo[cdunly8y8͛6lٳf=l]F5]b9TTWV AreS?m!h ^p9!Q=>\|Ay 73AI_Yt 2TZ@hԌBk dt*.JbKH~M8a ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l$gQ1%dˁ5_k 2[897{/sxobo9Zdɞņyسf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛8~&1}6{k"Ⲉ )9rkIa~ ~rp&) {]_:Mi,7ЮNx/<ф9b)I>^On_Jv7("Һsџ^y YWlDW O%}yHӇxA={$E{"]ѝ:6 ΍6lٳf͛6lٳf͞"kh'Jӭlfb4>ϋH&$#5?@?>/φ +X`zxo#sߕ\W忕UN5Fwo&e-AIadzcJ[DA_;lk @ٽ1}'^uѼk2V GnK"Ċ̀:|/h3kl;`oHbi^W:+O0y{E[` ػPx9+\ϖtɴ>u A1$qT J1j6){IH,䵵n.gaV 5_Z3JU[1O8_&m#HqZTBB֛Gl&hŖKsm/ZIZq9u_?sk" 2hj9u_?sk" 21\if]jjf1kJ9iň9_kgi^:CCHy duZO|7XʫWbE[[=KORC^G#{u<ٳf͛6l/pԅםi\YX^հڱ̬̄Cƣ(̪̤^ӮԬn/.Hfաǯ5S?0ጭLQDWʃ8֩x'<l0YZYFLjsZ汪j qQ^F0^[iM. ,*׋b<1>wꖺe*zzhY)ޓZVlE"wGsLvw麾{EmBbWrgf@?i=ťĉ8Kg!jX`?pb* Fݼj_X\Z]\HsrF S=GQ͛6l~d2ΞGq@oam!u'eU'mm>-̫C&?6>;_ұ71ٕ~(3翓XJ*)F÷Ņ@f c[)>XJ*)F÷ŞV$S=Nql*-˟̿4~_krk^%hZ+"6!U;2 ï*yYSHR TJBuO7>W^JtTy! ЊJ|_/Vw<KLf>+?/S?O$??΅ԑO){6*!k<:{{RE9C%=L)ռ^jS}v/&bMh>ȵϷ#'1!澌,ɉʰ}徱3s<~z?*/,VӢu gx"CHj:7:ι< \_D̊8.ۻx׸SSjP Y?=|KUGewr s^j_1Z뚝ė3* "kVkNX/xaa444ՍNyZծ}ZS/%i Ac^#t+~q%4Ӷ簿!۷ݳh꦳!a_˯-sfdӵes?_~uqn C?A#|g/<[ RB LL@䟢Eue5|BLg/<[ RB LL@䟢'֐yS&^GA`*+uE%@7dtV`E9 =L+8Z/(w,ЯN FN@~Pj~c5o#}Q{۔c$,eD!+KPW%歨y˳ǬiAdՖI"*II vw 6%F݂F3yj7^l}Y.#eHR@Ry/]|PAyמ.HҮM7[V_j"~hkQj/tnOe+(O{G!gMmӜ{|9O s1??Ŀ5;gYm X薜&j# [aֵ业 4I&iYѭ,K%`dUCons`ڿ!#.?-n4=KOmOB1.x$`BV>Vz^_)[K]ڵ,lHv`x7R&u:漾RNk6Y=U,97ToVyhP]ۥ R4~L_NIT{pg47Yuvмq7Fe T (%~&vJTw0W Y@9n-oḞ3,iA+3RvyQlٍ7Gϟ#!Rsc~b]T -ɉzrw4ڛaE]0ۊ/?ߘ~q>,, h9rb^6rXߚ}25, lRԘ mMO}I֬DVVKK#0VDʥ쬽i9ּ:ՔYܩIvUdrzr<[3iUv.$cuuVuxو~-bZ1+QXT2 &eJnټEC[5q0` Sc6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰ6iZj69#Yc%MEQ)Į-.0] BJUXʬ(0;WVp.hPhj*tBEt]9f ̶roMV|NLlHmD. cNs$qx(Z'eiō6JFJ?ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf`,u Poםo-xL VmSNԴۭ>rwT}"ȌX~ iږu܎Vq<2]J{|O*yQ/t (F"dB}yѯ4]bJ^7۰a\{2чF扢o]wFu*xZHcnUqF7|~w[cQVWEPkQ11?KH+wC|RPR'=[H+wC|RPR'>Z[]Euk*Om:,OGGVVjOC43“B,2xBYXTFOC43“B,2xBYXTFcf͛6lٰ~nѼ0c.E~)DQW wOдR[۩b;~/1c&!sE_i:Rwf_c_蚿Drꮡzڞ@%#G"w$g<`#ܯ5k@U[/ˢ/a=[~M_yu0W\5z­ɗ3@ Q=GuM'K%ӵ[8/'4nMAq+g;Y)A2,  S"pOPEF#{ce}lGuk%=H&EU`Ax-.G_alT`# ?*ơFEm a#'MtU.?UZҿhV/Gi?F;-Y<_N0~\~^.ǖ4ulmđ0edp9Əd&(:+J+ XMGB[YMAV QC,506lٳf͛6lٲ-~WyIuכ+_0އ[Pԧ2!?;%olɵKT %VztBrjnB[Xc27V߿L%olɵKT %VztBrjnB%8uG]xWZIZ٥w;3K6|)>Kݙڲ&6ڳ%շDZ*')%ѬL<h1jjqOWAkJoZ,//?eH9^+mo,բs}^#7[hxM?-.%]-ʏ䌮*EARGp5D-C ޒrWRGp5D-C k6lٳf͑3_|aGe)/̂FbRG" NYG˖zƻmd@C9ʅ)4܁ 3LIo~Q垹qY,z"{yrj!bM7 d L7͛6l inc5k =k,N;1+;Kg;iE$U+Z2 2)Vq]^[=1[J)$2taZѕbyKFdTx[&=OBv%maqt;1c'bV{A1O?eH9W}'?XE#4{A3V/Gi{o,բsʽKZW XE#4?Fo?eH8 )hҰ }<7Q&ְֹF(AC܍kXO\y#ɚ̷:W3/ fe-P :bo|Jim/%1vڨtH!j*X/钼nke,o q1]2o"1-Gڱ.5;1#LTJ"1WFO+ʰ{oέ崳ʲԡ,7#Պ٧+ʰ7#Պ٧ٴʱʰճڥ,ګYV屷h}1%9ˈ<0hFڞm|a"I/TǘjV$1IOQӐKB5F=>ȷ^<ˏ0ԭ@:PшV/Fi^# yc_ӗ*?-i_m4eV/Gi?F_[hxNoo˩ӛD׋Z1d$^2hБQ=bCcd$^2hБ.&X1ZĐĥ&!*St >ml-BJ ,h *78DEG@4e +(,jhZ<ڥꖑ&K{c1"05'KX5+Ho`V,WqpEhNSZ0j:N°jV$X#YT0М/O˟$~XQQUlm|ePتЀ?qW}'O+*]Tl {A2XE#4^#/-Y<_N5./dBycItaFV  e7iPYE#sxH)Ra `&z+sC[ 2!Txɢ:[BGF>Txɢ:[BGsZfaCcan knH ,BrNYY[Gkg[[D)1(DPMvUzPG@6agegem mmpġA5VnpV-f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg_95 $^lr.ԟݱ۱yEpT-Wi§ΰh+#=3˳!ɱ]Z[2ݸٹ#x>8k7(_<<}F+Z|i? &cB"r 8o *:ݽ"~?HYWC oAȟ-r/*] ]yDry.8d[ml46=>ad<~Ԏh~#AkIjYiRzӫal75霏>koe%eۃIƧsNoa[dԂɫ] GNR {8 t~Y[#}w?O [KH"^2`5p)$?ʿ)crc6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l?>?1nդJZ] Q;13PkM|^k;kZAgѼ [ͭ2S2 sFȒ,:H0dnEUrZ ^܊UÁִ?@orH@Gς~Ew ,@r ?X=i$Wp""cd~JHW?Rd(&]_ZLVuhmmn吏M *x& O2M{r昭!U?Cg?"-#-5 ]Hj2-G(".P%zgu+I#JS8at½\HkpX"؂h;_ZIfU EG_ [&+&f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l٠FLY)phqJFIF++2-http://ns.adobe.com/xap/1.0/ Adobe Fireworks CS5.1 11.1.0.205 Windows 2015-12-18T15:52:53Z 2015-12-18T15:53:28Z image/jpeg C       C  ,` !1AQ"2a#56BUqst3Rr7bu$48CSc%(T'DFdv ?Ȱl28Bփ^ee(z*? *Ax2ԫ?R,Jhz*? *Ax2ԫ?R,Jhz*? *Ax2ԫ?R,Jhz*? *Ax2ԫ?R,Jhz*? *Ax2ԫ?R,Jhz*? *Ax2ԫ?R,Jhz*? *Ax2ԫ?R"OޒlKߵ$Ӆ#I+:<{cY~҄ U[涄 8E1[=?iBU]SP.5)s|_sG#HiGlk?"PWxoo|OI?*ln/X)APntxƳ, Uw5wM>iJ Wв#N.RhqV#.FCHntxƳ, Uw9YR7F'#-HA@ȳ%U uN92)K ~K ? alf8R*Cʱ(O-G$ӥzIUVOj+y"u&GڎaĻ%/JIi0XvU~הLkS~S.cU˟bDǪʄo\O9Ɛ.ĸD]"hW-ZTpF!ɞ6꒒]XKӝi3TsD,'v{ySmڇRwpɣ'^DTntxƳ, Uw4=CYa곪ihkbK'怏v9@K{RCt9fRq ovݻO%!]Yu\L6I2($@1?e{ MqҮwũ${005zU&5uDF~j@ uMzc)Hę#I4ٗV{}"ϑ@3/L`ˇe&C(文O+&Vٵ%u%]{ -ܔf !ݐP>%% ݲŽXFԘHhKg~>6+,$9&ࣿFͥijܲܒU#4ɤ;)Kԣ0ϴڔV&1ĝ+ٯ.5-ȶve4-< ϟ5m~!%VĨ~YFӤ^x6.H뮭9'=>r_@ z)s7*~Kǵ,Q ʵIn(GХnAgȚGʃQ]UIg|㸖JYd%􆊲LL<k/Gb]g11TzTZݼF"O%hr\)u꓍pȔ<46K^'wi0љV1jrULIQkK!mERRڂ.+_Hv1fp&6CԐ^YnbCgOO#vM'H=S6Goi]Z&c.R|Sf-ҥ_EMV7Gs6V~r[&DjvF%S=hjڃޑQ(aRZm߷w~ܧ?qhDe!鐪JJBKPaq-Uc&_\څ Е]GZMQiJ.乖 !tJVPE>Ȓ=ȈJ3D^&*-G*JV /RDk-aR)2SJ *`{K+JihZ-&##.2C("mC*Y͐l\|o(D'ݓяpV5IN*-ʊN+rx ZФ(в4'$wnLqo:e˴)9U{ĥ,a ]z)qQ92 Dh8MR]ʲE?4Wbݧ#K{gXi1gUm5f|Dɫ*g"1#gdF=ݢ54'dN;%7Q'+%wϠ4V¢sei%z挙q4jq&l\%uz]|$3' G^}nCv({TOӹeTi*-r)FK3A嬈qdECn;mQ N!^ } Mš2)T9(nFޭո{jNOMUV*,;G]OU8]G#^x"7ۯ9Hfw_S Il3w흤\Ri9jZl=#$3̐hnkIKU&w< m旎>FG2Glk?"PWx ],.L9MK!8ԩ'0;kP]Q%};U)#t/)|X@+G(9ITNR` _eJQ\ʄʒ뇸/Aq PWtiI%q~imbBdExǼ]eF =|04՟!g5U!WZOOWeuh3$rQ`@LC+E & 6K:ˬ .ݮ,Tc#Ɛzh5C %K3f^cH䭿TfHB44rI˘ܢHA+)G̻~ km=}H|҄RFdscͶ[BT[am42k<[Yf~ʂEF\jm$[9!dJړ4h=*}ai~Lt%d%)A3DN  NhQ[\u ),n/!8,"_I!Zi-NbZu-B&LjɊBΞUS?=[B^}7 cqo4.79W5*z?oGAk!#k(4:ASKL|bGٻkW1@Xtᆡ!ʟNy[~#Q|BV=jM2hR`%=Ō+]٭Ѫ)2.lSWDTBJM> 4!&gȢع+nU=Y3dXR[>}90iGlk?"PWx ],TbJ'$V V)PE>J 4+?Ζ4#пp󧿲3Ua5PWATkjQY>[JOo'*7sG\%p+/V"jGەHmS_ڑ5X5M 6nETjif D t $,%=RhQ}*<_#iV)4תs[-TRb}K<vz;}=|1! -hi5geY#ZozhOqxZ)@r6YT 'wS}{(|s#r?wo?PQwsWgАTz%/ȿ֪,ڥ}Qupd"[hV ȐsM:id!%3>DDE4h(.'!}? Nj~1lȫ-Ə?(uJNU'ăq=5$EC `eQ9DIM8,DJ/zb {Tqq[$nQ|& ^>lp9s)8`..Fjsʽ/4w߹JfdgT_t_ƨG"sNpFkF,hRKe[γ!io)*.2ዃ:rbm%Oy R\<mw.5$E8ddڵvp󂣥-h)5ce\4?p~Y1gT~X"ub+)k'cĖ'̔H/@ rj$NBMI疕K'eHy)pj#)bD̢A`{w%x.Yy>`hWbXj?VhLcҶ^Y#UQaMi"ŀˍ($A׫PWTWh^?aC'&x9]a#KAE{RmITۧ*WF6~JgE  /^ nU))q(qhYe*d(PntxƳ, Uw*>]߰BH j ە?S/ƚ2'~.~фd%$Ǧ9_QVttN/=y[i&}L`J+WS$ArB?U$D4` IѻëUR~̸idOgeP ["Km)Ia"! enyƨ7_Eh\XZ/&-ywXb$yL4>wE =|04՟!gKBgBvy]f/ x/VS ".ӍXm *]9lV '8#Izbfu&I7&V_zo>ѹ*$^%or#W\rGB/!1{,s؜Q/QO&I8Eؤ)=¢zi )z\7[V D{ő}?wiݷ D1}V j/lsF6I؃K3>-]ߴHhMvMՓQFhLhD7dJU)+#le0B]I(t̳.A页Z]6Fc\3J\I̋8 rSF*lM(ݹ&a3 Ľ2etǝQ! -RD*.V- R,*)2\pfCN-Xٞ"m_EwЭxJ$IJm~  ZuKMwKO+OWi~J Խ`a 6O#&({ 좰ǍyQIu 0Ԕ)\Q% /QEϪE6EV&K iū3R3DW= bW\9 ~![H_a}e㊸YK:&M:q&:5ͮ$AQ4ڧ9!O8ds/2ΕId 7SSwi3ہt]VK"Uby d.i IWjT2UwJuJJdr221Z:_Shu5\R!3.He%}B%5-x-.#$jnId ~B-orƔ)LJh>\zcpez5E̜yL[/A57EԊ+jN \"IyR=Ks8Bv (p^GQPE%=+p#2R##&Ȍ]*層_Arې,ѧUaŐ^3emdFǒUuR/QT -%po!)NRN'w#9`]0[Q8gS%)$=|FGL4uU(oS='vg$}Atb5˸JtA#t/)|nuFrX5xR&~֖,.#)5(\Ѩpilm[3.{~c*؀=|04՟!gu4hƓWee4W_UX} =qo(PntxƳ, Uw*>]߰BH t%TYʸFOI*K$o|A*>} 6iDIIRO$d~$`:cM/n6^2MZ&5R_@ʨ}Gu[Ƅp:tFj:~oFM0ȪQ O7bC*=|04՟!g\̷*Qd5wؒI@r8=cJ,gýFhVX0Imr?!=ć\Z=ŒgYJT}!`}0,Jsίi5U5^R\x= Wjg[*<86~r0WmV=ZT㑓27PJ- _:{#5[K}Yʉ1(Z@YY>n['y>Kʷ 0.hj_5{! -hi5geY+q}Nʜڱ"""4)3>k?ݐRQ]cP} =B)[c0m&*P>U G"gYJT}!`}0,Jb)͓d] q|-q>Gbi~KOdfZȔI># y[[[|62߲mvF9 G]1Qfnr)[JyqR] /`Tb72lGĄ wmhZ<,!t{~ M9' !R!JpԙV. *JJIJaWr:V~UbjZiuFIO2Pm~1QrAW|p<"{p˞.n6ܷ=&ٚO/O,8[B$Q.2V9esM-tn jٗ'ƣi>~ )qQֳj?,[n OX)R ,-O?}!W!Jǁ22<# jarRSddmݏ'="bƒ8PyD8=]*~moCBz-.!~M42_Yp.;Z,:IƢ2\d 3,sgY[n7Mu.4O5G}R)RjK&}@?Vۈiω`2HRR}dd?ĪS*PRw%|H>~T೎g-Ώ~E*Gں?˻X)Q7яĪAn"]T5s\ ?䫱_r^1fLunQ #D_RAuSOdEYFq;M?ޟOi][Nu4 ,(\i 64kEtݥNv"y*#W@%(@J '-{0O]_RfԪeEm&e*꧵e?TWr:V~UMxבAjS?-^.l2NZԵk=QJ>3G IM^W)2q#7 Y 2pY56r,a Y k5jBQw%%ܒ"F#NӉun !i<v\q7*!cd\G⋰e`6c םtAlTٿR0x>}Uɜ0ʐ{W[m|y85 FMU(YnB%$ 6v(8O Cɵ?&CHtOeZoN,z!'{ZHQkmۊe!q :mE ?H,])Ҙ5_7Ŏ8POR{8z< EY+ʶǀ/&+iK҆$ ëӴ:BI nTYRRDNsJBuaj"-璖\!mWy.}1ZgPWUE'eR|)>J_{TNi eO]Q[~Aqm# 4ݧvN91R3O-M,/<~N${|spd R8r#JKO#Hs4۩RSQ9jOi% ePٵjă!/LoOjSFIڣ3po@ȳ%U C{WGw~  *&1aAX]( O}XukYDOi.oZ;K~KOdft̎eEA:ECvunm!g)FM>PLXܕ!~kM$ԯA,-ѵ n܂?.JUoH""`ԾjݘC@^[~jݐʳS np-(j/X)P#Ӊ-ƾxOYJ2~.y "eաFIjK{p2V@˴O4]5uX6ʲ5/N1@"\&Ch`ʤΤ&Om-/: 9ٝsoizB) 7KQDڄ}׭un#J4$![^qVA<̠76@PtIfE8|/yTu†Y*|3ARd&C$,}q\JQƑl,ْLң$)V%~ vSctxn8Ԇ~J==*

QvRTMH9i=8k뇄'_@:P*v]Zd[;AvQ9'*a @^#2r$vg eߵi(JE٦ ҉ƛ&CN%($ "(UhH)1ADH,eiMJ,gH? ?FF:<[Yf~ʅ? V)o8J? wExC%/AD"KZ u?p__O ʸQ2tϳjI~cR|.-m%4xY%efGʠ?;7Q.o÷-R둙5|u[qH& 5)yAm#XL ]}=<3ϖ|[l!#IIukus5)G3G sǶ5g(J@Zm5WR#RӃ>G@i.|̤iG6![|." Hvٺk2[,xJVD_Ay:>ER.9F#RvTj0>\i[Snڋ B$e#imPQCM,sSiOsBlu#B^/љ F,ܨK}g24"hө4c< tFb5ކPn2,.0w4M'*,~OK_`ܗO>GֿJemHm> I`m8-KQ""3ɷuyu}UF{$:|>_B) %'HM 餠q)I˗ޕz;ʴ^k3W:RxKgK{Y=F\WGkk?,PG:@{߼chWG!DϤ'g {GfV,ȞNxQ.~ag2 \)M~2TӉ{vA2Fy#ȂlMZ}o7U`d4/MN{Z|DcNhڔOiyI)'̏1UT4.nf&]uYI_3G{Et]ScT*sƍ,7yN3ϴ4U)UHQo7Qz7K FntxƳ, Uw qzf>j*}Ϭ=<6 pLGCgmF OzDdQ+zuѷʡ qeq+JRs.L<\=*>Uj&sSϪ4O(u _v7"sRIxWZ͉oBZᾕB ̉ho?oj1UiQҴ3/1Q5DFE qcju̲gKLT2PzSQ|Pi]X(i H$JR0J LnPZx%QU)R0{Yc >氭%<݉h/R*:ϓʺcv6lԙ'Jv)2.`7`5mD^ Wjg(B{ԥsju^ |;m,R^[hqyJ"1(ޑr>kH==µ*)tױO ?F7ݎĨDtYmQ)V: =S3mE-h->Et0 {]uBηON^M-,mR93i V;2 uRҧA`}-'ȼ5bG>ҿIsa87YvL=h.ۥ]jq|K*O'X|^z@o2O_-TVJsdg`:8 *2ŁFUj-3(Ziq?C-:Mz{h%̈́䶗VWjjDt Hel>]Ԛ崳|cKʕ&%>©e!p#<jז6\fL尔)xI@2077˧ ǫKo?L<0|%nNLDmuN ԩ:dܰ3QDqZ7m9.}T\ӛ}ܻgɩ\iss-iZ.%FgJ,Y˘^Pל= BRp]<iYڏ5_zj!*AyiNFDWQӝ, ,E^Ūu92ZE5=s3e`W+RkZV:+dvb('T[ҭJҒBT[|5G$Z49w%|MMmR uunRmL#+qaXV`BsyiZ]I'88V全eztK*!qiJvd0EĄKV =yّYGic 9^jĖO<$oFB j[^ރA i-6I,ZT}c"4i-4UĒ'2QdW] 5>X.V'MNKmJ֖q*3=Qe*.\V\vȼ)dn-#"޶ ס/J*>tG ;HJΣ7$0CPY,n5"Fͳv(ɶ7ciCwU5qMAI$4jn$5dӞd]awgjIqUǐQ*KQIFfئҤ j +,}0IݕvY:( m2HVݻy[aaN&?aڅ:<`X2$hd@)~H+fRYWoVKPEB+rUxtJIЭp;1W/ai&IԧRs0B2ʞۈ[ht2ȏzss={L~()[f[LVpGBУ)som՚AE+q2j"Y0^I }kLl^ɹ%L* 4p܉!iP#sdQd]}~β~"ӻ~j!ϙ)Ud|f1~ё8`]B[~tzƐ`W*Re!jl()'btw?YL!izQ3G"ڳ6 3 L%qVչ\m;9yx[3l2CjW!,ˀ0) XJFYQ- i$tԒJHF ڽ.W-z%*UkҚRsIJ%H[Ϳ;&{I 1"iSد@AS $8f'ԛi .ġ "JK@!U;fЭMnUTs -TgCxFmikǐĖI8ӉY,sGΚY]i:raZSU3jOE[DfiF {E-5]ʣUMtVk5&7^Կ7Gt./w -^ĝ Yh;J-77Dh1Ol*Qn[>żx>T*2KòKV\ij!wh z7H 1ym:eO)-ܘ7c,8\ϛ.}ajWHY/͝qHQᶔq^IR{;LtԜS1cɐ$R}Ȉu mΎW\*D4j2D;%dLl$ك.5@R*yYjfNM^[* +v3Ğ2P]O *"#"U*,:]3Ԛ6ÒBĝނVřy{<6wK]=?ny:RJ xVխ%p$x ~BUs6Lu c:ѥjR<6j#,8q[jnWSʹ3$94 iGgXI҉ܺp'PmH7Ɠ2`  W't_Zsۿ *>w-fꮡSz+Y4%lIwqq4&N2,AG]6TLr2Tl-EȳY>k#N:*\VZTm=z x62f\5MIⷛnj +@.;˥ѩn9EP}Z$vB7{+ $nO5>Ƹ:wRˏqB%n6a|8'g3كU=`iZ+wTML}4Z*hyquF*Bj.IQ uǦh0)D$t&K-is3V?o co֏iKk'k7>חj9!+K3R͑f\vߨK}>H'$ߩaD^nXʧO)OȍM K6 KW5% Qxvw.ԻKKNcj?`#?I˚c_qf [5woA$ӓ#,c;[il"hő&Nʽ]֍%j 5 ''O`I?ސTo3߃`哛>X-$R@bkE~cL;K̺$lE3ƃޓqnHu6Jlz矍Tis$y%kZw:ƣjoY6&RJ ֢SfF2^PSm+*n4\9G?ZI\IK-Ÿ tTۻѽQcǒY4%9 ']lmMRuѧ~#,fɳmm^̤a\o^n=JH"THSv3A%FY¾#bkuXQkkUj7a1 4:orQ9wOݴZ=;[+kF\-6nc!Eֺ֞Eʽ&XZV!8҄IA-P=ݠ7=‰W`ۑUqCx%I?i#Zދ\cJ]fqK\z#ǿ"]lC7[D4I3.3l>0;Ц6٪%j.❨-ێ)< ^zۥ\ JCmiu)4l,˴ʋFQi1)ͪ|Vhm{ dfޚ=ףbᡳ*f1PkbG"nu6c>i53NMl6(eiKZeḋlWbLebmI- BTdfF=n#VwuH3fz=tRih[D!l p.4ȇzHcv\i?%$~nE䠻mr[k*ZsRIzIQ,ԅ0BhQ4NVv\SRyZzezL+n9#voS*F\ʲtN[ D}FDssZvLU23R|'(+ғ#tcJ|ҘݼO' I~C-:8yQyN/twhFݓ:@hyr\e9ūK?[7DΔ:-OO5.K?)/g`IJiQe' V:1W.{Xybۦ1LY/)f]e0Q4ȇzHcv\i?%$~nE䠻P{r5,fggAMDum&Jp 1ȀG->/8IsR䖼uK~+nrOoM)qIIanMv4uNj1Z iK> BVrz/hlOrnL4g/8 =>HRܴ-ZɱʰDvȼ2Ɖ&%O>< >夶ϵƏZmlҞě6!z҅#%'yĮu3-D4HҴ"ٳ1<=,սE釴٨X0,T(ТĊmouM)KjҐ?8AP((Ԇ:6 dV7-{P]ۜ5(^ MvpN?东(~w6\Զ硜[3f{8>G!D 4u6-JR52ֵّ աFcu:L=Z6qNuKYk3`!/G#+jU((TUJu8yx z =F`0:c8f[L@W2z/h1VQS ILA.zbP-LnC:4GBr}lq]{DJV⹒K6ilwkӊOuFsq%խ(=3#A;kmz;@B4ӯICfG4֜q ާuNUyc)5e^Js>}9Ep"M 58Wsy3?!$ (Ia).DD]fI$ROy;2>O@ԬfCKu;:͓Y$@nm3-zNB:aFgnJ|$@2+׼Hauq:Ɏ+"*W"QRipi4t{\[eӹf,=Eu* y;gkKJJ ϼ/M,[)lEܧ5exIjV]J\BɔH$\T?hŵBmm0MBrQI 6`1T"9|fDxwЗQx) ##E- Dĥ[Pn:~&3zRq "ŕnEHhWYSnHsy$ܤA۷&C)4͓Ow)'E`*vۮǺ U15q"imKV )8်Run)1C4) |,n^#>Ү*X[s}NJAѱ)\9;bv鷭O:>㍬S $7Wx2Q3-[Φ>6-:C4{Vdvtbk*Qz=rRd^ԫ ,qR:F=T+^لU{RranyR[qY/!&]!¾kgDwTB%c9НpTh#$s\BQj˙3>}-GdfY6~[$ek$ /hjVpXR:cO2ډ2?c *YUu7Diʑ̳-/nnzS8>m0I!u|׃%8Н]VPJ!vԅ`uYM /uڅgP) pkjZ(h)8U:mR~UPnS-4ڢ8̔4Lޅj<=^3*.q <!mu>=ǐt2=s#W*ڵWZͲҾ(y%ӷ42γ:kݺГ>˴{вٗգptĦ#=N'&lU~ۧRS$(nǹ;{ o䋆bO,[Hϼ~k>*FR\fiA%"7F@~6m6_Yd&4d%v#+AoJUԑ,xJGcLyJLҮx@+? S>$"? G[BVTF}x>{2RrH}u=%IyQ)$x]:] zrڴmERK&yJ̶J%'3$$\ Ve#IP2reP)VQ)DC(Ҵ@t5[]{RpU.ĜѸ'5 [^+ pP6,)?F.Zam _hvr[ΑpgjO@y53N:M!2SJHHed"Ս(t]L5-AE%mýF]䥒-u·\T~ҥ-eQ,6i5%2|3KY3Ir0M92cؔ50Q0fO]BoKLz.KMepj9w]/ Ln9nN:]\GQmuY!jmJ]~_5V$SR5m6NIi̲Iz WiqToY)IQKS 5kPn -oHU[jEm*A˙=+zF󺩬\%ˊj I!WV7 q &$m"/  ;WK <*RZjNNB056$f{TXI!7L}(+:O SWRDf܊ڝ|$TyFh,skNWTuS]AyKuJ{LOrCOu|.J-ʻ"38O22FwvgaePsWU5}Hntpn Fi~,= ۆ9ɹW}n)EIr3 }5%ԤLvjTBzιJm$m#J̉ ci+[Vufة\+qFpfKml05(G ih*5ʼa[yh6^z]͓o›"[t\jd85'oahˣ)d0rc*tJjp^MKW#%nQ웒y 8ѩQ$ JVZX"hN<ytYksI%ZKjR&g.MB+׷>?}_^ø{N!]" a% N qdԟszRPd.D[Yњ[T4nZڊ*$ʟT%\2?#jS<@(_%VSnt׸(H&iJ Zלg^z& anԨa4y+J{5$) i$2Sm#׭]r2M/NO[`6@9Zg\ۤtH\4{{^?ɹ+ÑYwE6gڗ;JDFPPnXTӞ<><9Gʬ\P45N-4O K2232<³zAKm'RUUdp} J oF8m>ff DR,Stu1Q6ϳ˭%$d,<[v[w6޳(jq#z 5$|G`+ .U(IQE|g~,ͫŵn?`QoUs̘iD)k!hp$ccUh2K_& d/%JRGVF&KV)lR8R[HR>&@' NZ0G zo@ɝ۸MUi:Qr%&K<#y(SG %JYT^[z,]>(.%n?t7)VS4Fp]/j 7DOj'eAdq.}_f|GdٕN7ω3RLČ(_F8F&_vnv{= >{\ dp2Ħ8-܇[Y{'C#=?'=ٱ+Wk=K235O:RZVs;8IJIn,GCSF&OT4qWVS#[x('u(g {)2IΚ-6k.꫺Gu벰Î[ jm92i!.#4]z?LTMy73 !$/%#IEfjRnm.I TAΨjC4vm݌`M.+z-BM*y}B}^Q;]. [yif]%}  =__>Z8VE:P}\S>zqjp괗_i0Iw : B~f=U|ό.#+n"=Fvk v 5k4iBUe>۠3+6SI$rdm4 c>B|0`?4K[͝+ĪWS'&$Ȓ&I)7 E-Z z5z&-n>dN%YgnXdi٤xZue˿a@^Я T~^R%pKƖ#Q225RgZq`ic7-fyrhU/#Vd $У)&wU>>𢳢ñչ2-᳾9s<1EmP ۴ } SXDh^ȋ'E3u8uImz3ܓis ^RjiƷ{HANHWںygZ*?TsWiG7]0%/ZR%Ɏ[Y-ҜoI{yH#J =6էRCMJ,19gw.+FͶ2h>LBX:G8 kzw.җ"%- ˗vFiŒɷ(Fک)o"q-I#$m불io v?Ʋm)6J/4 *FF1թ[&kڂG 2]nn3q%IF3ǾOo6HDL֦!KeOR EVHG BDjoMnsZHq8[G*";hei.&mwR9 ɤ ݟHFͶ2h>LBX:G8 m~ܠ4kAsA-9QgEerZ $ 2#Q\k?/FpʣP:sT<&ihKh/Ng}"7i}PJEK#.c9ővq8JI/Qs9AnqI$! I&S!ĺ%GR> #;a+sivX[f|}}3c3a%ԀT D@b8&4$7NIipe>4ʹ((51)[b-d%8>ҳV0干Ԧ3<~;G R fַzKtiaQJY)uI6 2R |"em.Fۺ+\0d RJjL~}7mHKI:㏺H>ԥN[=2(ܐw--KI /+F mUhEFBl-H[\l[)dO$$If!vh#v#v#vl:V l44h t0$,555l/ / / f4ytg$$If!vh#v#v#vl:V l4h  t0$,555l/ / f4pytg$$If!vh#v#v#vl:V l4h t0$,555l/ / f4ytg$$If!vh#v#v#vl:V l4h t0$,555l/ / f4ytg$$If!vh#v#v#vl:V l4h t0$,555l/ / f4ytg$$If!vh#v#v#vl:V l4h t0$,555l/ / f4ytgDyK yK B../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE TREATMENT SCHEMAS.docyX;H,]ą'cDyK yK http://cancer.case.edu/cancer/media/caseedu/cancer-center/docs/clinical-res-office/protocol-templates/Protocol Summary.pdfyX;H,]ą'c$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vu #vk:V l t0"65u 5kyt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7$$If!vh#vt#v:V l t 6 065e4yt7DyK yK 4../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.docyX;H,]ą'cDyK yK 4../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.docyX;H,]ą'cDyK yK 4../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.docyX;H,]ą'cDyK yK T../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OF REPLACEMENT OF SUBJECTS.docyX;H,]ą'c$$IfI!vh#v #vh:V lX0,5 5haIytg$$IfI!vh#v #vh:V l05 5haIytg$$IfI!vh#v #vh:V l05 5haIytg$$IfI!vh#v #vh:V l05 5haIytg$$IfI!vh#v #vh:V l05 5haIytgs$$If!vh#v:V l t065ytP#Z$$If!vh#v^#vV#v#v :V l t0655H55 ytP#Z$$If!vh#v^#vV#v#v :V l4h t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4h t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4 t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4 t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4X t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4X t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4 t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4 t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4 t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l4 t06++55H55 f4ytP#Z$$If!vh#v^#vV#v#v :V l t0655H55 ytP#ZDText147# of DText148____DText149 record agentDText147# of DText148____DText149 record agent$$If!vh#v*:V l t0*5*ap ytP#ZDText150_____DText149 record agentDText150_____DText149 record agent$$If!vh#v#v8#v #v #v :V l t0*,5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v#v8#v #v #v :V l t0*5585 5 5 ap2ytP#Z$$If!vh#v*:V l t0*,5*ap ytP#ZDText149 record agentDText147# of DText148____DText147# of DText148____DText147# of DText148____DText147# of DText148____DText149 record agent$$If!vh#v*:V l t0*5*ap ytP#Z*$$If!vh#v#v8#v#vX#v#v :V l4a t0*+++++,55855X55 apFytP#ZkddL$$Ifl4a֞0hl(8X t0*44 lapFytP#Z~DText151___~DText151___~DText151___~DText151___v$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l4` t0*+++++ 558555X5d5 5 5  apnytP#ZkdQ$$Ifl4` 0$ @ hl(   8 Xd  t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#ZkdU$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#ZkdY$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd]$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd b$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$f$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd=j$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#ZkdVn$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkdor$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkdv$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkdz$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd~$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkdӂ$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd7$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#ZkdP$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkdi$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkdͫ$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#Zkd1$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#ZZ$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*558555X5d5 5 5  apnytP#ZkdJ$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#Z`$$If!v h#v#v8#v#v#vX#vd#v #v #v :V l t0*, 558555X5d5 5 5  apnytP#Zkdc$$Ifl 0$ @ hl(8Xd t0*,,,,44 lapnytP#Z$$If!vh#v*:V lp t0*,5*ap ytP#ZDd "d 0  # A"0/k U5%) T@=/k U5%)dv U8YPx]kl;  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\gijklmnorstuvwxyz{|}~Root Entry FData !WordDocumentFObjectPool _1347870859 F  Data h1TableqQCompObjq]$$If!vh5 5#v #v:Vl t65 5]$$If!vh5 5#v #v:Vl t65 5]$$If!vh5 5#v #v:Vl t65 5]$$If!vh5 5#v #v:Vl t65 5]$$If!vh5 5#v #v:Vl t65 5j0@@@ ~NormalCJ_HaJmH sH tH DA@D Default Paragraph FontRi@R  Table Normal4 l4a (k@(No Listj@j ~ Table Grid7:V0lSTUijklm}~    !"ijkn@00000000 0 0 0000 000 0 000 00 0 000 000 0 000 000 0 0STUijklm}~    !"ijkn00000000 0 0 0000 000 0 000 00 0 000 000 0 000 000 0 0l ~ j l  l 8@0(  B S  ?0. `1.  qn""ni*urn:schemas-microsoft-com:office:smarttagsState0http://www.5iamas-microsoft-com:office:smarttagsV*urn:schemas-microsoft-com:office:smarttagsplacehttp://www.5iantlavalamp.com/ nn im|~  "hkknn$'02Q>>Hb0gpp R *!&`().HLTPWdfo90OFS4\az5v53<C"SVXt`Tkwt| #)?&'4HOAcdehrR> -<Gb\c{["M+/-.4@5D=h~*CC;KTZ\`.ail"nRpvM!:/=FI,Q\gKww   U= S S ZU _ 6k o w  (  $ .% % 1 lJ .[ e m     ( -3 9 D N ET ie j y | 0  E P : mC eK M V ^ lb !t M  k ; T) "3 nG J fT X Y ` a Jx x x  9(-?J\X[]JmqesV"+,r-/IIKTdbix8/q3:>P9Y^_`;bh,1$)*13sABC@LW]]osu ),:D>HKCT+YWiBqq|z 2_ "V">#d*m.1`9DDYH.MBS4p+)CFKvNWX (-j7;@G[bvvX'*B2GLSzW\_Ij!%3UY*mXu7 *8A8RRnZA[iazsvH#  &!4:VAPCGLS\Z\Qz+ }V &3+)036VtGw {|R(02MYZr^^``aKcqiu9.R8<NWORQRjkx67>;LbNSfjuC$F,9yFNNRU \^wx7a9KiKY[`~bnf"nv8 ^ 3 =8 5= 2@ E F F R g[ ^ #_ l !<!K! !%!Q)!Q!"c!e!i!T"}""-!"K!"$"!)"+1"5"i9"<"e>"kB"K"kM"M"P"X"`"f"g"fh"k"q"@}" ### #} ##r#&#i$#T%#3&#-#6#9#8H#aY#o`#>a#kd#u|#W}#$:$}$$r!$*$6$9$;$A$xD$ L$FX$6Y$d^$a$Bh$p$t$~$c%%%$%'%0%<%V=%D%K%V%#\%ed%Q~%&&Z&;!&#&3&8&9& E&F&M&S&.Y&\&(r& t&az&|&;'' ' ,' ,'?'@'N'j'k'n')p'p(!(B((_0(;(E(`T(dX(b(em(kx(|() )x)@))m)()+)TG)R)S)T)W)^)hi)k)a***/*!?*C*J*T*;W*kX*h*qk*&r*z*{*E +R +d'+B2+3+7+=+@+kQ+yV+z`+`+?g+Ex+{+,,,",$,7-,5,7,8,8,9,&B,X,\,g,---@!-V#-:-BG-a[-\-_-k-k- ..e&.&.(.].zp.Uy.z.b /m/&/'/*)/0/0/3/5/PA/E/NR/S/]/`/00 000'0)0XE0>G0sP0:^0_0s0|0~0X~0g 1i.1<1\11j1jl1Ym1+|12(2*2,2Z12P62KB2P2Y2`2,v2{223 34393]O3GQ3S3(_3b3k3_v34g4#494<4B4E4Q4=V4Aa4b4Wc4jh4l4m4_5<5&5-5A5B5E5,I5I5K5~U5m5~566636<6J6HK6/L6Q6]6v_6a6Vg6Th6Xm6w6y6}6i 7777v-727pL7O7U7U7Y7i7[r7y788]8 8\ 848L8%8(85)8)8H>88ڲ88Q8S88V88Y8a8d8d8d8m8899#919299F9K999W9/9r9:::0:?:3::6::8:S:d:;;+;-0;4;<;z@;@;L;W;c;h;i;q;>t;wv;-;o<<|<<k<<f!<)<G<J<Y<b<q<q<j =W=$==d= ="='=:=x>=M=S=g=>>T>} >r!>">9>8=>A>FR>T>5[>mc>Fd>l>o>q>r>s>v>???l?#?R(?8?9?`A?/Q?U?yY?"q?@ @@@-#@&@-@.@(7@:@J;@w?@\@A[AAEA(AQ*A^/Ab1A8AFANARAaAfAvgAlApAuA~AB! B$ B B/BmB B$B'B0BGBHBPB}QBTBbBtByCRCCCqCC"C$C&C3C 5CJDCaGCGCJCPCPUC`CaCfCiCnCXoCqCrCuCC{DD=DD+D-DmF@FFFdFmFmF"uFtwFxFGGjGA$G/G/G5GxBG@QG \GdG]uGvGHbHfHdH.H0H{BHBHJHQHlTH~[HaHcHkoHIxHIIII*Io'I+I*5IF9I?I=HIOIiUIXI`ZI\Iw`I eI4J?JJ J JJ,J=J BJ[J]JkvJBK{1K-:K?KEKFKOKZK^KeK mKQL8 LL!L"L{0L.8L:LCLELELtRLJ[L]L`L`LrtLvL}L,MM MqMM MMM Mc!M)M,M_MfM=nMoM%wM}M4NaNN(NNNN{&N@NANiQN{jNoN6}NOOYEOHONOIWOg_OHaOfOkOoOqO^rOwO3PPP?P/PW1Pj9P=PAP:MPTP{XP^PaPlPuPQu QXQ{Q>Q#Q)Q1Q4Q6Q7Q/9QZQnQyQ{Q{Q~QRR|R{ RRRX#R%R3R9R;RRARWaRhRuRxRSSSS S2SD5S7S_>SDSDS*ISNSEZShkS+yS}STTTTT&T6TGToLT!STUT=WTfWTtgTkTA U-UbUvUE"U/U=U>U\CUFU\U5_U`U_hUFpUV_V#V$V5(V(V/V7VCVMVUV{ZV[VojVK WBWndW*X XcX9 X1-XBXBXBDX`EXpFX(MXXX_XcX,jXCwX%|X3YhYY ,YJYLYMYp\Y]Y_Y4iYGwY{Y}YZ ZPZZYZ_ Z3Z8Z@ZLZ%\Z^jZkZlZtZ[[Y[C$[)[M[Z[d[*f[^h[w[=\\"\"\.\>\?\U\V\[\c\P]C ]C!]Q&]:]eO]w]]j]q]r]*v]y] ^ ^^r^^,"^`*^M,^&C^E^G^x^_v _9__-_0_D9_/<_x?_?_S_va_c_im_t_fy_d_`M`j`!`l#`#`5`6`7`5E`O`s`Qu`z` aa>{{/ڲԲp/rʲ*lb`lglmmW m=mm@$m%m-m>m?m|AmhMm!Ymh[mg_memvpmnd n n"n-n*5n9n:nXDnBJn[Qn ononxnqo o@ooDoooN*o+o 6ow9o=oPoVoXoJbofooo~op p p8 p7p%8p=p3dpdp]tp%wpqlqoq6qqq"q"q+q62q5qY8qFqOq^q-aqtbqhqiqjkqkrqyqHzqrr rr}rryr*r:rOErFrSrP]rsfrqrts s ssl'sy's{.s4sAsCsGs9Rsfsqsbrs xszs|s~s6t^ tt;,te1tl4tU8t>t @t\UtwWtWt[t^tbtKptutu!u(u`)u*u:,u|-u8u!:u;uSu5UuXu`u ~uk~uv'v8v?vDvIveUvkv#lvlvomvfxvw w"wwww`w+w45wJ:wUw[w[fwfw'iwuwywxx6xlx$x*x/x1x!w|sx|o}}}}}3!}"}%}:(}*} ,}&/};C}kI}I}b} i}~}+~k~~c(~d0~9~:Q~R~V~W~_~`~e~o~ w~  G()u- 7e<9X8`iZqhk5:<8=L@BIMQF`:kw#.**8BT`7gnV|~_6H.b/788w<>Bt>)-/38=ܱ>cH>Q{t[  (6G8 _eVfk|- ^ & p$/7BDM$N\^jmtz| L6!V"(+n9_``{bety{Tj**-d.9@@M SZg|yE1)8;>?@IMWafXszt )/;tDIIET(V_Duy "%)1 8EFSadfegmnrhz9 i-8,:<h>4FMIYuhi_} t}$,N-LN YZj]e}I--7O=MTci*4?05\:;=oDrIRwmx4 }\^u&'*/:H\KwJN)X _dMjq~a@#$&25ACIKNWG5u& (/25R6=@fCCD?KL*bXfZw f\!^$@DKgoFS_<`behppv}~J;LMbi{~r = @]J?N[]:cu={{}~- 4~ )<Tde>qo &|'.>CU{WdY3\ `sllQtt $n$+E37S9;9MOxU_XL\lmm6n(yPz6i.369<8E+^aabLeksw .X(Nggo$s@ W 6'GQTtvz/ k ld(2PkZ_bSowc k M$'(+u-/BLPT\\]j7k&y h&9KBBHMN#NPVtY\[cll{rxz %&L,9h9QEMUaa!jcjjprkxxK}.k/N8:BCCH]m=t0t6?bpvy u-mA[CD#d c X&F+j/D000?MU&V+Wn~{^i %/0a2LWCdbnrxu e(9":<=#=@ATYf ghGjk;p yV 7:IfL>]dTnw&*.B46BRbyesu("(y58NOx[^enO,x`7}9[.`2`jrvWw   &*|0a@DLPXh]ipf|6<BGBHThfUq(,,29c>EKLMYAfo9F,'+/g=AJMQQan$!/8c>rCUIPRbn p=T { "*#@Mdho{z D }XM$%39mGGI_KC]^ `&p}uqx{n (3-1V5@ENSUW'b:cehf% G!d'-52U4:f=?7@V_`Kjpptv1x%Zg 02E@U_vcdhr /B:V=Auzz b ,Kv]#$l&!-.06`B[TcV[J]cs ,2569 :DFJQT\at{s}a%=$)+56;?DMN)P%Qr\Y^fLx[ D 6>.KwOS\U_]^fj%k8qt{ Gl"g58p::KKW__ik7qz m) Y''26-=9H^j%k*m ooZqyn{{:} 282K1STq]]$^aw,wyV"% *1N6:J _s_~`ii.lq&r8wNxYk,]27N;;B\lAoY~: N72t#N' *6>K@4CT [^ax2y~@I d".f5 <JpKPRSaSHlkwk}pV$K%UDHY^_EalxxZ48 !+c3H1O8PmWf@hckyz]%1GsLTQRW$X3[\flwou#=CI}Vaaf lqGu]">%CIE FK]YioN'-@Bbxz 'JKekf;C#P+ ,O3x@{DNDOiX/\Za{ 6$35>'#l泾RHmM)OX_glyp|4 "N*459w9a<TAY\M %)K-=?IJKPVhvdy]t \7?W8[\cfr{[@\/{HPVkW`dfod K!"))e*3GNO\\&]dry`+GNg.hixjt|] C*-1+7ISq]%BDNP\jzqv@}~ol,)C-O\_aCdm+pHqL$*+.TADmNUY(d^dxf ++,.Y2a8eSqFuvw!}  #)$- 13L=>nGRNXZ^TdCg%r7{}n*0895?rAA$CDIMSS)\bjrx7}~?,07m9;k;ZDO]_s?z;{z~S1 #%& ''>)W7F`ey^UK#(()8B O,R[a8bZk{kl  E);AJKX[]te}) ="##9*-7N7^;O]]_.htwy{^ \"369 B$CL]YfDgkUob= E>#+R16 LJN Q UV(hrf W(j*6=,BSSJZbwi1$29MHIJLYd_h l`@Unknowngz Times New RomanTimes New Roman5Symbol3& z Arial"hf\f!r4kk2qHX)?~2 APPENDIX ___chenkin0chenkin0  !"#$%&'()*+,-./0123456789;  FMicrosoft Office Word Document MSWordDocWord.Document.89q   FMicrosoft Office Word Document MSWordDocWord.Document.89q   FMicrosoft Office Word Document MSWordDocWord.Document.89qObjInfo WordDocument.SummaryInformation( DocumentSummaryInformation8` l bjbj .l$ ,$M00000   `MbMbMbMbMbMbM$NhQbM<  <<M00M   < 00`M <`M   0$ 08` F LM0M Q\Q Q ; "- EY   MM   M<<<<$$$ $$$ $$$ APPENDIX [record letter] NEW YORK HEART ASSOCIATION (NYHA) CARDIAC CLASSIFICATION The NYHA classification system relates symptoms to everyday activities and the patients quality of life. ClassSymptoms Class I (Mild)  No limitation of physical activity. Ordinary physical activity does not cause fatigue, palpitation, or dyspnea (shortness of breath).  Class II (Mild) Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.  Class III (Moderate) Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.  Class IV (Severe) Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.   RSUWsh i j k m | } ~  ! " h i j k l Ľ۵۵Ľ۽ۧħ۽۵۽۵Ěh~5CJOJQJ^J huthut huthxRh~hut huth~huth~5huthut5 hxRhxRhxR hxR5 h~5hihY[56B*phh^Kh~51STUfzkd$$Ifl0@ ,"  t0644 la $IfgdxRgdxR$a$gd~$a$gdY[ l i j k l m } ~ fzkd_$$Ifl0@ ,"  t0644 la $$Ifa$gd~ $Ifgd~ $IfgdxR ~ ! " {rrriii $Ifgdut $IfgdxRzkd$$Ifl0@ ,"  t0644 la $Ifgd~ i j {{{rrr $Ifgdut $IfgdxRzkd$$Ifl0@ ,"  t0644 laj k l |$a$gd~zkd|$$Ifl0@ ,"  t0644 la,1h/ =!"#$% Oh+'0  < H T`hpxAPPENDIX ___ chenkin0 Normal.dot chenkin04Microsoft Office Word@V@c^`@p0`՜.+,0 hp  UHHSk  APPENDIX ___ Title_1347870005 F  Data 1Table mCompObjqs$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5w$$If!vh55@5#v#v@#v:Vl; t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5s$$If!vh55@5#v#v@#v:Vl t655@5@@@ NormalCJ_HaJmH sH tH N @N  Heading 9 <@&CJOJQJ^JaJDA@D Default Paragraph FontRi@R  Table Normal4 l4a (k@(No Listj@j W Table Grid7:V04@4 0&Header  !4 @4 0&Footer  !.)@!. 0& Page Number\R@2\ Body Text Indent 2^CJOJQJaJH@BH V| Balloon TextCJOJQJ^JaJ D  000 #$@A   !"$%89;<OPSTghijkl()+,?@BCVWYZmnpq!"$%'(123>?00000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000y00y00y00y00y00y00y00y00y001y0 0 y0 0 y001@0@0@0@0@0@0@0y00y00- #$@A   !"$%89;<OPSTghijkl()+,?@BCVWYZmnpq!?@0@0@0@0@0@0@0@0@0@0@0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 @0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 @0@0@00{00J{00J@0@0@0@0@0@0@0 00 $ ! ! 8 O g  ( ? V m "     !!8@0(  B S  ?!"$%'(!"$%'(3    "hij++BBYYnnppqq!"$%'(03=!"$%'( ^ eI /S2 L*m%԰[H%԰t fFuJ$,U:wmm-@Ƥ{3%԰pX:QuKp@%԰'0xB%԰ gQ0kYjN@Y[(~c"\d/jzq> m%԰kx%԰}P{Ih^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH90^`056789;<B*CJH*OJQJS*TXo(ph88^8`7H*OJQJS*o( pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH90^`056789;<B*CJH*OJQJS*TXo(ph^`OJQJ^Jo(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHoPP^P`OJQJo(hHh^`OJQJo(hHhpp^p`OJQJ^Jo(hHoh@ @ ^@ `OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhPP^P`OJQJ^Jo(hHoh  ^ `OJQJo(hH88^8`7H*OJQJS*o(h"^`7H*OJQJS*^Jo(hHo pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(h^`OJQJo(hHhbb^b`OJQJ^Jo(hHoh2 2 ^2 `OJQJo(hHh  ^ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhrr^r`OJQJo(hHhBB^B`OJQJ^Jo(hHoh^`OJQJo(hH=0^`056789;<B*CJH*CJOJQJS*TXo(ph88^8`7H*OJQJS*o( pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hH0^`0CJ OJPJQJ^JaJ o(hpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH3'0xBI [HpX:uKp@ ^> mt kx}P{mS2 mm-d/j@Y[~ckYuJ$ gQ                                    ꆒ)                                  ꆒ                 2                  ꆒ:        f5|t       HG.o  $N~ T5*JaQW+XO" T#0&|s)*7%?LDFII%ZL.7MMNPO"UYdwff0hZok2t,VvV|~CW 2.4Z9K(MV'Ap~#o.q#7Mc>5tV&?&7t!E,>`Mpp^tNy   !"$%89;<OPSTghkl()+,?@BCVWYZmnpq3@dOh@UnknownGz Times New Roman5Symbol3& z Arial;" Helvetica5& zaTahoma;Wingdings?5 z Courier New"1h2f2f2f!x4d 2qHP ?W2Patient Registration ChecklistKDesimo1chenkin0\               ObjInfoWordDocument:DSummaryInformation( DocumentSummaryInformation8(     !"#$%&')*+,-./i2345678:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghmnopqrstuvwxyz{|}~`  bjbj :D"""8"$"#h##4$$$$$$shuhuhuhuhuhuh$jhmh$$$$$h$$h'''$X$$sh'$sh''2`d$# ke"I%dCb.eh0hqb&m%m\dmd8$$'$$$$$hh'X$$$h$$$$$$dbd b APPENDIX B ELIGIBILITY CHECKLIST PROTOCOL# Protocol Name Research Staff will complete the eligibility checklist for the PI. Name ________________________________________ Medical Record # _________ Physician _______________________________________ Study ID #_______________ Inclusion Criteria: ALL questions must be answered YES in order for a patient to be eligible. 1( Yes ( No2( Yes ( No3( Yes ( No4( Yes ( No5( Yes ( No6( Yes ( No7( Yes ( No8( Yes ( No9( Yes ( No10( Yes ( No Exclusion Criteria: ALL questions must be answered NO in order for a patient to be eligible.1( Yes ( No2( Yes ( No3( Yes ( No4( Yes ( No5( Yes ( No6( Yes ( No7( Yes ( No8( Yes ( No Study Coordinator: __________________________________ Date ____________ Treating Physician/ PI ________________________________ Date ____________     PAGE  PAGE 2 Prepared by: _________________________________________ Date _________ Treating Physician/ PI __________________________________ Date _________ of  NUMPAGES 1   #$@ 2 ~       " # $  jhWh CJaJh h!h.7M jhWhWCJaJ h.7MhWhW h.7M5h~hW5hVhbOVhV56hV56B*phhk0+hV5 hV5h@/nhV55  #$@A     $IfgdW $$Ifa$gd.7M $$Ifa$gd~gdVgdV$a$gdV  qeWN $IfgdW $$1$Ifa$gdV $$Ifa$gd~kd$$IflFh#@ t06    44 la qe\S $IfgdW $Ifgd7 $$Ifa$gd~kdu$$IflFh#@ t06    44 la qeYP $IfgdW $$Ifa$gdV $$Ifa$gd~kd$$IflFh#@ t06    44 la qeUL $IfgdW$ $Ifa$gdV $$Ifa$gd~kd_$$IflFh#@ t06    44 la ocZZ $IfgdW $$Ifa$gd~kd$$Ifl;Fh#@ t06    44 la qe\\ $IfgdW $$Ifa$gd~kdM$$IflFh#@ t06    44 la  ! qe\\ $IfgdW $$Ifa$gd~kd$$IflFh#@ t06    44 la! " $ % 8 qeOF $IfgdW$ ,$If^a$gd $$Ifa$gd~kd7$$IflFh#@ t06    44 la$ % & 2 3 7 8 9 : ; < = I J N O P R S T U a b f g h i j k l ߾ߺ߮h0& jhWh0&CJaJhW ht5 h,5h~h~5h~hW5h~h, hi\h hWhCJaJh!hWh CJaJh  jhWh CJaJh]h CJOJQJaJ48 9 ; < O qeOF $IfgdW$ ,$If^a$gd $$Ifa$gd~kd$$IflFh#@ t06    44 laO P S T g qeTK $IfgdW$ !$Ifa$gd $$Ifa$gd~kd!$$IflFh#@ t06    44 lag h i j k l qooocWN $IfgdW $$Ifa$gd, $$Ifa$gd~kd$$IflFh#@ t06    44 la qe\\ $IfgdW $$Ifa$gd~kd $$IflFh#@ t06    44 la qe\\ $IfgdW $$Ifa$gd~kd$$IflFh#@ t06    44 la  qe\\ $IfgdW $$Ifa$gd~kd$$IflFh#@ t06    44 la       " # ' ) * , - 9 : > @ A C D P Q U W X Z [ g h l n o q r ~      " # % & ( ) / 0 1 3 4 : ; < = > E hWhMhM0JmHnHuhM hM0JjhM0JUhjhU h@/nhVhVh,h~hW jhWh0&CJaJh0&A    ( qe\\ $IfgdW $$Ifa$gd~kdj$$IflFh#@ t06    44 la( ) + , ? qe\\ $IfgdW $$Ifa$gd~kd$$IflFh#@ t06    44 la? @ B C V qe\\ $IfgdW $$Ifa$gd~kdT$$IflFh#@ t06    44 laV W Y Z m qeXO $IfgdW $If`gd $$Ifa$gd~kd$$IflFh#@ t06    44 lam n p q qe\\ $IfgdW $$Ifa$gd~kd>$$IflFh#@ t06    44 la    ! " qllddddbbbb$a$gdVgdpkd$$IflFh#@ t06    44 la " $ % ' ( 1 2 3 > ? $a$gdV$a$gd0&$a$gdt $h]ha$gdVh]hgdV &`#$gd hVhh7t0JmHnHujhM0JU hM0JhM hWhM 8 001F:pV. A!"#$% Oh+'0 (4 T ` l x Patient Registration Checklist KDesimo1 Normal.dot chenkin05Microsoft Office Word@^в@X/ke@je@X/ke՜.+,0  hp  UHHS Patient Registration Checklist Title_1347868431 F  Data 11Table9_CompObjq$$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655#5Y $$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5$$If!vh555#v#v#v:V l t0655@5@@@ HNormalCJ_HaJmH sH tH DA@D Default Paragraph FontRi@R  Table Normal4 l4a (k(No List4@4 HHeader  ! 801WXY9:;=>QRTUhiklUVWYZmnpq^_00000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000000001WXY9:;=>QRTUhiklUVWYZmnpq^_00000000000000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0000000[ : Q h  V m    / 189TXY==TTkkYYppAEGGIKTW$'02Q>>Hb0gpp R *!&`().HLTPWdfo90OFS4\az5v53<C"SVXt`Tkwt| #)?&'4HOAcdehrR> -<Gb\c{["M+/-.4@5D=h~*CC;KTZ\`.ail"nRpvM!:/=FI,Q\gKww   U= S S ZU _ 6k o w  (  $ .% % 1 lJ .[ e m     ( -3 9 D N ET ie j y | 0  E P : mC eK M V ^ lb !t M  k ; T) "3 nG J fT X Y ` a Jx x x  9(-?J\X[]JmqesV"+,r-/IIKTdbix8/q3:>P9Y^_`;bh,1$)*13sABC@LW]]osu ),:D>HKCT+YWiBqq|z 2_ "V">#d*m.1`9DDYH.MBS4p+)CFKvNWX (-j7;@G[bvvX'*B2GLSzW\_Ij!%3UY*mXu7 *8A8RRnZA[iazsvH#  &!4:VAPCGLS\Z\Qz+ }V &3+)036VtGw {|R(02MYZr^^``aKcqiu9.R8<NWORQRjkx67>;LbNSfjuC$F,9yFNNRU \^wx7a9KiKY[`~bnf"nv8 ^ 3 =8 5= 2@ E F F R g[ ^ #_ l !<!K! !%!Q)!Q!"c!e!i!T"}""-!"K!"$"!)"+1"5"i9"<"e>"kB"K"kM"M"P"X"`"f"g"fh"k"q"@}" ### #} ##r#&#i$#T%#3&#-#6#9#8H#aY#o`#>a#kd#u|#W}#$:$}$$r!$*$6$9$;$A$xD$ L$FX$6Y$d^$a$Bh$p$t$~$c%%%$%'%0%<%V=%D%K%V%#\%ed%Q~%&&Z&;!&#&3&8&9& E&F&M&S&.Y&\&(r& t&az&|&;'' ' ,' ,'?'@'N'j'k'n')p'p(!(B((_0(;(E(`T(dX(b(em(kx(|() )x)@))m)()+)TG)R)S)T)W)^)hi)k)a***/*!?*C*J*T*;W*kX*h*qk*&r*z*{*E +R +d'+B2+3+7+=+@+kQ+yV+z`+`+?g+Ex+{+,,,",$,7-,5,7,8,8,9,&B,X,\,g,---@!-V#-:-BG-a[-\-_-k-k- ..e&.&.(.].zp.Uy.z.b /m/&/'/*)/0/0/3/5/PA/E/NR/S/]/`/00 000'0)0XE0>G0sP0:^0_0s0|0~0X~0g 1i.1<1\11j1jl1Ym1+|12(2*2,2Z12P62KB2P2Y2`2,v2{223 34393]O3GQ3S3(_3b3k3_v34g4#494<4B4E4Q4=V4Aa4b4Wc4jh4l4m4_5<5&5-5A5B5E5,I5I5K5~U5m5~566636<6J6HK6/L6Q6]6v_6a6Vg6Th6Xm6w6y6}6i 7777v-727pL7O7U7U7Y7i7[r7y788]8 8\ 848L8%8(85)8)8H>88ڲ88Q8S88V88Y8a8d8d8d8m8899#919299F9K999W9/9r9:::0:?:3::6::8:S:d:;;+;-0;4;<;z@;@;L;W;c;h;i;q;>t;wv;-;o<<|<<k<<f!<)<G<J<Y<b<q<q<j =W=$==d= ="='=:=x>=M=S=g=>>T>} >r!>">9>8=>A>FR>T>5[>mc>Fd>l>o>q>r>s>v>???l?#?R(?8?9?`A?/Q?U?yY?"q?@ @@@-#@&@-@.@(7@:@J;@w?@\@A[AAEA(AQ*A^/Ab1A8AFANARAaAfAvgAlApAuA~AB! B$ B B/BmB B$B'B0BGBHBPB}QBTBbBtByCRCCCqCC"C$C&C3C 5CJDCaGCGCJCPCPUC`CaCfCiCnCXoCqCrCuCC{DD=DD+D-DmF@FFFdFmFmF"uFtwFxFGGjGA$G/G/G5GxBG@QG \GdG]uGvGHbHHfHdH.H0H{BHBHJHQHlTH~[HaHcHkoHIxHIIII*Io'I+I*5IF9I?I=HIOIiUIXI`ZI\Iw`I eI4J?JJ J JJ,J=J BJ[J]JkvJBK{1K-:K?KEKFKOKZK^KeK mKQL8 LL!L"L{0L.8L:LCLELELtRLJ[L]L`L`LrtLvL}L,MM MqMM MMM Mc!M)M,M_MfM=nMoM%wM}M4NaNN(NNNN{&N@NANiQN{jNoN6}NOOYEOHONOIWOg_OHaOfOkOoOqO^rOwO3PPP?P/PW1Pj9P=PAP:MPTP{XP^PaPlPuPQu QXQ{Q>Q#Q)Q1Q4Q6Q7Q/9QZQnQyQ{Q{Q~QRR|R{ RRRX#R%R3R9R;RRARWaRhRuRSSSS S2SD5S7S_>SDSDS*ISNSEZShkS+yS}STTTTT&T6TGToLT!STUT=WTfWTtgTkTA U-UbUvUE"U/U=U>U\CUFU\U5_U`U_hUFpUV_V#V$V5(V(V/V7VCVMVUV{ZV[VojVK WBWndW*X XcX9 X1-XBXBDX`EXpFX(MXXX_XcX,jXCwX%|X3YhYY ,YJYLYMYp\Y]Y_Y4iYGwY{Y}YZ ZPZZYZ_ Z3Z8Z@ZLZ%\Z^jZkZlZtZ[[C$[)[M[Z[d[*f[^h[w[=\\"\"\.\>\?\U\V\[\c\P]C ]C!]Q&]:]eO]w]]j]q]r]*v]y] ^ ^^r^^,"^`*^M,^&C^E^G^x^_v _9__-_0_D9_/<_x?_?_S_va_c_im_t_fy_d_`M`j`!`l#`#`5`6`7`5E`O`s`Qu`z` aa>{{/ڲԲp/rʲ*lb`lglmmW m=mm@$m%m-m>m?m|AmhMm!Ymh[mg_memvpmnd n n"n-n*5n9n:nXDnBJn[Qn ononxnqo o@ooDoooN*o+o 6ow9o=oPoVoXoJbofooo~op p p8 p7p%8p=p3dpdp]tp%wpqlqoq6qqq"q"q+q62q5qY8qFqOq^q-aqtbqhqiqjkqkrqyqHzqrr rr}rryr*r:rOErFrSrP]rsfrqrts s ssl'sy's{.s4sAsCsGs9Rsfsqsbrs xszs|s~s6t^ tt;,te1tl4tU8t>t @t\UtwWtWt[t^tbtKptu!u(u`)u*u:,u|-u8u!:u;uSu5UuXu`u ~uk~uv'v8v?vDvIveUvkv#lvlvomvfxvw w"wwww`w+w45wJ:wUw[w[fwfw'iwuwywx6xlx$x*x/x1x!w|sx|o}}}}}3!}"}%}:(}*} ,}&/};C}kI}I}b} i}~}+~k~~c(~d0~9~:Q~R~V~W~_~`~e~o~ w~  G()u- 7e<9X8`iZqhk5:<8=L@BIMQF`:kw#.**8BT`7gnV|~_6H.b/788w<>Bt>)-/38=ܱ>cH>Q{t[  (6G8 _eVfk|- ^ & p$/7BDM$N\^jmtz| L6!V"(+n9_``{bety{Tj**-d.9@@M SZg|yE1)8;>?@IMWafXszt )/;tDIIET(V_Duy "%)1 8EFSadfegmnrhz9 i-8,:<h>4FMIYuhi_} t}$,N-LN YZj]e}I--7O=MTci*4?05\:;=oDrIRwmx4 }\^u&'*/:H\KwJN)X _dMjq~a@#$&25ACIKNWG5u& (/25R6=@fCCD?KL*bXfZw f\!^$@DKgoFS_<`behppv}~J;LMbi{~r = @]J?N[]:cu={{}~- 4~ )<Tde>qo &|'.>CU{WdY3\ `sllQtt $n$+E37S9;9MOxU_XL\lmm6n(yPz6i.369<8E+^aabLeksw .X(Nggo$s@ W 6'GQTtvz/ k ld(2PkZ_bSowc k M$'(+u-/BLPT\\]j7k&y h&9KBBHMN#NPVtY\[cll{rxz %&L,9h9QEMUaa!jcjjprkxxK}.k/N8:BCCH]m=t0t6?bpvy u-mA[CD#d c X&F+j/D000?MU&V+Wn~{^i %/0a2LWCdbnrxu e(9":<=#=@ATYf ghGjk;p yV 7:IfL>]dTnw&*.B46BRbyesu("(y58NOx[^enO,x`7}9[.`2`jrvWw   &*|0a@DLPXh]ipf|6<BGBHThfUq(,,29c>EKLMYAfo9F,'+/g=AJMQQan$!/8c>rCUIPRbn p=T { "*#@Mdho{z D }XM$%39mGGI_KC]^ `&p}uqx{n (3-1V5@ENSUW'b:cehf% G!d'-52U4:f=?7@V_`Kjpptv1x%Zg 02E@U_vcdhr /B:V=Auzz b ,Kv]#$l&!-.06`B[TcV[J]cs ,2569 :DFJQT\at{s}a%=$)+56;?DMN)P%Qr\Y^fLx[ D 6>.KwOS\U_]^fj%k8qt{ Gl"g58p::KKW__ik7qz m) Y''26-=9H^j%k*m ooZqyn{{:} 282K1STq]]$^aw,wyV"% *1N6:J _s_~`ii.lq&r8wNxYk,]27N;;B\lAoY~: N72t#N' *6>K@4CT [^ax2y~@I d".f5 <JpKPRSaSHlkwk}pV$K%UDHY^_EalxxZ48 !+c3H1O8PmWf@hckyz]%1GsLTQRW$X3[\flwou#=CI}Vaaf lqGu]">%CIE FK]YioN'-@Bbxz 'JKekf;C#P+ ,O3x@{DNDOiX/\Za{ 6$35>'#l泾RHmM)OX_glyp|4 "N*459w9a<TAY\M %)K-=?IJKPVhvdy]t \7?W8[\cfr{[@\/{HPVkW`dfod K!"))e*3GNO\\&]dry`+GNg.hixjt|] C*-1+7ISq]%BDNP\jzqv@}~ol,)C-O\_aCdm+pHqL$*+.TADmNUY(d^dxf ++,.Y2a8eSqFuvw!}  #)$- 13L=>nGRNXZ^TdCg%r7{}n*0895?rAA$CDIMSS)\bjrx7}~?,07m9;k;ZDO]_s?z;{z~S1 #%& ''>)W7F`ey^UK#(()8B O,R[a8bZk{kl  E);AJKX[]te}) ="##9*-7N7^;O]]_.htwy{^ \"369 B$CL]YfDgkUob= E>#+R16 LJN Q UV(hrf W(j*6=,BSSJZbwi1$29MHIJLYd_hQRTUhiklUVWYZmnpq3@;;e;;@UnknownGz Times New Roman5Symbol3& z Arial"h2f2f!42qHP)?H2 APPENDIX ___chenkin0chenkin0ObjInfoWordDocumentl.8SummaryInformation(DocumentSummaryInformation8 Oh+'0  ( H T ` lx CASE xxxxKovach, NicoleVersion date:NormalUser2Microsoft Office Word@@rW?@\@\$O%`  bjbj .8vvvv;\22222222[[[[[[[$\hY_b[22222[22[2 22[2[2& mhev<NYl \0;\_R6__;2222222[[ 222;\2222   APPENDIX [record letter] ELIGIBILITY CHECKLIST Study # Title.. Name ________________________________________ Medical Record # _________ Physician _____________________________________ Inclusion Criteria: ALL questions must be answered YES in order for a patient to be eligible. 1( Yes ( No2( Yes ( No3( Yes ( No4( Yes ( No5( Yes ( No6( Yes ( No7( Yes ( No8( Yes ( No Exclusion Criteria: ALL questions must be answered NO in order for a patient to be eligible.1( Yes ( No2( Yes ( No3( Yes ( No4( Yes ( No5( Yes ( No6( Yes ( No7( Yes ( No8( Yes ( No Study Coordinator: ____________________________________ Date ____________ Treating Physician/ PI __________________________________ Date ____________  019?TWX: = > ? K L U V b c l m y z U Z [ 䳫h!QhHCJaJ jh!QhHCJaJ h.7MhHh!QhH5hHhH6B*phhHhH6B*phhHhH56B*phhthH5 hH5hihA56B*phh^KhH5601WXY9 : $IfgdH $$Ifa$gdH $$Ifa$gdHgdHgdH$a$gdH$a$gdH$a$gdA : ; = > Q th__ $IfgdH $$Ifa$gdHkd$$IflFY@,"#Y t06    44 laQ R T U h th[R $IfgdH  $If^ gdH $$Ifa$gdHkd$$IflFY@,"#Y t06    44 lah i k l  th__ $IfgdH $$Ifa$gdHkdF$$IflFY@,"#Y t06    44 la th\S $IfgdH $$Ifa$gdH $$Ifa$gdHkd$$IflFY@,"#Y t06    44 la th\S $IfgdH $$Ifa$gdH $$Ifa$gdHkd$$IflFY@,"#Y t06    44 la th\S $IfgdH $$Ifa$gdH $$Ifa$gdHkd/$$IflFY@,"#Y t06    44 la th\S $IfgdH $$Ifa$gdH $$Ifa$gdHkd$$IflFY@,"#Y t06    44 la th\S $IfgdH $$Ifa$gdH $$Ifa$gdHkdu$$IflFY@,"#Y t06    44 la U V toocWN $IfgdH $$Ifa$gdH $$Ifa$gdHgdHkd$$IflFY@,"#Y t06    44 laV W Y Z m thTK $IfgdH$ 8 $If` a$gdH $$Ifa$gdHkd$$IflFau,"@ t06    44 la[ g h q r ~    $ A E I L T W ] _ h! B hWhHh!QhHCJaJ jh!QhHCJaJhH5m n p q th__ $IfgdH $$Ifa$gdHkd^$$IflFau,"@ t06    44 la th__ $IfgdH $$Ifa$gdHkd$$IflFau,"@ t06    44 la thXO $IfgdH$ $If^ a$gdH $$Ifa$gdHkd$$IflFau,"@ t06    44 la thXO $IfgdH$ $If^ a$gdH $$Ifa$gdHkdG$$IflFau,"@ t06    44 la thXO $IfgdH$ $If^ a$gdH $$Ifa$gdHkd$$IflFau,"@ t06    44 la thXO $IfgdH$ $If^ a$gdH $$Ifa$gdHkd $$IflFau,"@ t06    44 la  thXO $IfgdH$ $If^ a$gdH $$Ifa$gdHkd0 $$IflFau,"@ t06    44 la      ^ _ togggggg$a$gdHgdHkd $$IflFau,"@ t06    44 la,1h/ =!"#$% Oh+'0  < H T`hpxAPPENDIX ___ chenkin0 Normal.dot chenkin02Microsoft Office Word@@(j(ZUG[ZJ%${ڞ[3g{ǔRe4+K/ܠԲJnvR15ޯqRg*y[.O=-l XWLxly7^{+l;ږ.G5˺2SAkY6xN:^"}v;k C1R㓓R3vVCjX #iNu“n`GTFb$O9MtT/Wf{i=_AdS8IsA{'؉.Jcl8u;xjlUpR͘S0`k}3mv xmnH0OޢU? (}ԧUJDy:mݴݕ1O?w+ ʱOk0AOjyoWZp ڛbwX" @\W!ƿ GpfMjnǻvDAp&55>-ϟx'u>6:CtӆNjxm=VnE!Erk9!SFl}fow]:_[c&ވyccI7Ľ&3ל]G\3βfk\{kޞk>ەm=Ӗot0VQ",ɽ9,͇=-P-`#;aj68{ 6+u׋sCEq^!%9 kg:hΣ-IGM^:_i=Np,kL$f x Oό 6ܛcO5X6AJb&/^qj:^`ۼ|9d,?P_}YM ӏ an\-x: gڪhMu%(bJBv هEo^)'ل3xD^S||MS HxsÉ-e8Ș'g/)s;F>=r0m!K-֥˃>GoB5p7 מѾI"壝nM'}Fݶ\f-Fk]߸[O̧f^¥ٞE;{U[%1=3cYX@!Ǖu:԰|lu#p4( ETe[):VkyhCpnڛ]*Yu6sCW WYU*UvڭvP>}-܂<- CnD ZvT[dY3*^]]] [$K\k$nN}N<;W岠\֧_ZP~ȚA|Ekk"D;.]5X˲s;PO8qa:.Mm}j1&ݙ/ui tq9sR.нZVܙ>_,|3]kݹ2D; ԝZ1?݃ޔLyI5\)-*~yG o} -?7|ɧ{a#NfNC?.jy !Ŗ5:Ly%ݬPW?ŨFq^}0~LqOC כ:1#&o"3ď/3G /G;Gܐ{rɪCC>YUOM%{V(-~xޯVH{}I=_sld~. F|eɅ ʪs,yoi⌷meicq 'O#W4G {R.]xZ~!ֈ,t=iS6D_\ʕ-^;ӵ֝!AԺs,@ݙ=ﶦ }2ţcI~c+Y9o A8wIQ<͈ D>Ǟų>Zֲߞ0:⃙lLjƳ۷g">&1ׄmӘsgĵ:>U!ݲԦ䃯2Iؿ1B'+SCh/^T>⋦j~>U>> -~J58w~6| }|s6c̓UjaA8sOF?膼ݯFdl}_v[8pEڥ_c?$F:hޏ_cW]BY9ҝzR 2.l>Qmt=ktb 9L3]Z>\6sFխVh>_R@ݙխV>Zw%;pՊ }ыO_o=~o㕿vL򷃌/}!D!ޫ޳^h~m oœi)w}֜7O?@X }FקCB{hŨ׼1OvU{'~}t`ʋn,yXb6^\%4||1|7147e}Mx}h6֓NΉЩ6~~y+BƎ%LD { ~>zNaЫzYC$6_Gm&E}oEr5j.-p.كFg7M`:kH{~_խіMALY˄wJgy+[cQ_Ϥ }|xy`/35ѕIgSo}=Tg^=5FzC3+ZgE]6qѥ롞!uktytgR 2.l>Q PϐOTP0t=3#͕qa:.8a.4x͏k\re>(u_uzGrA:?lm40Jqz܄s, k/Zwyt=/'1azLp@0] ;ΡQ˸1tB2LJ}rL| mm}{1"lRu>?}sRNߗ/uoWwa> ^{͟To0~j9[PW.bF9ww>/ryl3.rໃ.ax;%Dd $$50  # A"%U0P5kLaʥ$@=$U0P5kLaʥ`aYz$x] p\u%k6 p`-lA &`bLT%NCv&)3e;p<&Jg/oϕ~Zγ^ѱ qW@|}<>}5 q8M~p~6-[=[.kO8qBړmĝW#Y/bqcnmmÄ u|ɻ[)N}W9 2fʛt|6L綿?~Pb&NqSbsY >~dm"⟮J̳8!3ɜf{=s5\B||]U0K%2:K+ͲՅN,^睻Qmc)QB-ѹ{\jک+cHmRsj C#ǐse~N?j1dZ! cC!,Wi<9 qK?.3~>WŸ;ysgӵ/ޟ3y⛲\^[x]s)r]ysrqDAf +if-X'^ÙWթc~ piکSu+>=;6} xcW>}j=T~k|Əu|\KL(o¯7FAYYoF|F~^Af :o-Jv/W|{%Qs_%[ c4c5jbWa9~ͯhk7<6A 3[5}ˑrbvW[UُK, & o\.n3]ӸRtSϖsнBl-"ݻsK<E̹BG"[Z/wolW5މx7S;iME2A} \Wz9ݩ ޸bZكa2sf8܇x@!_|oF]E_c̋҅" *{e߂hcEԺgGpm{Bqnv GEیb}8}(s__㿡134m[א5EBmk}[eo '+Y>ouY9R#ر7}WoƒK9Z \hO|tNVOV^:CE8<}R~/H@u tZX㝿aod;4"_,|Muߟvx?WNT6i0u?FYy+dleI s||T|7pif$C=ICy >iVVόusxZ뚋aʁ%+bCmؐRcSǸhNݵ$/\=t^PR~l>nl;Ӧ0; > >e>/ͤdž!WyAiNvc; j^p?o͇iC`gޭr/αݵ˸1pNvuiԏ`<dW;][Q\+@& J^vo}S]4ѰcNM!_O!>X o;Z7ؿ.>ZQ__S[hOi5`W|ހa]9x烓)]z>{{t,OO\(>M/$6Q1|"i7R{{"3af{ͅ5:p퇛}J?uEW 2ߋ!NmӴ(Eg͜2 W-Pdn` \^v_ฦ*X/6`l~ʱc܋3 r9]Keܳ,/\MlL %Z/,^/wDdW;/:5/lyAmz ĆKfq/V;a; uM@ t^s썉j@A]P.j,!0Ї;5}13LA]4!ϧ#PXKokN(K}]B] ֥.O.K9ÈoBB4m/ vs(Ιm.et4LQԥm.yN%aZ.eyjbs$]:p"mХ19ɶA2]:}$]:p"mХbQQC']:th"tch lt6~52t)߃6l0 kTS@Ñ}5lSS@а? hQr߄}5,o|c1hX סjXi mؐmU19]Keܳ,/\MlL bC VGmBȝl4}(鼠6ABlȶAê˭ۢ֬Fd۠aU鼠 ؉Mm}͡Mq%]ݍ;10Vwmа4wG0wmа^0 i5_4j7֛k4,``E,a4,Wliuw4(+tM.}BKں.FF_\ХOht)Х>M¡\] x4 Cե`3Ӻ؃!]rwc's˸gY^ؘ jt)Ćlt=z0;6RP*?/lyAm.ؐm.U[EC3ɶA'?/lyAs̱O6 4 #O6 4 O6 4ƃ O6 4{]ud.C 9WK.}1KK9_KOK+YKےe}K_Wț5+YK*.-GI.hަi|mhPmj\͕Œ4q9e)q_D_wh~5 ip>kZ6hgF%y2Y&6cиq5 ?څ0;6h~q`oA6h 꺨5m?ִۚ4nS1h8I6|*ϱzQ<Zec%p':Ա4wG0w͝CpӸ=I_>ѸH֣40wj0"bҸjܹI_h$+I_g ~ AhK.u5t)O~4% lt)\K gu)cC TTO0rw- qϲp51&R 6R{a"wmХ*T~^p?ئ] !]r/Zfm.U;N~^p?ئ&cmó6fcGzpN ^{Pw[[ZocJz5 5k5kjY&jVf}5+JfY9ÈoZ~uBO5T`۠YsLR~}δf8q,6h\-a#wגp, W1hjcAbEsmf1͚K>f͡f= l4k:-jX*mЬ9Ysp?cЬqAgs(&pP Щ|h6`lȶR1Yqp-/\6^0񾻖 ,&/L jN 6ԝ*wLkPwB ۆ wm>>AmB !ۆ[u鼠Zjnd۰.|<?wL}'wCbc$6~WnɷfkwJ_[[ YA; r5oi_' M[v `y:-]HB1ğ\~_^FqGl]Ņb|Ezkĥ9::1_᳆ix~^b3S\~8LBE8~KWJ'%$ xB;=f[仵=>[Roȳ=ݨĢ9=пD<.VI?&okb>7g7c)mgT!/&м폕̻U?fE6ʎ}Xݱ폕j!R?Tu5o2Kit)W[ХJ.Kit)Х>M¡\] x lt)\K gu)cC TTO0rw- qϲp51&R 6R{a"wmХ*T~^p?ئ] !]r/Zfm.U;N~^p?ئ&c ͡1#m8< lti'b+p|*6660xT&mХmХ;PNk-ԥ5\.݁cE,Kw.cJu3K{Z uYҽKR.}u)J.݋?&t^ԥ EP.9L`۠K.Ȅ3Ӻtu鳙A<0rw- qϲp5.@]l&mХ19ɶA0]: #]:L`۠K*Ţ֡X> ltӥp?;bХ;p5mХ;ziyd#ݵ˸1p1JN t Ms~p']r..}<ѥS.^P[ Z}]F2KW.e.K_]t)]F2K}6+] x^6RU؏MRhcƆltݍaZ.eyjbc:/MХmХ*8 Dd۠KUC~M bC T^n-4r']rw~MM0o lt|60ydk`۠Kyb$r>[:#1q<6ХQ^5P^0҃K9f_DRKr1 ~uԥ'E*ץGPTKںuԥ?*OR0ХGP6Ctm.at5/֥#K t$90kI^{八tm. AN tґp?cХ#K tZ,j:uA0]:` αM ltA6>`?#ѭy[Oߋl=Y爿xr!~㿠^c5>?I!.R~o[Ľ2--fimw5֥޺m{0q{/؁33ޭsat>~)^_@4b"wW{] LשyJ5W껚ڔ۱_mW7 1BYF}鳲e:yggygݻ.Ǿ0Sg_=}=_tC?b}0!9 ic_kʯ|WiO+s= <ܢ믹c 8Wo ꖭ.8Y[l1"Dd "?20  # A""Oi?j>!@=!Oi?j>TEvUh|!x]p\u~%v] Cp#@6?121 D4NJb` $&IiIW&ߎ$`{ L xc˃iwoyo:y=ݷY?c)yoo_q&w:NjyqNe?9/CWSiтG8}ii#՜v{ ]- 8w ~hishmq鶖8 ŕ'N6[rx| ^pO:%s.^sF1txxyX3_?w-z.*h57imim̓N;Es-sv4F!AOjE4Լsעoǵ;Ex=薞<4wxoy /;4硙 Uon^*8_9jΖgm5;NM?`/$V]r1O8;ѯH? ZodU٭fhڲѯ]W+$־)CIJF}ݰ9#4🰪;f*^2,vϱ2#kѲ}5Z77x.m`.Զ9&ҲԳ:Wʑߠ9)}ִWQ涸ʳratί䅵.LK5ٲڈrz3="<$[mG[q ^xvC1?A)q㼰o mZ^7Bgx5yܥw]m0qyFm\e^<)KQ  k˚y{b&ďk)x ׎ _ģZ8x\:'s5nu#&b5_㽧@}ڠ9ɵrw5ECݳq=G s{0W։jO nR<+ռp==j>=󥽮̼-;5hzDZ[q/7- <iSxeQOL][)+Ʊ_3JulZ^gPv늳gŢ @q6GĻ0DfFDds$5EUt<9RΩ'? hAi{ΧvyO>/Kc#k=ު-v+kRm5 /;q6uMxI•ZڻpRFV<3Fsr-f~>,8n!C9ϫ$G}7Ga%$t{֒*s51簿o~?XӦ1ɶ<7Qj+ q}Kyas뛽 w쯦1G;ۍ ǀ]9.voY ۨ?6߆_4xK/rmطh%ܳ l9bw͝!:B>w͝!Z=tz i7J .U?N97H5CbVҰ q ~%5>=ըyۄ?`쳧ԍrՆS3:'DqpSp>ڙ)+:<łgU?]Kq^!p/|b:ҽJw> WMg?Ᏹ?[*"+E|\G^p{akG.mU]cJqg'˵;ty>V GaE^Q%YK"p)qt\p8;o؎$or Juߙrg=ĝFC>;Bmm:.O7lGuv7{j3ΘĝFC>Bmm:.xo{O̷({誘}dpZ=pFs r%h<9n4wk^L`8 9x%~ל sscHJg O<]F6Ky.=l.w5] ХhtaC}5}p{gbm.8d] \C̴.E7l۠Keو `=kI\d9%.ߘ a]*s`=ĝmt}o4.vئ.oضAk֡%l۠KecҸPa ޛ tXC #ô tX' aʕGbm.Vra!|0LH̷mХz/ХKWurFΒ.U17ĬvW׫K.}=Kk_{.~uQҥ*T%] Х*oBP.-Оy,6҂K 3Ӻ@X̷mХTt{֒*sJ\d5@H q{;6҂K g#Хҥbm.-QC T B|;t,}]:OGfi%ܳ l9 W;6Y%ٶA*tvO7Ch55CbVӥ.=ѥo֥O{#ԥ' mK.=i.R?ϺtRQ7K.U@t)%̧}]qȺvv֙i]>oضAܳt{֒*sJ\d51't)|ö TE{;6RDi\M ] ߰m.ZC9JٶARq67a t&ʹ{Y{6c+mtf%ٶAnV{-Lӥ҇5G55CbVӥ.Ukե]qOHK_^t] FR.F't)C>ѥߊѥ#ma8ԪK.gm.8d] \C̴.E7l۠Keو `=kI\d9%.ߘ a]*s`=ĝmt}o4.vئ.oضAk֡%l۠KecҸPa ޛǾmtiFC#G2mtiF'#ȕʕ/}]Qrx Co۠K3z7Kw.=?ԥBChtҥ*Ɛtҥ*q ^:%Sw/gY*9=5Sg/ҙu~Ng&got&G[=Lt&?Jgz& ϳ|>">"q]ǰ;ǰq|<^ݡ|uo`ߴ(+6uuTmv"p)qt\p8&pT)wCnt\8xvئoGu>73ΘĝFC>LJm:.8;=#յ;貵y.4͝h<y]ZwV{~PsV̍!1g/i TJga@ӫ3:i@ޝFNZWzuFWw~zuJW'#Ы$ 6U{6:.qZY{N7^oضAܣCsqg*sߛ( >WmЫ2Zk)0G;6UX4.vئ&սZ!eG >r ۍUg#9@·͝!|`o7;C^yz:zrHW^U17ĬW^UkW;zƎ껤W?ԫo^}mg.UQ7W AOz5O{o۠W^'ʷ;L<Ճ ߶A#k%YK"p)qPz5Oz`·mЫCٶAOo}('z06|5Z4Oo۠W^'ʷ>^=D{m^=졨9Ls&÷m/0]??盳smj/{655K"kI*"*ti޳29eMd5qazMp;m;eLk;&ضP"zCζ 5<{kBmmzMpme+Mת&ضLP"zyg!XtM?7F|S^µ'V(vܿ^} ~8z;@Ʊ8v˜GE8nC<~Ew&6qb8 [r9_+~~D^wE]וO3}Ct}-sKIWy9_kmHvE_oga᩵E:_,Zb76򈈔uΗĵF<1O!^_ ͓ I>;+<>,]sךZu>ء/lNlN߶l&`kw(>96c?}]Mrg)Z}Z Wq}wxaDc}3pGn69@nt\كq/0';|A;Qqĝmt},Uj;|s|6k ipB/&+hwݍ;_#vdn4wk;Go|Rą>m2(j l۠eq6'=|ö ^^kf(qg +sKƅt\ބ=M ߉W\H?#nҷUp\&}OKs~nҷmNs4 i؁TP^75v4)$f<<)B_\UN.;ԥKկK&]zW*Kh]:ET叶z.}tA7K&]0jե93m.)4,:3KsKm.E2qw- W>ąL4Gt:6\cwmХ9EaDKsKm.QCsTN'}]Sti.YLt{Rm.QU) #ZUp\ l۠Kg\h;#pg]:Zӥ)OѥА5M!1RCѥ֥Ny].=l@>t;]z] ХjtaKÆt)Xm#ХX3?mt)!RZgu)Oa]*sw#'9E]KUO+qj|c:.ORmt=z1;6R`Gi\M ] ߰m.ZC9JٶARq67a=mt鰲"Gi9mt鰲O"ȕÔ+|]:B`o۠K^0KgI ]5]:KT._ ~('uikK R7Z%]G[=Y?tA7K Mh áV]Z=XʷmХER^guit鱔o۠K 社9E]KUO+qj|3.-.=mti!z1;6҂K g#ХҥRm.-QC TK B|;t,|]:OvGfiwݍ;Jpg]:By!;6Ye½.]f Q.sSHjХ'4Mú.Ov]ti<ԥ'-Х]GItRT@~[`~J<&Az2F_to۠Q1Y.3Q~ 6hTQm)Z}Z Wq}B7l۠QeQ9@ٶA;JBmm:.OhTm4ֺ̽,lM Qζ U>*  {l2ﱛ=46l}]K w7c+Fs?=.6͝(ձl7;C^pBv=tPOWז I 榐*WU4tӫ/h꟥׫}iOPWh Ы/hj=Y?5ziONhj>UW쥙o۠W1Y.3W~ 6UQ)Z}Z Wq}B7l۠WeQ!9@ٶA;JBmm:.OUm̽-l} Qζ zU>*  {xڷmڭ#ݴ}ۆ{>1\9+p"|`<6SVa^=B[jNҫ*榐Nҫ*zvҫ^_'(ԫo^NzU叶z^OzU ֫?!z}&WUN^#6 EN˷; ҫ;Ҿm^xe)Z}Z W㛝 ҫ;Ҿm^aζ zuBѫwFW'HH zu-l}:A鎴o۠W':.{gzu'3m^ݩ졨9L#;iwݍ;JpgSɅ:B>wmЫ;^ 0zu(՗4z{rHW9^>K׫W2^:4NX:RAmOke4G{>V>S _Bh оS;%i߼FNF}/f|qvvׯa>oضA݈j`NwגpJ\ߘ a+saζ W>Qj;lq}B7l۠}e{ak]`wmо2Ti\MMcd|;oP_")ߎC|s|}'߰mCW|^2myY'3mCݙW||>Qw ug^ԝCTw Cg{ 5w^EPs>#>Ηor?w0r}|"K@1E 4}_\%e|^/4nrt_5¼3aW}[kaṱOK~N}1='\4]cFI~[aiuAwBL&M>[;&iżC nQ /r,c^[|3Qrhwg"{}c"zr8^"m s9fF5&3ixw|49sCxOBLIu(n|w:^[~Wd zwoHg̥iz 1TableSummaryInformation( DocumentSummaryInformation8@ CompObj:r ՜.+,D՜.+,8 hp  UHHS}  CASE xxxx Title  8@ _PID_HLINKSA*../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OF REPLACEMENT OF SUBJECTS.docT../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.docT ../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.docT ../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE OBJECTIVES.doc7a{http://cancer.case.edu/cancer/media/caseedu/cancer-center/docs/clinical-res-office/protocol-templates/Protocol Summary.pdfPR../../nkovach2/AppData/Local/Microsoft/Users/ecollin0/AppData/Local/Microsoft/Windows/Temporary Internet Files/OLK188A/EXAMPLE TREATMENT SCHEMAS.docSMhttps://case.edu/cancer/research/clinical-research-office/protocol-templates  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q2s2&6FVfv2(&6FVfv&6FVfv&6FVfv&6FVfv&6FVfv&6FVfv8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@_HmH nH sH tH d`d Normalhhd]h^h%B*CJOJQJ_HmH phsH tH t t Heading 1,Level 1,H1$ & F@&5;CJ_HmH sH tH r r Heading 2,Level 2,H2$ & Fxx@&5CJ_HmH sH tH h h Heading 3,Level 3$ & Fx@&5CJ_HmH sH tH r r Heading 4,H4,?1)?,?,?)$ & Fx@&5CJ_HmH sH tH RR  Heading 5$$@&^a$>*OJQJaJXX  Heading 6$$@&^a$5>*OJQJ\aJ``  Heading 7$$@&^a$5>*B*OJQJ\aJphhh  Heading 8$$|@&^`|a$5>*B*CJ OJQJ\ph   Heading 9J $$ # 8 xHX d@&]^a$6B*OJQJaJph3fDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List / WP Defaults= 8`0p@ P !$`'0*-%B*CJOJQJ_HmH phsH tH 4@4 -Header  !4 @4 Footer  !.)@!. Page NumberB2 Body Text,BT,btD$ # 8 xHX d]^a$OJQJNBN Text1!$dh1$]^a$OJQJTRT _# d1$]^ `B*OJQJhph6U`a6  Hyperlink >*B*phTPrT Body Text 2$^a$B*OJQJ]phVYV  Document Map-D M CJOJQJ^JT/T  Char Char1%B*CJOJQJ_HmH phsH tH v^v Normal (Web)&ddd[$\$]^B*OJPJQJ^JaJph.. mw-headlineFV F FollowedHyperlink >*B* phHH  Balloon TextCJOJQJ^JaJ@/@ A-Guided<_HmH sH tH b/b Default 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH XQX Body Text 3 $^a$6B*OJQJaJphVTV Block Text!$^a$B*OJQJ]aJph*W !* yStrong5\.X 1. yEmphasis6]B' AB 5Comment ReferenceCJaJ8R8 5 Comment Text%CJ@jQR@ 5Comment Subject&5\lrl ("rNormal18 'dhxx]^!B*OJQJaJmHphsHtHJ/J '"r Normal18 CharCJ_HaJmHsHtHRR Hdefault)d7$8$]^ OJQJaJ~~ BSynopsis Right Column* & Fdxx]B*OJQJaJphtH LSL ,BBody Text Indent 3+xCJaJp/p +BBody Text Indent 3 Char)B*CJOJQJ_HaJmH phsH tH T/T B Header Char%B*CJOJQJ_HmH phsH tH DD List Paragraph .^m$jj s Table Grid7:V/0/VV -jText"0$dx]^a$B*OJQJphjj a-tabletext 1d<<]^B*CJOJQJaJphPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w<  jw M )\} \!$()_-515CLW\[`cPfjs~{_z@ 1FRv\ IXZ[\]^_deqwy n0aeimHLz  M>g *CF]1!#&)+.x4:>EQIOW[^dggijj]mtE|~ƃ{ђŗ  5;~f!gfS  !#)+139;ACIKQSY[acikqsy{9O ";Tm %@[vt      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHJKLMNOPQRSTUVWYbcfghijklmnoprstuvxb&'''Y(x((6)U)-.. %*6C`lrw 9EKO[`XXXXXXXFFFFFFFFFFFFFFFFFFFFFFFF (*+FHIdfjqs:::!T!  /XR$-hʙGn>RBR$Y)phqTF@H 0(  (    s >A?"Picture 2S"`?  S jAL CompCancerCenter_h_Pantone_GREY_Badge#" `?B S  ?Hl @:st)Text111 _Hlt391027958 _Hlt391027959 _Hlt399938527 _Hlt399938528 _Hlt410916287 _Hlt410916288 INTRODUCTIONText133 TREATMENTPHARMACEUTICAL REFERENCESECOGIMWGPILL1PILL2VES _Hlt391632583 _Hlt391632584 _Hlt401139261 _Hlt401139262 _Hlt391632988 _Hlt391632989 REGISTRATIONDELAYS _Toc86574218 _Toc93682114 _Toc93822164 _Toc124035369_GoBack _Toc249164576 _Toc249164577 _Toc249164573 STATISTICAL COMPARISONText149Text150Text151 _1347870859 _1347870005 _1347868431K !!""""""""''''..Jmtttt; $B`@@@@ @@@@@@ !"#$%&@'@(@L !)!""""""""''''..Jmtttt2  &$B`R................ ................. ..........‰.É.ĉ.ʼn.Ɖ.lj.ȉ.ɉ.ʉ.ˉ.̉.͉.Ή.ω.Љ.щ.҉.Ӊ.ԉ.Չ.։.׉.؉.ى.ډ.ۉ.܉.݉.މ.߉..........##*00;mmrnns 2 2 7 E L b b g u |           !"$#%&      !"#$%&'()*+,-./0)'(*+.,-/0312458679:=;<>?B@ACDGEFHIJKNLMOPQ)00:DD qr   6 D K R R f t {   % %       !"$#%&()'*+-.,/0231457869:<=;>?AB@CDFGEHIJKMNLOPQ=R*urn:schemas-microsoft-com:office:smarttags PlaceName=P*urn:schemas-microsoft-com:office:smarttags PlaceType:B*urn:schemas-microsoft-com:office:smarttagsStreet;C*urn:schemas-microsoft-com:office:smarttagsaddress>>*urn:schemas-microsoft-com:office:smarttags PostalCode8A*urn:schemas-microsoft-com:office:smarttagsCity9?*urn:schemas-microsoft-com:office:smarttagsState9Q*urn:schemas-microsoft-com:office:smarttagsplace RQPPQPRQRRPRQRPCBAQ?>RQRRPAQRQRPCBAQ?>RQRRPRQRRPRQRRPRQRRPRQRRPRQRRPRQRRP?QRQRRPAQ & **@6M6j9s9::X@[@uCCQ%QlQoQ\bgb,d6d;eGePX !#nx,:d9Bx$xxx||||H~O~i~o~wz:d333333333333330: 'G^&''Y((6)-.d<P=Q=Q=U=W=X=X=kGkGGGJJAMOMOOORTTSVSVKYKY]]bbÿÿPQ^_EFqr67[\s|0: 'G^&''Y((6)-.d<P=U=W=X=X=kGkGGGJJAMOMOOORTTSVSVKYKY]]bbÿÿPQ^_EFqr67[\s|%Ff؞n~ κlta' Ml J>4hjw%fNMO'Z)N,yP*bt),| ,-xZX00\_o0|:L2ؑ*3Fr4w"64q%b9$b, ;0@?2`pI> K`tLN*N,~COҀ[SQ#Tn#SUlKʙ)W2ZȪbXyB&Y<X/waJ>u'l.PrmrFc n4`xQypb;zr(39zNCo}T 0^`0o(0^`0o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........^`o(^`o(. 0 ^ `0o(.. 0 ^ `0o(... HH^H`o( .... rr^r`o( ..... `^``o( ...... .`.^.``o(....... !!^!`o(........hh^h`o(88^8`o(.p0p^p`0o(..@ 0@ ^@ `0o(... xx^x`o( .... HH^H`o( ..... `^``o( ...... P`P^P``o(....... ^`o(........ \^`\o(D\D^D`\o(.0^`0o(..0^`0o(... ^`o( .... X X ^X `o( ..... `'``'^`'``o( ...... -`-^-``o(....... 44^4`o(........808^8`0o(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.0^`0o(.00^`0o(.p0p^p`0o(..@ 0@ ^@ `0o(... xx^x`o( .... HH^H`o( ..... `^``o( ...... P`P^P``o(....... ^`o(........hh^h`o(88^8`o(.$ 0$ ^$ `0o(..N 0N ^N `0o(... ^`o( ....   ^ `o( ..... `^``o( ...... `^``o(....... X X ^X `o(........ ^`OJQJo(^`OJ QJ ^J o(o p^p`OJ QJ o( @ ^@ `OJQJo(^`OJ QJ ^J o(o ^`OJ QJ o( ^`OJQJo(^`OJ QJ ^J o(o P^P`OJ QJ o(hh^h`o(hh^h`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........h^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hHh  ^ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh| | ^| `OJQJo(hHhLL^L`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hH hh^h`o(hh^h`o(.0^`0o(..0^`0o(... 88^8`o( .... 88^8`o( ..... `^``o( ...... `^``o(....... ^`o(........ hh^h`OJQJo(^`OJQJo(hH^`OJ QJ ^J o(hHop^p`OJ QJ o(hH@ ^@ `OJQJo(hH^`OJ QJ ^J o(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJ QJ ^J o(hHoP^P`OJ QJ o(hHhR^`5689;<>*@.B*CJH*CJOJQJRHdTXo(phwhhH_h^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hH\^`\o(.0t\t^t`\o(.p0p^p`0o(..@ 0@ ^@ `0o(... xx^x`o( .... HH^H`o( ..... `^``o( ...... P`P^P``o(....... ^`o(........h^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hHh^`OJQJo(hHh ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.h^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hH ^`OJQJo( ^`OJ QJ o(o p^p`OJ QJ o( @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o P^P`OJ QJ o(h>ɾ^ɾ5689;<>*.*䴳*ϴ(8^85689;<>*@.B*CJH*OJQJRHdTXo(phhH_h^`OJ QJ o(hHh ^ `OJQJo(hHh ^ `OJ QJ ^J o(hHohx^x`OJ QJ o(hHhH^H`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHhR^`5689;<>*@.B*CJH*CJOJQJRHdTXo(phwhhH_h^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hH t\t^t`\o(.0D\D^D`\o(.@ 0@ ^@ `0o(..0^`0o(... HH^H`o( .... ^`o( ..... P`P^P``o( ......  ` ^ ``o(....... X X ^X `o(........\^`\o( \ ^ `\o(.0^`0o(..0^`0o(...   ^ `o( .... @ @ ^@ `o( ..... `^``o( ...... x`x^x``o(....... HH^H`o(........^`^Jo(.h^Jh^Jh^Jh^Jh^Jh^Jh^Jh^Jh^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hHh88^8`OJQJo(hHh^`OJ QJ ^J o(hHoh  ^ `OJ QJ o(hHh  ^ `OJQJo(hHhxx^x`OJ QJ ^J o(hHohHH^H`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hH\^`\o( \ ^ `\o(.0^`0o(..0^`0o(...   ^ `o( .... @ @ ^@ `o( ..... `^``o( ...... x`x^x``o(....... HH^H`o(........h^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJ QJ o(hH ^` o(   ^ ` o(.$ 0$ ^$ `0o(..N 0N ^N `0o(... ^`o( ....   ^ `o( ..... `^``o( ...... `^``o(....... X X ^X `o(........  ^` o(hH.  ^` o(hH.  ^` o(hH..  ^` o(hH...  ^` o(hH)  ^` o(hH) ^`o(hH ......  ^`o(hH.......  ^`o(hH........h8^8`OJQJo(hHh^`OJ QJ ^J o(hHoh ^ `OJ QJ o(hHh ^ `OJQJo(hHhx^x`OJ QJ ^J o(hHohH^H`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hH88^8`^Jo(.0^`^Jo(.@ 0@ ^@ `0^Jo(..0^`0^Jo(... HH^H`^Jo( .... ^`^Jo( ..... P`P^P``^Jo( ......  ` ^ ``^Jo(....... X X ^X `^Jo(........h 8^8`o(hH.1h ^`hH.h  L^ `LhH.h  ^ `hH.h x^x`hH.h HL^H`LhH.h ^`hH.h ^`hH.h L^`LhH.0^`0o(. xx^x`hH. HLH^H`LhH. ^`hH. ^`hH. L^`LhH. ^`hH. X X ^X `hH. (#L(#^(#`LhH.h8^8`OJQJo(hHh^`OJ QJ ^J o(hHoh ^ `OJ QJ o(hHh ^ `OJQJo(hHhx^x`OJ QJ ^J o(hHohH^H`OJ QJ o(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJ QJ o(hHhh^h`o(^`o(.0^`0o(..0^`0o(...   ^ `o( .... @ @ ^@ `o( ..... `^``o( ...... x`x^x``o(....... HH^H`o(........%u'l:L29z&Yq%b9SUmFf n#TpINMO'),/wa~ o};z,yP*ta' _o0,~COMl [SQbXw"6 ;ZX0 ,)Wjw%>30@?tLNr4xQy K%%                                            m                                            mm       m        !㠷@Щ1j6jEY                                    |        *                  hqck/E f$iVZck/iVZ hq2 dc%E]UkjJNU/|38|GMT"~~6)3wdG%'5&KLRZX}.DV]`+ 1;QXp I &z . \ r  b ( t z>BRf4izHYw\j dwINI3KAVfwOU[q W,02539*EU\FzM{ s4e30[nBF&)Z4x_!zz7{ ||? S R_ u dy !3""Z"#,#.#&<#lp#$-$0>$C$[K$ W$]$M%)P%K3&V&f& ''{8'N'h'r'-(y(~( )0)P)Eb)Eg)=s*/+++HT+W+,,$,P-{-~%.{.|./S/>b/~z/0K0?1U1]1h12&2h293"g3pj3(4s4OO5E6L6g6 7K77-797c71^9g9Vp9q9@r9u9+x9-:*>:2^:a:r:Ww:x: ;l;U_;;<:<<<<~`<`===&=c= >>}>4a>c>j>@)@6@\b@KAilAB$B,BCZMC$DFDGD}D,E0E]ENpEmF6GvAG2SGhGkGHHq$H_HpHhIc#IW~IAJFJ`JghJUpJhaKLRLXLqnLM;,MmEMVMBNNNON`NdNrN2O#iO}OgPI`P@dPiPlQR ReRSn$S2SASTcTjT7U>UNCVGIWSUW]UW)xWHXKXjXNlXIY UYWYYuYZ*ZP#Z?7ZfDZWZ6dZl[~[mf[3\)]?h]^^,^_!_J0_Jj_r_P `Y`vTa`arAb!ccv\vk]vovGw]]wjwxxlxy!x$x*xIxmLxgkxyy#y!%z)z5z?zIKzBXz)az{U{PV{D|U|[|~|q~F~*~g7~V_~v'K[R{ );xOoe)?'^v~c9MG8e.7V YC5=>I!R5~tXh 6*P`zRAS$W*Y|qN.,>+'Sf(LS`'z?l*?|5[Z_?]f ]_ ZoFxIqEgx#sV=@H~!?Mz 6"y aiaK7Ex/=f"39Xq #;yJln# %y0p>FZ^gxim@R@G'HS6(pg{ng z9EGPZ !DGL`a+1EiXfH!N&m+_EI WB[jw5'6.o FFOD<'m r9jvwu*Og:tzOPAuKCP]^gW? h! n7JY$:7_zv/TV#a>e $AY=$Mt\TA1U\R+*7C8aBsi!"1MMVr#ACTK\l/9^8`~I5Bb&+`q0!BDEat`/;,L p&DDY ->1^o+?ZiipKT&60Li/~Y7l@9s5@UWe}"&Zq70XGX[b:9\odn{'~_FFc4z!DL@e[k]|N"f$B%+5Y>K#hU&QBy K8?P0p!y%S8>2+fss6_"ʱRj3{Pe8=,e?3Tx*'4=:ʰ@89:<?@@@BD@L@@Unknown G.[x Times New Roman5Symbol3. .[x Arial7..{$ Calibri3Z PTimes;. HelveticaCChicagoArial5. .[`)TahomaI Arial Unicode MS?= .Cx Courier New;WingdingsA$BCambria Math"1h ' 'zKGO%$O%$!4}} 2qXR?qN2! xx@px  CASE xxxxKovach, NicoleUser%                           ! " # $